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Abstract 
This thesis explores the potential roles of neutrophils in the host response to tuberculosis. 
First, a review of literature identifies the capacity of neutrophils to phagocytose and kill 
mycobacteria as well as their ability to influence the development of acquired immune 
responses. The effect of HIV infection on neutrophil function is also explored.  
Novel assays are presented to assess phagocytosis of mycobacteria (flow cytometry) and 
restriction of mycobacterial metabolism (bio-luminescence) by human neutrophils. 
Subsequently neutrophil function is investigated in HIV-infected antiretroviral-naïve patients 
and control participants from the same community. Results show that HIV-infected patients’ 
neutrophils restrict mycobacterial metabolism less effectively and undergo more rapid cell 
death than those of controls. The HIV-infected cohort is followed over 6 months of 
antiretroviral therapy; during this time all studied functions improve towards the levels of 
HIV-uninfected participants.  
In vitro studies on other modifiers of neutrophil antimycobacterial function are inconsistent 
but there is some evidence for an effect of zinc chloride in arresting neutrophil cell death. 
Augmentation of human blood with live or dead neutrophils before infection with 
M.tuberculosis significantly impacts on both mycobacterial control and supernatant cytokine 
responses. In particular, necrotic neutrophils facilitate more growth of M.tuberculosis and 
reduce Th1 cytokine responses while increasing IL-10 release.  
Further investigation into the influence of neutrophils on the development of 
antimycobacterial immune responses utilises a mouse model to study BCG vaccination. 
Macrophage Inflammatory Protein-2 (MIP-2)-mediated recruitment of additional 
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neutrophils to the vaccination site significantly increases release of interferon-γ from 
restimulated splenocytes versus controls three weeks after vaccination, while 1A8 anti-Ly6G 
antibody-mediated neutrophil depletion pre-vaccination significantly decreases 
downstream interferon-γ release versus controls. 
Finally the prognostic significance of neutrophilia in active tuberculosis is investigated. This 
analysis on 1236 patients finds that neutrophilia, itself predicted by pulmonary disease and 
white ethnicity, is an independent risk factor for fatality.  
5 
 
Table of Contents 
Abbreviations used in this Thesis 
 
Chapter 1  Introduction 
1.1    Neutrophils 
1.2    Tuberculosis 
1.3     Neutrophils may be important in the early response  
to mycobacterial infection 
1.3.1    Animal data supporting an early protective role for neutrophils 
1.3.2   Neutrophils are recruited to the sites of infection,  
phagocytose mycobacteria and become activated 
1.3.2.1  Neutrophils are rapidly recruited to the site of  
mycobacterial infection 
1.3.2.2    Neutrophils interact with and phagocytose mycobacteria  
including M.tuberculosis   
1.4    Neutrophil killing of mycobacteria 
1.4.1     Potential mechanisms of neutrophil killing of mycobacteria 
1.5     Neutrophil – macrophage co-operation and the  
initial outcome of mycobacterial infection 
1.6     Neutrophils have direct influence on the development  
of the acquired immune response  
1.7     Neutrophils accumulate in active TB, especially in the context  
of a poorly functioning acquired immune response 
1.8     The potential impact of HIV-1 on neutrophil  
anti-mycobacterial function 
1.9     Conclusions 
 
 
Chapter 2 Materials and Methods 
2.1   Human Participants 
2.2    Animals 
2.3     Mycobacterial culture, preparation and storage 
2.4     Whole Blood Lux Assay 
2.5     Cell depletion / CD15+ cell isolation using magnetic beads 
2.6     Granulocyte isolation using Percoll and blood  
granulocyte augmentation 
2.7     Serum Generation, Heat Inactivation and Pre-opsonisation 
2.8     Neutrophil Lux Assay 
2.9     Flow cytometry of human blood 
2.10     Neutrophil phagocytosis assay 
2.11     pHrodo™ labelling 
2.12     Neutrophil cell death assay and neutrophil supernatants 
2.13     Mouse air-pouch generation, neutrophil depletion,  
neutrophil recruitment, vaccination and sampling 
2.14     Mouse spleen preparation and splenocyte restimulation 
12 
 
16 
17 
22 
23 
 
23 
26 
 
26 
 
29 
 
32 
35 
38 
 
43 
 
45 
 
51 
 
52 
 
 
53 
53 
58 
58 
61 
63 
65 
 
67 
68 
69 
69 
71 
72 
73 
 
75 
Page No. 
6 
 
2.15     Enzyme Linked Immunosorbent Assays (ELISA) 
2.16     Luminex® 
2.17     Interferon-γ Release Assays    
2.18     Quantitative cell enumeration 
2.19     Confocal Microscopy 
2.20     Measurement of absorbance 
2.21     Analysis of causes of neutrophilia and mortality 
2.22     Statistical Methods 
2.23     Principal Component Analysis 
 
 
Chapter 3  Development and validation of assays 
3.1   Introduction 
3.2 Samples must be cooled to room temperature to enable accurate 
measurement of luminescence 
3.3  Neutrophils restrict bioluminescence of BCG-lux and  
M.tuberculosis-lux in a dose-dependent manner 
3.4     Lysis of neutrophils is not required in these experiments  
for accurate measurement of antimycobacterial effects 
3.5     Neutrophils are not lost due to adherence to walls of  
luminometer tubes 
3.6     The phagocytosis assay demonstrates clear populations  
of neutrophils defined by the presence and location of organisms  
3.7     Significant clumping of organisms does not occur at  
lower organism concentrations 
3.8    Internalisation increases with Multiplicty of Infection,  
but not in a linear fashion 
3.9     Internalisation is inhibited by low temperature and results  
are comparable with those using acid-resistant fluorophores 
3.10    Trypan blue stains dead and fixed cells 
3.11     Non-heat inactivated autologous serum is optimal to demonstrate  
significant phagocytosis and mycobacterial restriction 
3.12     Neutrophils are responsible for an early drop in luminescence  
in the whole blood lux assay 
3.13     Discussion 
 
 
Chapter 4 The impact of HIV on neutrophil anti-mycobacterial function 
4.1    Introduction 
4.2     Patient characteristics and Exclusions 
4.3    HIV infection impairs the ability of neutrophils to control 
  M.tuberculosis 
4.4     Depletion of neutrophils from blood has a greater effect on  
restriction of mycobacteria than depletion of any other cell type,  
but the effect tends to be less in HIV infection and inversely  
correlates with viral load 
4.5     Phagocytosis of M.tuberculosis by neutrophils is not affected  
 
 
79 
80 
81 
81 
81 
82 
82 
83 
85 
 
 
86 
86 
87 
 
88 
 
89 
 
95 
 
96 
 
97 
 
99 
 
103 
 
104 
105 
 
110 
 
116 
 
 
121 
121 
122 
124 
 
126 
 
 
 
127 
 
Page No. 
7 
 
by HIV infection 
4.6     Neutrophils from HIV-infected individuals demonstrate  
accelerated necrotic cell death when exposed to M.tuberculosis 
4.7     Neutrophils from HIV-infected individuals are hyper-activated 
4.8     Human Neutrophil Peptide 1-3 levels in supernatants are not  
affected by HIV infection 
4.9     Blood supernatant cytokines are most affected by  
CD14 depletion and relatively little by CD15 depletion 
4.10     Discussion 
 
 
Chapter 5 The effect of antiretroviral therapy on neutrophil  
anti-mycobacterial function 
5.1     Introduction 
5.2     HIV-infected adults had robust virological and immunological  
response to antiretroviral therapy 
5.3     Direct restriction of M.tuberculosis-lux by neutrophils isolated  
from HIV-infected patients improves over 6 months of  
antiretroviral therapy 
5.4     The impact of neutrophil depletion on the control of  
M.tuberculosis-lux by whole blood of HIV-infected people  
after 6 months antiretroviral therapy returns to that seen in  
HIV-uninfected people  
5.5   Phagocytosis of M.tuberculosis does not change over 6 months of  
antiretroviral therapy 
5.6     The risk of accelerated neutrophil cell death on exposure to  
M.tuberculosis in HIV infection declines over 6 months of  
antiretroviral therapy 
5.7     The risk of neutrophil hyperactivation declines over 6  
months of antiretroviral therapy 
5.8     Human Neutrophil Peptide 1-3 levels in supernatants of neutrophils  
cultured in presence of M.tuberculosis are not significantly  
affected by antiretroviral therapy 
5.9     The effect of cell depletion on blood supernatant cytokine release  
remains similar to baseline after 6 months of antiretroviral therapy,  
although CD4 cell depletion has more impact on analyte profile 
5.10     Discussion 
 
 
Chapter 6 The effect of manipulating neutrophil function or  
number on antimycobacterial activity, cell death and  
cytokine profile 
6.1     Introduction 
6.2     Inhibitors of reactive oxygen and reactive nitrogen intermediates  
do not influence the ability of neutrophils to restrict  
mycobacterial luminescence 
6.3     Zinc, Vitamin B12 and Vitamin D have variable direct effects on  
 
 
 
130 
 
132 
132 
 
134 
 
136 
 
 
143 
 
143 
144 
 
144 
 
 
148 
 
 
 
149 
 
150 
 
 
151 
 
151 
 
 
153 
 
 
156 
 
 
159 
 
 
159 
160 
 
 
162 
 
Page No. 
8 
 
mycobacterial luminescence but only zinc improves proportional  
restriction versus vehicle alone 
6.4     Vitamin B12 does not affect neutrophil cell death but N-acetyl-
cysteine and especially zinc chloride reduce neutrophil cell death  
6.5     Zinc chloride at physiological doses may reduce neutrophil cell death  
in HIV-infected people, although results are inconsistent 
6.6     The addition of live neutrophils improves, while the addition of  
necrotic neutrophils impairs, control of M.tuberculosis in whole blood 
6.7     The addition of either live or necrotic neutrophils to  
M.tuberculosis-infected whole blood significantly affects  
supernatant immune responses 
6.8     Discussion 
 
 
Chapter 7 The influence of neutrophil augmentation or depletion prior  
to BCG vaccination on the development of an acquired immune  
response in the mouse 
7.1     Introduction 
7.2     Optimising the pouch model 
7.3     1A8 treatment reduces the proportion of granulocytes at the  
site of vaccination but does not affect organism burden 
7.4     1A8 treatment does not affect spleen cellularity or lymphocyte  
proportions at 3 weeks but may increase the proportions of  
neutrophils and eosinophils 
7.5     1A8 treatment does not affect the percentage of TNF-secreting  
CD4+ cells upon restimulation 3 weeks after vaccination 
7.6     1A8 treatment reduces IFN-γ release upon splenocyte restimulation  
3 weeks after vaccination 
7.7     MIP-2 treatment increases cell counts and proportion of granulocytes  
at the site of vaccination but does not affect organism burden 
7.8     MIP-2 treatment does not affect spleen cellularity or cell proportions  
at 3 weeks restimulation 3 weeks after vaccination 
7.9     MIP-2 treatment increases the percentage of TNF-secreting  
CD4+ cells upon restimulation 3 weeks after vaccination 
7.10     MIP-2 treatment increases IFN-γ release upon splenocyte  
restimulation 3 weeks after vaccination 
7.11     Discussion 
 
 
Chapter 8 Neutrophilia in active tuberculosis 
8.1     Introduction 
8.2     Patient characteristics 
8.3     Neutrophilia is common in patients with tuberculosis and is  
not associated with non-mycobacterial bacteremia 
8.4     Determinants of neutrophilia 
8.5     Neutrophilia independently predicts mortality 
8.6     Predictive model for survival from tuberculosis 
 
 
 
 
164 
 
165 
 
169 
 
172 
 
 
175 
 
 
180 
 
 
180 
182 
184 
 
185 
 
 
189 
 
192 
 
193 
 
194 
 
195 
 
196 
 
197 
 
 
201 
201 
202 
204 
 
205 
208 
211 
 
 
Page No. 
9 
 
 
8.7     Discussion 
 
Chapter 9 Conclusions and Future Directions 
9.1     The roles of neutrophils in host response against tuberculosis 
9.2     Potential therapeutic and clinical applications 
 
Bibliography 
 
Appendix A – Acknowledgements  
Appendix B – Published & Accepted manuscripts relating to thesis 
 
List of Tables 
 
Table 1.1. Animal models suggesting role of granulocytes / neutrophils in  
early control of mycobacterial infection. 
Table 1.2. In vitro studies of neutrophil killing / restriction of mycobacteria. 
Table 1.3 Potential mechanisms of mycobacterial killing in neutrophils. 
Table 1.4. Mouse models resulting in excessive neutrophilic influx  
in response to mycobacterial infection. 
Table 1.5. Reported prevalences of neutrophilia, lymphopenia and  
lymphocytosis in tuberculosis patients. 
Table 2.1. Inclusion and exclusion criteria for laboratory studies. 
Table 2.2. Experimental conditions used for cell depletions.  
Table 2.3. Fluorochromes used in this thesis.  
Table 3.1. Results from the phagocytosis assay (six donors) according  
to multiplicity of infection. 
Table 3.2. Characteristics of tuberculosis contacts recruited (n = 9). 
Table 4.1. Participant characteristics at baseline enrolment. 
Table 4.2. Potential predictors of neutrophil antimycobacterial activity. 
Table 4.3. Participant characteristics at baseline enrolment for activation study. 
Table 5.1. Summary of experiments performed at each visit. 
Table 6.1. Ratio of luminescence of BCG-lux in cell-containing samples  
vs serum-only samples at various time points (6 donors). 
Table 6.2. Participant characteristics for ex vivo zinc supplementation studies.  
Table 6.3. Results from luminescence readings in ex vivo zinc supplementation  
experiments. 
Table 6.4. p- and q-values for Principal component Analysis of raw Luminex™  
data from augmentation experiments. 
Table 8.1. Characteristics of tuberculosis patients entering baseline analyses (n = 
855). 
Table 8.2. Predictors of neutrophilia in patients with tuberculosis (n = 855). 
Table 8.3. Predictors of all-cause mortality in patients with tuberculosis (n = 718). 
Table 8.4. Predictive model for mortality in tuberculosis patients. 
Table 8.5. Case fatality according to score from predictive model (1 point  
for each of albumin < 30 g/L, platelets < 150 x 109 /L, neutrophils > 8 x 109 / L,  
age > 50 years). 
Table 9.1 Potential therapeutic applications relating to neutrophils in  
tuberculosis, and further research required. 
 
212 
 
218 
218 
223 
 
225 
 
259 
261 
 
 
25 
 
34 
36 
47 
 
49 
 
57 
64 
78 
101 
 
113 
123 
127 
134 
143 
161 
 
167 
169 
 
173 
 
203 
 
206 
209 
213 
213 
 
 
224 
 
Page No. 
10 
 
List of Figures 
 
Figure 1.1. Neutrophil-Macrophage interaction in the early stages of  
tuberculosis infection. 
Figure 2.1. Basic description of the cohorts of participants recruited for this thesis.  
Figure 2.2. The Percoll gradient after centrifugation. 
Figure 2.3. Gating strategy for cell death assay.  
Figure 3.1 Investigation of time out of incubator on mycobacterial luminescence.  
Figure 3.2. Restriction of mycobacterial luminescence by neutrophils is inversely 
proportional to multiplicity of infection and requires viable cells.   
Figure 3.3. Lysis or washing of cells results in artefactual increases in  
luminescence only.  
Figure 3.4. ‘Time to peak’ and effect of reading time on measured luminescence in  
serum-only and neutrophil samples.  
Figure 3.5. Gating strategy and interpretation for phagocytosis assay.  
Figure 3.6. Assessment of clumping.  
Figure 3.7. Determining optimal multiplicity of infection to demonstrate 
phagocytosis.  
Figure 3.8. Phagocytosis is inhibited by ice. 
Figure 3.9.Use of pHrodo™ to evaluate neutrophil phagocytosis of mycobacteria.  
Figure 3.10. Trypan blue stains dead and prolonged fixed cells.  
Figure 3.11. Investigation of opsonisation.  
Figure 3.12. Serum is required for mycobacterial viability.  
Figure 3.13. Investigating the early fall in luminescence in the whole blood  
BCG-lux assay.  
Figure 3.14. The relative effect of different cell depletions on early measured  
mycobacterial luminescence. 
Figure 4.1. The impact of HIV on the ability of neutrophils to control M.tuberculosis.  
Figure 4.2. The impact of cell depletions on control of M.tuberculosis-lux in blood.  
Figure 4.3. Evaluation of cell death in neutrophils from HIV-infected and  
HIV-uninfected donors.  
Figure 4.4. Activation status of neutrophils in HIV-infected and –uninfected 
individuals.  
Figure 4.5. Cytokine and chemokine analysis of 96-hour supernatants of cell-
depleted and undepleted blood infected with M.tuberculosis-lux.  
Figure 4.6. Cytokine and chemokine raw results from 96-hour supernatants of  
cell-depleted and undepleted blood infected with M.tuberculosis-lux.  
Figure 5.1. Virological and immunological response to antiretroviral therapy.  
Figure 5.2. Improvement in neutrophil antimycobacterial activity over 6 months of 
anti-retroviral therapy.  
Figure 5.3. The impact of cell depletions on control of M.tuberculosis-lux in blood 
after 6 months of antiretroviral therapy.  
Figure 5.4. Evaluation of cell death in neutrophils from HIV-infected donors over  
6 months of antiretroviral therapy.  
 
 
 
 
 
 
 
42 
 
54 
66 
73 
88 
91 
 
94 
 
95 
 
98 
100 
102 
 
103 
106 
107 
108 
110 
114 
 
115 
 
128 
129 
131 
 
133 
 
137 
 
138 
 
146 
147 
 
149 
 
152 
 
 
 
 
 
Page No. 
11 
 
Figure 5.5. Cytokine and chemokine analysis of 96-hour supernatants of cell-
depleted and undepleted blood infected with M.tuberculosis-lux  
Figure 5.6. Cytokine and chemokine raw results from 96-hour supernatants of  
cell-depleted and undepleted blood infected with M.tuberculosis-lux. 
Figure 6.1. Investigation of potential modifiers of neutrophil-mediated control  
of BCG-lux.  
Figure 6.2. Effect of high dose zinc chloride on neutrophil cell death in the  
presence of BCG.  
Figure 6.3. Investigating the ex vivo effect of zinc on cell death of HIV-infected  
patients’ neutrophils.  
Figure 6.4. Luminescence of M.tuberculosis-lux after incubation in whole blood  
augmented with viable, necrotic or no neutrophils.  
Figure 6.5. Principal Component Analysis of cytokine response in  
augmentation experiments.  
Figure 6.6. Raw Luminex™ data from neutrophil augmentation experiments.  
Figure 7.1. Summary of system and timescale for murine experiments into  
neutrophil effect on BCG efficacy. 
Figure 7.2. Optimising the pouch model.  
Figure 7.3. Flow cytometry gating strategies for pouch aspirates from  
BCG-vaccinated mice.  
Figure 7.4. Results from flow cytometry of pouch aspirates on 1A8-treated and  
2A3 control mice.  
Figure 7.5. Gating strategy to determine splenocyte cell populations.  
Figure 7.6. Total cell counts and sub-population proportions of splenocytes in  
1A8-treated and 2A3 control mice.  
Figure 7.7. Gating strategy and results of intracellular cytokine analysis on  
BCG-restimulated splenocytes from 1A8-treated and 2A3 control mice.  
Figure 7.8. Results of IFN-γ ELISA on supernatants of BCG-restimulated splenocytes  
from 1A8-treated and 2A3 control mice.  
Figure 7.9. Results from flow cytometry on pouch aspirates of MIP-2-treated and  
control mice.  
Figure 7.10. Total cell counts and sub-population proportions of splenocytes in  
MIP-2-treated and control mice.  
Figure 7.11. results of intracellular cytokine analysis on BCG-restimulated  
splenocytes from MIP-2-treated and control mice.  
Figure 7.12. Results of IFN-γ ELISA on supernatants of BCG-restimulated splenocytes  
from MIP-2-treated and control mice. 
Figure 8.1. Comparison of neutrophils counts between contacts and cases.  
Figure 8.2. Effect of site of disease and ethnicity on neutrophil count in active  
tuberculosis.  
Figure 8.3. Tuberculosis case fatality rates according to predictor variables.  
Figure 9.1. The potential roles of neutrophils in mycobacterial infection.   
Figure 9.2. Neutrophil-Macrophage co-operation in the early stages of tuberculosis 
infection. 
 
 
 
 
154 
 
155 
 
163 
 
166 
 
168 
 
171 
 
173 
 
174 
182 
 
183 
186 
 
187 
 
188 
190 
 
191 
 
192 
 
194 
 
195 
 
196 
 
197 
 
205 
207 
 
211 
220 
221 
 
 
Page No. 
12 
 
Abbreviations used in this thesis 
   
Ab 
 
Antibody 
ADC 
 
Albumin / dextrose / catalase 
ANOVA 
 
Analysis of variance 
aOR  Adjusted odds ratio 
APC 
 
Allophycocyanin 
ART 
 
Antiretroviral therapy 
ARV  Antiretroviral 
ATP 
 
Adenosine triphosphate 
BCG 
 
Mycobacterium bovis BCG 
BD  Becton Dickinson 
BPI 
 
Bacterial/permeability-increasing protein 
BSA 
 
Bovine serum albumin 
BSL 
 
Bio-safety level 
oC  Degrees centrigrade 
CARD9  
 
Caspase recruitment domain containing protein 9 
CCL  C-C chemokine ligand 
CCR  
 
C-C chemokine receptor 
CD 
 
Cluster of differentiation 
CFU 
 
Colony forming units 
CI  Confidence interval 
CO2  
Carbon dioxide 
CR 
 
Complement Receptor 
CRP 
 
C-Reactive protein 
CXCL 
 
C-X-C chemokine ligand 
CXCR 
 
C-X-C chemokine receptor 
Cy5.5 / 7 
 
Cyanin 5.5 / 7 
DC 
 
Dendritic cell 
DNA 
 
Deoxyribonucleic acid 
EDTA 
 
Ethylenediaminetetraacetic acid 
EGF  Epidermal growth factor 
ELISA 
 
Enzyme-linked immunosorbent assay 
ENA-78 
 
Epithelial cell-derived neutrophil-activating peptide-78 
FBC  Full blood count 
FGFb  Fibroblast growth factor-basic 
FITC 
 
Fluorescein isothiocyanate 
fMLP 
 
Formylated-Met-Leu-Phe 
FMN 
 
Flavin mononucleotide 
FSC (-A / -H) Forward scatter (-Area / -Height) 
g 
 
grammes or gravity 
G-CSF 
 
Granulocyte Colony-Stimulating Factor 
GFP 
 
Green fluorescent protein 
GM-CSF 
 
Granulocyte-Macrophage Colony-Stimulating Factor 
13 
 
Gr-1  Granulocyte Receptor-1 
Gro-α 
 
Growth-related oncogene-α 
HBSS 
 
Hanks’ balanced salt solution 
HGF  Hepatocyte growth factor 
HIV 
 
Human immunodeficiency virus 
HNP 
 
Human neutrophil peptides 
hsp 
 
Heat shock protein 
ICAM 
 
Intercellular adhesion molecule 
IFN 
 
Interferon 
IGRA  Interferon-γ release assay 
IL 
 
Interleukin 
IMDM 
 
Iscove’s modified Dulbecco’s medium 
iNOS 
 
inducible nitric oxide synthase 
IP 
 
Intra-peritoneal 
IP-10 
 
Interferon-inducible protein of 10 kDa 
IQR 
 
Inter-quartile range 
IRIS  Immune reconstitution inflammatory syndrome 
KCH 
 
King’s College Hospital 
kDa 
 
Kilodalton 
Kg  kilogramme 
L  Litre(s) 
lb/sq.in. 
 
pounds per square inch 
LFA-1 
 
Lymphocyte function-associated antigen 1 
LL-37 
 
Cathelicidin 
LN  Lymph node 
L-NMMA 
 
NG-Monomethyl-L-Arginine 
LPS 
 
Lipopolysaccharide 
LTB4 
 
Leukotriene B4 
Ly6G  Lymphocyte antigen 6G 
M 
 
molar 
M.tb 
 
Mycobacterium tuberculosis 
MAb 
 
Monoclonal antibody 
MACS™  Magnetic Activated Cell Sorting 
mcg 
 
microgrammes 
mcl 
 
microlitres 
MCP 
 
monocyte chemotactic protein 
mg 
 
milligrammes 
MHC 
 
Major histocompatibility complex 
MIG 
 
Monokine induced by interferon-γ 
MIP 
 
Macrophage Inflammatory Protein 
ml 
 
millilitres 
mm  millimetres 
mM 
 
millimolar 
mmol  millimoles 
14 
 
MMP 
 
Matrix metalloproteinases 
MOI 
 
Multiplicity of infection 
MyD88  
 
Myeloid differentiation primary response protein 88 
n  Number 
N/A  Not applicable 
NAC 
 
N-Acetylcysteine 
NADPH 
 
Nicotinamide adenine dinucleotide phosphate 
NAS  N-Acetylserine 
Nef 
 
Negative factor 
NET 
 
Neutrophil extracellular trap(s) 
ng 
 
nanogrammes 
nm 
 
nanometre 
nM 
 
nanomolar 
NR 
 
Not recorded 
NS  Not significant 
NUHT 
 
Newham University Hospital Trust 
OADC 
 
Oleic acid / albumin / dextrose / catalase 
OR  Odds ratio 
PBS 
 
Phosphate Buffered Saline 
PD-1  
 
Programmed death-1 
PE 
 
Phycoerythrin 
PECAM-1 Platelet endothelial cell adhesion molecule-1 
PerCP 
 
Peridinin chlorophyll protein 
pg  picogrammes 
PNP 
 
P-Nitrophenol-phosphate 
PPD 
 
Purified protein derivative 
RLU 
 
Relative light unit(s) 
ROS 
 
Reactive oxygen species 
rpm 
 
Revolutions per minute 
RPMI-1640 Roswell Park Memorial Institute-1640 
SD Standard deviation 
SDF-1α 
 
Stromal cell-derived factor 1α 
SPF 
 
Specified pathogen free 
SSC 
 
Side scatter 
T 
 
Time 
TB 
 
Tuberculosis 
TCR 
 
T cell receptor 
TGF-β 
 
Transforming growth factor-β 
Th1/2 
 
T-helper Type 1/2 
TLR 
 
Toll like receptor(s) 
TNF 
 
Tumour necrosis factor 
UCT 
 
University of Cape Town 
UK 
 
United Kingdom 
VEGF  Vascular endothelial growth factor 
15 
 
Vitamin C  L-ascobic acid 
Vitamin D Dihydroxycholecalciferol 
VL Viral load 
vs versus 
ZnCl2 Zinc chloride 
μM 
 
micromolar 
 
 
 
 
 
 
 
 
 
16 
 
 
1. Introduction 
 
“...Investigations on the “early” formation of the tubercle, dealing with its development in 
the first few days, have largely overlooked the truly early changes occurring in the first few 
hours.” 
(Long and Vorwald 1931 [1]) 
 
Mycobacterium tuberculosis infects human populations throughout the world and continues 
to kill millions. Despite decades of research, the determinants of susceptibility to this 
infection remain poorly understood. Among the various components of host response to 
mycobacterial challenge, few have been less well studied or proven more controversial than 
the role of neutrophils.  
Neutrophils are short-lived, easily activated, and cannot be cryo-preserved: experimental 
work is therefore challenging and prone to variability. Consequently, the available literature 
is replete with contradiction and inconsistency. Nevertheless, in this chapter I aim to 
synthesise what has been published on this topic and introduce the concepts fundamental 
to my thesis. After a brief introduction to neutrophils and tuberculosis immunology, I will 
consider the following themes: 
 Neutrophils as direct mediators of protection against tuberculosis 
 Neutrophil influence on the development of acquired immunity 
 The pathological role of neutrophils in established tuberculosis disease 
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1.1  Neutrophils 
Neutrophils, or polymorphonuclear granulocytes, are the most numerous leucocytes in 
human blood and are essential for life [2]. Professional phagocytes, their role has long been 
understood to be the rapid clearance of microbial (especially bacterial) infection and other 
acute insults to the host. In this capacity they are mobilised promptly, follow gradients of 
attractant signals to sites of infection or injury, deploy killing mechanisms either intra- or 
extra-cellularly and die in situ before clearance by mononuclear phagocytes. Neutrophil 
products are locally destructive to the host and result in suppuration: a process which may 
be useful to the host in acute infection [3] but which results in pathology with repeated 
episodes of inflammation.  
Several stages are essential for neutrophils to be able to perform these functions: 
production in and mobilisation from bone marrow; endothelial adherence and trans-
migration to tissues; chemotaxis; priming and activation; phagocytosis of pathogens; 
oxidative burst, and degranulation. Certain key molecular players are involved in many of 
these stages.  
 Granulopoiesis in bone marrow is largely dependent on Granulocyte Colony-
Stimulating Factor (G-CSF) and to a lesser extent Granulocyte-Macrophage Colony-
Stimulating Factor (GM-CSF), Interleukin-6 (IL-6) and Interleukin-3 [4]. G-CSF 
production can be up-regulated by IL-17, at least in mice [5]. 
 Egress from bone marrow is largely negatively regulated via expression of stromal 
cell-derived factor-1α (SDF-1α, also known as CXCL12) binding to CXCR4 on mature 
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neutrophils [6]. During inflammation, higher circulating concentrations of G-CSF 
down-regulate CXCR4 and release stored neutrophils; thus G-CSF acts to increase 
both production and release of neutrophils. Other mediators in blood directly attract 
neutrophils from bone marrow sinusoids, including chemokines (especially IL-8 or 
the murine homolog Macrophage Inflammatory Protein-2 (MIP-2)), Leukotriene B4 
(LTB4) and the Complement component C5a [6].  
 Endothelial adherence initially involves rolling and weak tethering, mediated largely 
by Selectins (L-Selectin on neutrophils, E-Selectin and P-Selectin on endothelium) 
with subsequent firm adhesion primarily between β2-integrins on neutrophils (Mac-1 
[CD11b:CD18; Complement Receptor 3] and Lymphocyte function-associated antigen 
1 (LFA-1) [CD11a:CD18]) and the intercellular adhesion molecules (ICAM) 1 and 2 on 
endothelium. Finally paracellular or trans-cellular migration to the tissues involves 
neutrophil integrins interacting with endothelial ICAMs and then other members of 
the immunoglobulin superfamily (eg junctional adhesion molecules and platelet 
endothelial cell adhesion molecule-1 (PECAM-1) [7]). Expression of the receptors 
involved in this process is up-regulated by inflammatory mediators including G-CSF, 
IL-8, IL-1β, IL-17 and tumour necrosis factor (TNF) [7], C5a and LTB4 [8]. 
 Migration through tissues involves neutrophils following a gradient of chemo-
attractants, notably IL-8, C5a, LTB4 and bacterial products (eg formylated-Met-Leu-
Phe (fMLP) [9]): mediators of potential importance in mycobacterial infection are 
considered below. Neutrophil proteases and matrix metalloproteinases may 
facilitate migration through the extracellular matrix. 
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 ‘Priming’ and ‘activation’ were terms initially used to describe changes in the 
capacity of the neutrophil to undergo respiratory burst [10], but are now also 
recognised to involve altered surface marker expression [9] and an enhanced 
responsiveness to other stimuli [11]. For example, activation involves loss of L-
Selectin and up-regulation of CD11b as neutrophils progress from weak tethering to 
firm adhesion of the endothelium. Priming and activation are triggered by the same 
mediators responsible for adherence and chemotaxis, including host (eg IL-8, TNF) 
and microbial (eg fMLP and lipopolysaccharide) factors, which bind to neutrophil 
cytokine or pattern recognition receptors. Many of the up-regulated surface 
receptors are provided by granules and secretory vesicles fusing with the outer cell 
membrane; concomitantly, other receptors are endocytosed during the activation 
process [11]. The end result of priming and activation is a significant increase in 
phagocytic and microbicidal function [9, 11].  
 Phagocytosis is the process by which cells engulf and internalise other cells, microbes 
or foreign material. Ingested material can be either opsonised – predominantly with 
complement components or antibodies – or non-opsonised. The principal opsonin 
receptors on neutrophils are the Fc receptors for antibodies (FcγRIIA (CD32), FcγRIIIb 
(CD16) and FcγR1 (CD64, a high affinity receptor expressed after priming) [12]) and 
the complement receptors (predominantly CR1 (CD35) which binds C3b, CR3 
(CD11b/CD18; Mac-1) and CR4 (CD11c/CD18) which bind iC3b, as well as separate 
receptors for C5a, C3a and C1q [13]). Direct pattern recognition in the context of 
mycobacteria is considered below. Ligation of these receptors triggers the formation 
of a phagosome, via membrane involution or the extension of pseudopods to 
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‘capture’ the ingested particle. The phagosome must then ‘mature’. Key components 
of the maturation process are oxidative burst and degranulation. 
 The oxidative (‘respiratory’) burst is the process of generation of reactive oxygen 
species (ROS) by NADPH oxidase. This enzyme is assembled upon priming and 
stimulation, with most delivered into the phagosome from secondary granules [12]. 
NADPH oxidase transfers one electron from NADPH to molecular oxygen, thereby 
generating superoxide anions. These can subsequently dismutate to hydrogen 
peroxide, while further interaction with granule products generates other cytotoxic 
ROS [14]. In particular, myeloperoxidase from azurophil granules mediates the 
formation of hypochlorous acid.  
 Degranulation refers to the discharge of granule contents either into the phagosome 
or extracellularly (exocytosis). Granule membranes fuse with the phagosomal or cell 
membranes during this process, and thus not only deliver antimicrobial agents to 
internalised pathogens or the extracellular space, but also introduce new receptors 
and enzymes to the surface of the cell (eg integrins) or to the phagosome (eg NADPH 
oxidase) [11]. Although there is considerable overlap of content and function, 
granules are generally classified into four groups. These are defined according to 
their order of appearance during granulopoiesis; broadly speaking, they are 
deployed in reverse order: 
- Secretory vesicles. Contain albumin and surface receptors (eg Mac-1, CD35 and 
CD16), probably formed via endocytosis of outer membrane during late neutrophil 
maturation [15] rather than budding from the Golgi. 
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- Tertiary granules. Contain predominantly cathepsin and gelatinase. 
- Secondary (or specific) granules. Contain cathelicidin, lactoferrin, lipocalin, alkaline 
phosphatase, collagenases, lysozyme and the NADPH oxidase. 
- Primary (or azurophil) granules. Contain azurocidin, α-defensins (eg human 
neutrophil peptides), myeloperoxidase, neutrophil elastase, proteinase-3, cathepsin 
G and bacterial/permeability-increasing protein (BPI). 
Secondary and tertiary granules also contain matrix metalloproteinases (MMP) 8 and 9 
[7]. Thus reverse deployment of granules first delivers the receptors from secretory 
vesicles necessary for firm adhesion to endothelium and trans-migration into tissues as 
well as the receptors for binding opsonised microbes. Subsequently, proteases and 
gelatinase are released from tertiary granules – perhaps to aid migration through the 
extracellular matrix. Next, and ideally after phagocytosis, components of the NADPH 
oxidase are delivered by specific granules to begin the oxidative burst and, finally, the 
most powerful antimicrobial substances are provided by primary granules. 
 
The progression through these various stages is complex, and may depend at least in part of 
the concentration of relevant mediators (for example, IL-8 may, as its concentration 
increases, preferentially drive L-selectin shedding, up-regulation of β2-integrins, initiation of 
the oxidative burst and degranulation [11]). 
Beyond these primary functions as antimicrobial effector cells, more recent evidence has 
also implicated neutrophils as important cells in the orchestration of immune responses. 
There is now ample evidence that they secrete cytokines (albeit more from studies in mice 
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than humans, as discussed below), and other products can also be immunomodulatory. For 
example, granule products attract and activate mononuclear phagocytes [16]. Neutrophils 
may also influence other immune cells via cell-cell contact and their pattern of cell death: 
this is considered in more detail below. Other studies have suggested that neutrophils may 
not always die in situ and can undergo retrograde chemotaxis [2] – an attribute that may 
have particular importance in the context of BCG vaccination [17]. 
 
1.2   Tuberculosis 
Mycobacterium tuberculosis is an acid-fast, Gram-positive, bacillus whose natural host is 
humans. The bacteria are believed to be transmitted primarily via respiratory droplets, 
which are inhaled or ingested by people close to an infected index case. Traditional 
understanding of the host response involves phagocytosis of bacteria by mononuclear 
phagocytes (classically alveolar macrophages), which – at the site of infection or after 
migration to draining lymph nodes – summon predominantly CD4-expressing lymphocytes 
and form a granuloma [18]. Central to this process are the so-called T-helper Type 1 (Th1) 
cytokines, especially interferon-γ (IFN-γ) and tumour necrosis factor (TNF) [19]. Type 2 T-
helper cells and their cytokine products (eg IL-10, IL-4) are believed to be broadly 
detrimental in terms of protective immunity [20].  
The host may eliminate the infection within the granuloma, may entirely fail to control 
bacillary growth and allow progressive primary disease, or may ‘contain’ the bacteria in 
small but viable numbers (‘latent’ infection) [18]. Latent infection may reactivate (post-
primary disease) after any interval, predominantly as a result of immunosenescence or 
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immunocompromise. Primary or reactivated infection can progress within the lung or be 
disseminated to any organ, leading to the myriad clinical presentations of tuberculosis 
disease [21].  
The available tuberculosis vaccine, Mycobacterium bovis BCG, was first used in 1921. There 
is a wide range of reported efficacies, but it is generally agreed that the vaccine confers 
protection in childhood, especially against disseminated disease [22]. Protective immunity is 
usually inferred from the ability to generate an effective Th1 response (especially IFN-γ) in 
response to mycobacterial antigens [22].  
These paradigms, albeit here simplified, have existed for many years and have informed the 
majority of tuberculosis research. Neutrophils, although known for many decades to be 
among the first cells encountering M.tuberculosis bacilli [1, 23], have received relatively 
little attention.  
 
1.3 Neutrophils may be important in the early response to mycobacterial 
infection 
1.3.1 Animal data supporting an early protective role for neutrophils 
Evidence from the last two decades has suggested an important early function for 
neutrophils in host defence against mycobacteria: animal studies supporting this hypothesis 
are summarised in Table 1.1.   
Despite the findings in Table 1.1, the evidence is by no means consistent: in separate 
experiments, Seiler et al [24] concluded that granulocyte depletion had no effect on the 
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bacterial load of mice infected intravenously with 106 CFU of M.tuberculosis, M.bovis BCG or 
M.fortuitum. Saunders & Cheers also found no effect of granulocyte depletion (via RB6-8C5) 
on downstream bacterial burdens after 105 M.avium were introduced intra-nasally or intra-
peritoneally into wild-type or beige mice [25]. Zhang et al only demonstrated a detrimental 
effect of neutrophil depletion (via MAb NIMP-R14) on M.bovis BCG counts in IL-10 knockout 
mice rather than wild type following intranasal infection of 8 x 106 CFU [26]. Elsewhere, 
genetically ‘susceptible’ mouse strains infected with M.tuberculosis have been shown to 
exhibit enhanced early lung neutrophilia which correlates with reduced survival rates [27, 
28], as discussed in more detail later. 
In humans, it has been demonstrated that the risk of latent tuberculosis infection in 
contacts of patients with active disease is inversely proportional to the peripheral blood 
neutrophil count [29]. Data from a cohort of HIV-1-infected people in Soweto has also 
revealed that among those on anti-retroviral therapy the risk of tuberculosis is reduced by 
75% for each increase of 1.0 x 109/L in peripheral blood neutrophil count [30].  
These animal studies and epidemiological data suggest that the early protective functions of 
neutrophils in mycobacterial infection should be further explored.  
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Table 1.1. Animal models suggesting role of granulocytes / neutrophils in early control of 
mycobacterial infection. 
Study Animal Organism Route and 
dose 
Intervention Outcome 
Appelberg et al, 
1995 [31]
  
Mouse M.avium Intravenous; 
10
6 
CFU 
1.) Granulocyte 
depletion via MAb RB6-
8C5* in wild-type mice 
 
2.) Infusion of wild-type 
neutrophils into 
‘susceptible’ beige mice 
1.) Increased CFU 
compared to control 
wild-type mice 
 
2.) Decreased CFU 
compared to control 
beige mice 
Bermudez et al, 
1998 [32] 
 
Mouse M.avium Intravenous, 
10
7 
bacteria 
Admininstration of G-CSF Decreased CFU 
compared to control 
Petrofsky et al, 
1999 [33]
 
Mouse M.avium Intravenous, 
10
7 
bacteria or  
5 x 10
7 
bacteria 
Granulocyte depletion 
via MAb RB6-8C5* 
Increased CFU 
compared to control (if 
intervention at Day 0 , 
not at Day 14) 
Pedrosa et al, 
2000 [34]
 
Mouse M.tuberculosis Intravenous, 
10
5 
CFU 
Granulocyte depletion 
via MAb RB6-8C5*  
Increased CFU 
compared to control (if 
intervention within 
first week) 
Sugawara et al, 
2001 [35]
 
Mouse M.tuberculosis Airborne, 
~200 bacteria 
per animal 
NF-IL-6 mice with 
defective neutrophil 
function 
Increased CFU 
compared to wild type 
Fulton et al, 
2002 [36]
 
Mouse M.bovis BCG Intra-tracheal, 
3 – 5 x 10
3 
CFU 
1.) Granulocyte 
depletion via MAb 
RB6-8C5* 
2.) Neutrophil 
recruitment to lungs 
via intranasal MIP-2 
1.) Increased CFU 
compared to 
control 
2.) Decreased CFU 
compared to 
control 
Seiler et al, 2003 
[37]
 
Mouse M.tuberculosis Airborne,  
10 – 100 
bacteria per 
lung 
Granulocyte depletion 
via MAb RB6-8C5* 
Impaired granuloma 
formation 
Sugawara et al, 
2004 [38] 
 
Rat M.tuberculosis Airborne, 
~200 bacteria 
per animal 
Neutrophil recruitment 
to lungs via tracheal LPS 
Decreased CFU 
compared to control (if 
intervention within 
first week) 
Barrios-Payán et 
al, 2006 [39] 
 
Mouse M.tuberculosis Intra-tracheal, 
10
5 
bacteria 
Granulocyte depletion 
via MAb RB6-8C5* 
Increased CFU 
compared to control 
Martino et al, 
2010 [40]  
Mouse M.bovis BCG Skin (ear), 10
6 
CFU 
Neutrophil depletion via 
MAb NIMP-R14 
Increased influx of 
myeloid derived 
suppressor cells to site 
of infection with 
impaired downstream 
T cell responses 
* Note that caution should be applied to those experiments utilising the RB6-8C5 monoclonal antibody to 
effect depletion of granulocyte receptor-1 (Gr-1) positive cells: this may target the Ly6C antigen, expressed on 
plasmacytoid dendritic cells, monocytes and CD8+ T cells, in addition to the Ly6G antigen on neutrophils [41]. 
BCG = Bacille Calmette Guerin; MAb = Monoclonal antibody; MIP-2 = Macrophage Inflammatory Protein-2; 
CFU = Colony forming Units; LPS = lipopolysaccharide; G-CSF = Granulocyte-Colony Stimulating Factor 
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1.3.2 Neutrophils are recruited to the sites of infection, phagocytose 
mycobacteria and become activated 
Experimental work attempting to explain the observations detailed above has been limited 
and often conflicting. Only two facts are known with reasonable certainty: that neutrophils 
are rapidly recruited to the site of mycobacterial infection, and that they can phagocytose 
mycobacteria. 
 
1.3.2.1 Neutrophils are rapidly recruited to the site of mycobacterial infection. 
This was first noted in early observational work with animal models of infection (eg [1, 23, 
42]) and has since been confirmed by researchers using various organisms, animals and 
routes of infection [24, 26, 39, 43-48]. Most authors have noted that the accumulation is 
prompt: for example Long et al [1] describes the response at multiple sites after intravenous 
infection as ‘spectacular at one hour’, Feng et al [48] document hepatic infiltration by 
neutrophils within two hours of systemic challenge with Mycobacterium avium in wild type 
mice while Shigenaga et al [47] saw a polymorphonuclear cell reaction in rabbit skin after 
BCG infection within three hours, peaking at twelve hours. Abadie et al [17] documented 
neutrophils arriving at the site of dermal BCG infection by four hours. Zhang et al [26] using 
intranasal inoculation and Antony et al [44] using intrapleural inoculation found that the 
response peaked at twenty four hours. Only one model of intratracheal BCG pulmonary 
infection suggests a slower influx over one or two weeks [49]. 
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The mechanism by which the neutrophils are attracted to sites of mycobacterial infection is 
not fully characterised but, as discussed above, is most likely to arise as a response to 
cytokine and chemokine secretion from cells at the site of primary infection. These may be 
resident alveolar macrophages, whose pro-inflammatory response to mycobacterial 
challenge includes the secretion of IL-8, G-CSF, GM-CSF, TNF, MIP-2 [19, 50], cathelicidin (LL-
37) [51, 52] and probably LTB4 [53]. These cell products will also contribute to neutrophil 
priming and activation as they undergo endothelial adherence, trans-migration and 
chemotaxis. 
It should be noted however that there are other cellular targets at the site of initial 
infection, many of which may contribute to recruitment of neutrophils:  
 Resident dendritic cells in lung or gastrointestinal tract are potent antigen-
presenting cells and are significantly implicated in the early interaction with 
mycobacteria [54-59]. Ahrens et al have demonstrated that BCG-primed dendritic 
cells introduced experimentally into mouse lungs drive significant neutrophil 
recruitment [60].  
 Macrophage and dendritic cell-derived IL-23 and IL-12 (in combination with IL-6 or 
IL-1-β and transforming growth factor-β (TGF-β)) also activate the IL-17 pathway via 
γδ and Th17 T cells [61] to promote neutrophil influx: indeed it has recently been 
shown that M.tuberculosis infection in the absence of IL-17 reduces neutrophil 
recruitment to the lungs in mice [62]. These effects are probably mediated through 
the induction of cytokine release by other cells including epithelium, endothelium 
and fibroblasts – reviewed recently by Nembrini et al [63]. Intuitively this would be a 
slower mechanism of cell attraction, postulated by some to be responsible for a 
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second wave or ‘late-phase’ neutrophilia [5]. However, BCG challenge in mice has 
revealed IL-17 mRNA in lungs within the first day [64] and models of other infections 
suggest that even early (up to 18 hours) neutrophil recruitment can be significantly 
impaired by IL-17 receptor deficiency [65].  
 Epithelial cells can produce, among other cytokines, the neutrophil attractants IL-8, 
G-CSF, GM-CSF, Growth-related oncogene-α (Gro-α) and epithelial cell-derived 
neutrophil-activating peptide-78 (ENA-78) [63, 66-69] as well as up-regulating ICAM-
1 which will facilitate neutrophil migration through the epithelial layer [67]. They are 
also crucial intermediates in the IL-17 pathway [70]. 
 γδ-T cells are also known to secrete IL-8 and interact directly with neutrophils via 
CD30:CD30L binding [49, 71], in addition to their production of IL-17 discussed 
above.   
 Finally, it remains possible that the first cell encountered by inhaled or ingested 
mycobacteria may be the neutrophil itself: human studies on induced sputum even 
from healthy volunteers always reveal a significant population of neutrophils (27.3% 
to 47% of identified cells in the studies reviewed by Balbi et al [72]), believed to 
predominantly inhabit the larger airways. Studies in the mouse using fluorescently 
labelled M.tuberculosis have shown that following aerosol infection, neutrophils in 
the lung do indeed take up the bacteria [58]. Neutrophils are known to secrete a 
variety of molecules upon activation (as discussed later), of which at least IL-8, G-
CSF, Gro-α, IL-1β, TNF and LTB-4 are capable of further amplifying the neutrophil 
response [24, 33, 38, 73-77]. There is also in vitro evidence that neutrophils may 
produce IL-17, perhaps associated with the autologous synthesis of IL-15 [5]. Granule 
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products such as human neutrophil peptides (HNP) can also drive ongoing 
recruitment [78], as described in more detail below. 
 
Interesting observations from investigators in the early to mid-twentieth century indicated 
that the increased speed and extent of reaction to repeated mycobacterial challenge in 
‘sensitised’ or immunised animals still predominantly consisted of a polymorphonuclear cell 
infiltrate (eg Lemon and Feldman [42] (who quote examples from M.tuberculosis infection 
of skin, pleura and conjunctiva), Long et al [1] and Newhook et al [43]). One recently 
postulated mechanism for this phenomenon implicates IL-17 and IL-23 as key mediators 
[79], perhaps released from memory Th17 cells (in this case mediating pathology in BCG-
vaccinated mice post-M.tuberculosis infection). In addition, Lyons et al [80] have described 
enhanced IL-8 production from guinea pig macrophages in response to in vitro 
M.tuberculosis challenge 6 weeks after BCG vaccination.   
Whatever the initial signal, the local endothelium will become activated in response to 
inflammatory cytokines, with increased expression of adhesion molecules including ICAM-1, 
E-Selectin and P-Selectin [81]. This will contribute to a continuing neutrophil influx, as would 
any initiation of the complement cascade via generation of C5a. 
 
1.3.2.2 Neutrophils interact with and phagocytose mycobacteria including M.tuberculosis.    
It is well established that neutrophils can interact directly with and internalise mycobacteria 
[1, 24, 38, 58, 82-90]  including in vivo in humans with tuberculosis infection [91, 92]. Indeed 
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only one study which assessed neutrophil phagocytosis of mycobacteria has failed to 
demonstrate it [34]. 
As discussed earlier, the interaction between organisms and host cells is likely to be 
mediated via either direct recognition or opsonisation: 
 Direct recognition: studies conducted twenty years ago suggested the presence of 
pattern recognition receptors mediating the interaction between neutrophils and 
M.tuberculosis [83]; more recently evidence has accumulated for the role of Toll Like 
Receptors (TLR), and especially TLR2 in this capacity [82, 93, 94]. Two studies confirm 
the dissemination of M.avium [48] and M.tuberculosis [95] infection in TLR2 deficient 
mice – the former paper attributing this in part to a defect in early neutrophil 
function [48]. The mycobacterial target is thought to be surface lipoarabinomannan 
[96] or 19kDa lipoprotein [93]. TLR4 is also likely to be important in this regard since 
blocking TLR4 reduces neutrophil IL-8 production in response to BCG [97] and some 
authors contend that Complement Receptors 3 and 4 can bind M.tuberculosis 
directly [82]. Limited evidence exists for the role of mannose-binding lectin in 
enhancing neutrophil phagocytosis [98], although all these receptors are less well 
studied in neutrophils than in macrophages. 
 Opsonisation: as with other organisms, opsonisation appears to enhance 
mycobacterial internalisation – evidenced by the increased internalisation when 
serum is added to in vitro systems. Majeed et al [85] noted a 68% reduction in 
phagocytosis of M.tuberculosis by Ficoll-isolated neutrophils when serum was 
inactivated, and a 78% reduction without any opsonisation at all. Although 
investigators have been able to enhance phagocytosis using pooled serum from 
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purified protein derivative (PPD) negative [83] or non-vaccinated [99] individuals 
(presumably via complement components), others have demonstrated a specific role 
for antibodies. De Valliere et al discovered that the proportion of BCG organisms 
associated with Ficoll-separated human neutrophils increased from 75% before 
vaccination to 90% afterwards [88]. In these experiments, mycobacterial 
internalisation also increased, from 65% to 82%; by means of comparison, 
mononuclear phagocytes only internalised 23% of organisms before vaccination and 
32% after.  
In summary, neutrophils are recruited to sites of infection where they recognise 
mycobacteria, either directly or via opsonisation, and internalise them. Extravasation, 
stimulation by cytokines from cells at the infection site and interaction with microbial 
products will result in priming and activation. There is also now good evidence for the 
synthesis and secretion of cytokines and chemokines by polymorphonuclear granulocytes, 
including in the context of mycobacterial encounter. LPS-elicited alveolar neutrophils from 
rats with M.tuberculosis [38], morphologically-identified neutrophils in rabbit BCG lesions 
[47] and Ficoll gradient / nylon wool column-purified guinea pig neutrophils challenged with 
attenuated M.tuberculosis in vitro [100] have all revealed cytokine mRNA. In addition to the 
molecules detailed earlier, neutrophils produce IL-12, IL-6, IL-10, interferon-inducible 
protein of 10 kDa (IP-10), monokine induced by interferon-γ (MIG) and MIP-1α and MIP-1β 
[101, 102]. Cytokine or chemokine production at the protein level has been demonstrated in 
response to M.tuberculosis [34, 38, 74, 75, 103], M.avium [33] and BCG [26]. The 
transduction of stimulatory signals into activation phenotype and protein synthesis involves 
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a number of intracellular pathways beyond the scope of this thesis (reviewed recently by 
Kato & Kitagawa [104]).  
 
1.4   Neutrophil killing of mycobacteria 
Perhaps the most controversial question in this field is whether or not neutrophils can kill 
the mycobacteria they have internalised – especially virulent M.tuberculosis. Table 1.2 
summarises the in vitro studies directly addressing this issue (only one study per research 
group is included). Although a distinction is made in this table between ‘killing’ (a reduction 
in CFU as compared with inoculum) and ‘restriction’ (a slower increase in CFU versus 
controls), this may in part simply reflect test conditions: experiments which were 
terminated after only hours tended to demonstrate ‘killing’ whereas those allowed to 
proceed in co-culture for longer periods (presumably beyond the time when neutrophils had 
undergone cell death) tended to demonstrate ‘restriction’. ‘Restriction’ in this sense may 
therefore in fact represent early ‘killing’ to reach a lower baseline with subsequent growth 
at a similar rate to controls.   
As can be seen, a variety of models have been employed with differing results – but this is 
perhaps informative. Indeed the answer to the question ‘Can neutrophils kill mycobacteria?’ 
may be ’sometimes’. Whether or not they achieve success in one particular circumstance 
will be the result of numerous host and organism-specific factors, and may well be critical to 
the outcome of mycobacterial challenge: if efficient, neutrophils could theoretically halt the 
infection at a very early stage, but if ineffective then not only will the disease progress 
locally but the neutrophils might even traffic organisms to distant sites – especially if bacilli 
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reach the systemic circulation. Indeed Myers wrote in 1955, “When tubercle bacilli invade 
the body by any portal of entry they are ingested by neutrophiles, many of which enter the 
blood stream and are soon focalized in various places” [105]; a theory of granulocytic ‘Trojan 
horses’ has also been proposed more recently by Eruslanov et al [27], Eum et al [91] and 
Abadie et al [17], who observed neutrophils carrying live bacilli to draining lymph nodes. 
Furthermore, when Redford et al [62] demonstrated that anti-IL-17 treatment of mice 
during M.tuberculosis aerosol infection significantly reduced lung granulocyte numbers, this 
also correlated with a 100-fold decrease in the number of bacteria that were able to 
disseminate to the spleen, thus strengthening support for this theory. 
The importance of host variability in the outcome of this initial interaction has been noted 
by several authors who have used human cells for their experiments. Kisich et al [87], for 
example, found that killing of M.tuberculosis differed dramatically between donors: without 
cytokine stimulation, 2 out of 6 could not effect killing at all; when TNF was added to the 
culture killing varied between 50% and 95%. Neufert et al [93] commented on the fact that 
Percoll-isolated neutrophils were either consistently activated or consistently not activated 
upon challenge with 19kDa lipoprotein depending on the individual.  
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Table 1.2. In vitro studies of neutrophil killing / restriction of mycobacteria. 
Study Host / 
Donor 
Neutrophil 
purification 
method and 
validation 
Organism MOI 
(Neutrophils: 
Mycobacteria) 
Experimental 
read-out 
Time point 
after 
infection 
Killing / 
Restriction 
Smith et al, 
1979 [84]
  
Mouse Peritoneal irritation 
and harvest. >75% 
neutrophils by 
microscopy 
M.microti 
M.lepraemurium 
c. 1:2.5 
c. 1:10 
Microscopy / 
length 
estimation 
2 to 20 
hours 
- 
- 
Jones et al, 
1990 [106]
  
Human Ficoll gradient. 
Purity NR. 
M.tuberculosis 
(attenuated + 
virulent) 
10:1 or 1:1 Labelled CO2 
release + CFU 
1 hour and 
2 hours 
K 
Denis, 1991 
[107]
  
Human Ficoll gradient. 97% 
neutrophils 
(method NR). 
M.tuberculosis 1:1 to 100:1 CFU 30, 60 and 
120 minutes 
- 
Nibbering et 
al, 1993 
[108]
  
Human Ficoll gradient. 
Purity NR. 
M.fortuitum 1:1 CFU 60 and 120 
minutes 
K (although 
only in the 
presence of 
serum) 
Newman et 
al, 1997 
[109]
  
Human (HIV 
infected and 
uninfected) 
Ficoll gradient.  
95 – 98% 
neutrophils by 
microscopy 
M.avium 1:1 Radiometric 
assay (Bactec  
460TB) 
3, 4, 7 and 
10 days 
R 
Aston et al, 
1998 [110]
  
Human Ficoll gradient. 
Purity NR. 
M.bovis BCG 
M.tuberculosis 
1:15 
3
H-uridine 
incorporation 
+ CFU 
4 and 24 
hours 
- 
- 
Bermudez 
et al, 1998 
[32]
  
Mouse Ficoll gradient.  
> 97% neutrophils 
by microscopy 
M.avium 1:25 CFU 4 hours K 
Majeed et 
al, 1998 [85]
  
Human Ficoll gradient. 
Purity NR. 
M.tuberculosis 
(attenuated) 
10:1 CFU + 
radiometric 
assay 
2 hours K 
Hartmann 
et al, 2001 
[111]
  
Human Ficoll 
sedimentation. 
Purity NR. 
M.avium 1:5 CFU 15, 30, 45, 
60 and 120 
minutes 
K 
Kisich et al, 
2002 [87]
  
Human Percoll gradient. 
Purity NR. 
M.tuberculosis  c. 1:10 CFU 1 and 24 
hours 
K 
Coffey et al, 
2004 [112]
  
Human Ficoll gradient. 
>95% neutrophils 
by microscopy. 
BCG 1:1 Radiometric 
assay (Bactec  
460TB) 
48 hours R 
Sugawara et 
al, 2004 [38]
  
Rat LPS-induced 
alveolar 
neutrophils. >99% 
neutrophils by 
microscopy. 
M.tuberculosis  10:1 (+ in vivo) CFU ‘Over night’ K 
de Vallière 
et al, 2005 
[88]
  
Human Ficoll gradient. 
Purity NR. 
M.bovis BCG 1:1 
3
H-uridine 
incorporation 
+ CFU 
1, 3 and 7 
days 
R 
Eruslanov et 
al, 2005 [27]
  
Mouse Percoll gradient. 
>95% purity by 
microscopy. 
M.tuberculosis Various 
3
H-uracil 
uptake
 
24 hours - 
Reyes-
Ruvalcaba 
et al, 2008 
[113]
  
Human Ficoll gradient. 
>99% CD66b+ by 
flow cytometry 
M.tuberculosis 
M.gordonae 
M.gordonae 
(attenuated) 
100:1 
100:1 
100:1 
CFU 
 
24 hours - 
- 
K 
Corleis et al, 
2012 [114] 
Human Histopaque / 
Percoll gradient. 
99% by 
haematoxylin 
staining. 
M.tuberculosis 
M.smegmatis 
10:1 to 1:5 CFU 30 minutes 
to 6 hours 
- 
K 
Only one study is included per research group. K = killing (reduction in number of CFU); R = restriction (slower 
increase in CFU). BCG = Bacille Calmette-Guerin; CFU = Colony Forming Units; HIV = Human Immunodeficiency 
Virus; CO2 = Carbon dioxide; NR = Not Recorded; LPS = Lipopolysaccharide 
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1.4.1   Potential mechanisms of neutrophil killing of mycobacteria 
If neutrophils are indeed potentially capable of killing or restricting the growth of 
mycobacteria, the next question must be how? The potential mechanisms are detailed in 
Table 1.3. 
HNP, members of the α-defensin family, have attracted considerable attention regarding 
their potential anti-mycobacterial function. Stored in the azurophil granules of neutrophils, 
they are cationic proteins with six conserved cysteine residues connected by three 
disulphide bridges. They are thought to bind anionic molecules including components of 
plasma membranes resulting in disruption of membrane integrity and leakage of cellular 
contents [78, 115]. Intracellularly, other anionic proteins and DNA may well be targets for 
damage. Their potential to kill mycobacteria, including virulent M.tuberculosis, has been 
demonstrated in vitro by Kalita et al [116], Sharma et al [117] Miyakawa et al [118] and 
Martineau et al [29]. Sharma et al used exogenously administered HNP-1 in a mouse model 
of TB infection: after 4 weeks using a daily dose of 5mcg per animal there was at least a log10 
reduction in the number of CFU recovered from lungs and livers compared to controls [66].  
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Table 1.3 Potential mechanisms of mycobacterial killing in neutrophils. 
Mechanism Studies supporting 
killing or restriction 
via this mechanism in 
neutrophils 
Studies not supporting 
killing via this 
mechanism in 
neutrophils 
Notes 
Oxidative pathways Borelli et al, 1999 
[119]  
Kisich et al, 2002 [87] 
Gonzales-Cortes et al, 
2009 [120] 
Jones et al, 1990 [106] 
Brown et al, 1987 [121] 
 
Oxidative burst may be 
important in inducing 
apoptosis in neutrophils which 
have phagocytosed 
mycobacteria [122, 123]  
Reactive nitrogen 
intermediates 
Nil identified Kisich et al, 2002 [87]  Killing not inhibited by NG-
Monomethyl-L-Arginine (L-
NMMA) 
Human Neutrophil 
Peptides (HNP) 1-3 
Martineau et al, 2007 
[29] 
Sharma et al, 2000 
[117] 
Miyakawa et al, 1996 
[118]  
Kalita et al, 2004 [116] 
 
Nil identified Also proven effective in animal 
model: daily dose of 5mcg 
HNP-1 per rabbit for 4 weeks 
led to log10 reduction in the 
number of CFU recovered from 
lungs and livers compared to 
controls [66]  
Cathelicidin (LL-37) Martineau et al, 2007 
[29] 
 
Nil identified Potent chemotactic agent. 
In macrophages can induce  
autophagy which enhances 
elimination of M.tuberculosis 
[124] 
Lipocalin-2 Martineau et al, 2007 
[29] 
 
Nil identified Binds siderophores to reduce 
iron availability to pathogens 
Neutrophil Extracellular 
Traps (NETs) 
Nil identified Ramos-Kichik et al, 
2009 [125]  
NETs stimulated by 
M.tuberculosis but did not 
restrict growth 
mcg = microgrammes; CFU = Colony forming units. 
However, their utility during in vivo neutrophil-mycobacteria interaction must be considered 
cautiously following the results of two independent studies which have demonstrated 
failure of fusion of the neutrophil phagosome with azurophil granules [89, 126], a 
phenomenon replicated with M.avium, M.kansasii, M.smegmatis and M.tuberculosis. 
Furthermore, the gene lysX has been identified in M.tuberculosis, homologous to the 
Staphylococcus aureus mprF [127]: this serves to increase the lysine content of membrane 
lipids, thereby decreasing the negative charge and reducing susceptibility to HNP.    
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Despite these caveats, the function of HNP may not be limited to killing within 
polymorphonuclear cells. In vitro, free HNP can be taken up by macrophages and this 
enhances their control of M.tuberculosis [117]. Tan et al have also demonstrated 
phagocytosis of granules or entire apoptotic neutrophils by mononuclear cells and 
trafficking of their contents to endosomes – again with enhanced restriction of growth 
[128]. 
HNP are also thought to possess numerous other functions in the course of infection, 
including modulating cytokine production, promoting chemotaxis – especially of 
mononuclear phagocytes – acting as opsonins and even influencing T cell / B cell interaction 
and antibody response [78]. To what extent these aspects are significant in human 
mycobacterial infection remains unclear: all that is known for certain is that HNP are present 
in high concentration at the disease site of active TB (for example, Ashitani et al [129] 
discovered bronchoalveolar fluid α-defensin concentrations of 1,245 ± 314 ng/mL in 
patients with TB versus 14 ± 4 ng/mL in controls). 
Cathelicidin (LL-37) is another anti-microbial peptide of interest. A potentially important 
chemotactic agent [130], cathelicidin has also been demonstrated to induce autophagy and 
then promote the autophagosomes to co-localise with mycobacterial phagosomes in 
macrophages [124]. This Vitamin-D dependent pathway enhances the elimination of 
M.tuberculosis. Although neutrophil production of cathelicidin is also enhanced by 1,25-
dihydroxy Vitamin D [131] and neutrophils have been demonstrated to undergo autophagy 
[132], the link between these phenomena and their importance for restricting mycobacteria 
has not been specifically investigated in this cell type.  
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Coffey et al have demonstrated that the leukotriene LTB4 enhances neutrophil-mediated 
killing of M.bovis [112], although this is likely to be via the enhancement of one of the above 
pathways rather than any direct mycobactericidal effect. 
The ability of neutrophils to directly kill organisms, probably via non-oxidative mechanisms, 
may be of great importance as a ‘first line of defense’ against tuberculosis which will be 
successful in some people but fail in others. Even if it does fail, components of their armoury 
may still be used by mononuclear phagocytes. 
However, the role of the neutrophil is unlikely to end there, and to consider killing as their 
sole purpose or capability would be overly simplistic.  
 
1.5   Neutrophil – macrophage co-operation and the initial outcome of 
mycobacterial infection 
Regardless of whether neutrophils are mycobactericidal, the data presented above confirm 
that neutrophils accumulate at sites of mycobacterial challenge and rapidly phagocytose 
bacilli. Described as short-lived cells in the steady-state, with highly cytotoxic contents, they 
must subsequently be removed from tissues: this process is usually dependent on 
mononuclear phagocytes recruited from the circulating blood. It is thus perhaps not 
surprising that neutrophils secrete products which attract inflammatory monocytes. This 
was noted in experimental tuberculous pleural effusions in 1983 [45], when a putative but 
un-named chemo-attractant was identified. More recently using an alternative model of 
inflammation, Soehnlein et al have suggested that LL-37 and Heparin Binding Protein from 
neutrophil granules may be the most important early mediators of this process [130] – 
although there is likely to be redundancy in the system: several of the cytokines and HNP 
39 
 
detailed earlier as neutrophil products are capable of driving monocyte recruitment from 
blood, and Fietta et al have demonstrated in vitro that mycobacterial lipoarabinomannan 
itself stimulates macrophage chemotaxis [86].  
Once monocytes have migrated into tissues and matured, the cytokine profile of both 
monocytes and neutrophils may well drive further accumulation and activation [75, 130, 
133], although it is possible that an anti-inflammatory pattern will predominate. Indeed, 
mounting evidence suggests that there is considerable plasticity in neutrophil cytokine 
responses, and that production of the regulatory cytokine IL-10 could be the dominant 
outcome of some microbial or inflammatory challenge [26, 134]. Although IL-10 may be 
essential for regulating inflammation in mycobacterial disease [26, 135], in excess it may 
impair macrophage responses, the development of effective acquired immunity and long-
term control of infection [26]. Evidence from patients with melanoma suggest that these 
‘suppressive neutrophils’ may be induced by Serum Amyloid A [134], a protein known to be 
elevated in M.tuberculosis infection [136].   
Whichever cytokines they may release, the ultimate fate of most neutrophils is to die in situ 
and be ingested by mononuclear phagocytes. The mode of neutrophil cell death (and 
subsequent response in the phagocytosing macrophage) may be crucial to the progress of 
mycobacterial infection: see Figure 1.1. Most studies which have addressed these questions 
have witnessed accelerated apoptosis in neutrophils following mycobacterial internalisation, 
possibly dependent on oxidative processes [82, 90, 120, 122, 123], enhanced by high local 
concentrations of TNF [94] and potentially mediated via TLR2-dependent pathways [82], 
although whether this advantages host or pathogen is unclear. Apoptosis is traditionally 
considered as an ‘anti-inflammatory’ process, inducing TGF-β and prostaglandin E2 but 
reducing IL-6, IL-8, IL-12 and TNF production in the phagocytosing macrophage [137]. 
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However, it is recognised that at times the ingestion of an apoptotic cell, especially one that 
has consumed a pathogen, may result in a pro-inflammatory outcome [138], perhaps due to 
the expression of heat shock proteins [123] or activation of the macrophage by neutrophil 
proteases [139]. The pattern of cytokine release from the neutrophils before death may also 
be critical in determining this response, as discussed above. 
Perhaps not surprisingly then, assessment of the subsequent reaction in the phagocytosing 
macrophage has yielded divergent results: pro-inflammatory (primarily greater TNF release) 
in the work of Perskvist et al  [122] and Persson et al [123] using M.tuberculosis with Ficoll-
isolated human peripheral blood cells, but anti-inflammatory in the experiments of D’Avila 
et al using BCG with Percoll-isolated murine bone marrow neutrophils and peritoneal-
derived macrophages [90]. Although the difference in host or organisms may be the sole 
explanation for this disparity, it may be that both outcomes can occur in vivo, with an 
advantage conferred either to the host or pathogen (Figure 1.1). None of these studies have 
assessed the viability of mycobacteria at the point of macrophage phagocytosis, but one 
could postulate that if they had been killed then the best outcome from a host perspective 
would be ‘quiet’ anti-inflammatory clearance of the neutrophil (Outcome 1, Figure 1.1), 
whereas if they were still viable then macrophage activation and antigen presentation 
would be preferable (Outcome 4, Figure 1.1). From the pathogen perspective, evading killing 
in the neutrophil and then inducing a ‘tolerogenic’ macrophage response may well enable 
propagation of the infection (Outcome 3, Figure 1.1), a theory already proposed for other 
intracellular organisms including Leishmania species [140].  
Necrosis is usually considered an undesirable mechanism of cell death, driving further 
inflammation and cell recruitment. There is also evidence from macrophage models that 
while apoptotic cell death achieves mycobacterial control, necrosis does not [141]; 
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furthermore, necrosis may prevent the cross-presentation of mycobacterial antigens to 
bystanding antigen-presenting cells via apoptotic vesicles [142, 143]. However, if a 
neutrophil cannot kill an ingested organism then theoretically necrosis could become a 
‘salvage’ mechanism ensuring that an inflammatory reaction is more likely (although still not 
guaranteed [137, 144]) in a macrophage when it phagocytoses the neutrophil.  
It should be noted that various other aspects of neutrophil-macrophage co-operation in 
intracellular infection have been proposed, including: 
 Ingestion of HNP by macrophages, trafficking into endosomes and subsequent 
enhanced killing, as discussed above [117, 128, 145].  
 Direct cellular contact driving transcriptional changes – Hoshino et al [146] for 
example discovered that using co-stimulatory receptors neutrophils can up-regulate 
the production of pro-inflammatory cytokines in M.tuberculosis infected 
macrophages. 
 Potentially direct transfer of live organisms from neutrophil to antigen-presenting 
cell, although only observed hitherto with dendritic cells [147]. 
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Figure 1.1. Neutrophil-Macrophage interaction in the early stages of tuberculosis infection. 
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1.6   Neutrophils have direct influence on the development of the acquired 
immune response  
Neutrophils are thought to directly impact the development of T cell responses, beyond 
their interaction with macrophages. Neutrophils in mice and humans produce IL-12 (p40 
and p70) as well as chemokines such as IP-10, MIG, MIP-1α and Monocyte chemoattractant 
protein-1 (MCP-1) [33, 37, 148] which can attract T lymphocytes and direct their 
maturation. However, neutrophils might also produce IL-10 during BCG or M.tuberculosis 
infection, thus in some circumstances might limit protective acquired immune responses 
[26, 135]. Other neutrophil products could also be important. HNP administered to mice 
intranasally enhanced subsequent antigen-specific antibody production as well as 
proliferative CD4+ T cell responses and the production of IFN-γ, IL-5, IL-6 and IL-10 by T cells 
[149]. A component of neutrophil secondary granules, lactoferrin, improved the outcome of 
vaccination when administrated as an adjunct to BCG. In these mice, IFN-γ production by T 
cells increased and disease burden reduced during subsequent M.tuberculosis infection 
[150].  
Neutrophils might communicate with dendritic cells (DCs) to deliver activation signals and 
possibly even directly transfer organisms or antigens [147]. T cell responses following 
activation by DCs that had interacted with neutrophils were enhanced in experiments using 
M.bovis: both CD4 T cell IFN-γ release and CD8 T cell cytotoxicity were increased [147]. 
Neutrophil-DC cross-presentation and increased lymphocyte proliferation has also been 
described in response to M.tuberculosis [143]. In vitro DCs that acquired M.tuberculosis 
antigen via an apoptotic neutrophil migrated more efficiently than directly infected DCs 
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[151]. Furthermore, neutrophil depletion in mice (using the 1A8 Ly6G-specific antibody) 
reduced DC migration to lymph nodes and delayed T cell activation during M.tuberculosis 
infection [151]. Also in a mouse model, but with BCG as the pathogen, depletion of 
neutrophils using MAb NIMP-R14 enhanced recruitment of ‘myeloid derived suppressor 
cells’ to the site of infection which then impaired downstream T cell responses compared to 
mice with intact neutrophil populations [40].  
Although these results suggest that neutrophils enhance the ability of DCs to elicit T cell 
responses, in a non-infection model DC-induced CD4+ T cell activity was impaired in the 
presence of neutrophils [152]. This could result from ‘competition’ for the hen egg lysozyme 
antigen used in this study, wherein neutrophils destroy proteins before antigen 
presentation has occurred. This phenomenon could explain an observation seen in B cell-
deficient mice where an excessive neutrophil influx to the site of BCG vaccination actually 
impaired downstream T cell responses and protection from subsequent infection with 
M.tuberculosis [153]. 
In some circumstances granulocytes might present antigen directly. Neutrophils identified in 
tuberculous pleural effusions on the basis of CD16, CD11b and CD64 expression and 
characteristic light scatter, expressed major histocompatibility complexes (MHC) II as well as 
the co-stimulatory molecules CD83 and CD86 [94]. This surface marker pattern is more akin 
to that of DCs, although the ability to present antigen was not directly tested.  
Activated lymphocytes produce IFN-γ, which induces a gene expression pattern in 
neutrophils associated with enhanced function.  However, in vitro IFN-γ had no effect on the 
capacity of human neutrophils to limit mycobacterial growth [87], and in mice in vivo IFN-
γinhibited neutrophil accumulation in infected lungs and impaired neutrophil survival 
during M.tuberculosis infection [154]. Overall, there is more evidence for pro-inflammatory 
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rather than suppressive effects of neutrophils on macrophages, DCs and T cells in early 
mycobacterial infection. However, the response may well be flexible and a range of 
outcomes are possible depending on neutrophil number and behaviour. Indeed, as 
discussed above, a suppressive influence may well be appropriate if the neutrophils had 
effectively cleared the infection. This flexibility carries the risk of inappropriate outcomes 
however, from inadequate immune activation through to excessive inflammation. These 
factors may have particular significance in the context of BCG vaccination as well as in 
determining the initial host response to M.tuberculosis exposure. 
 
1.7   Neutrophils accumulate in active TB, especially in the context of a poorly 
functioning acquired immune response 
Although the classical formation of a granuloma involves the co-operation of mononuclear 
phagocytes and lymphocytes, it is clear that neutrophils are often still present at sites of 
active mycobacterial disease [91, 92, 129, 155, 156]. Indeed there even appears to be some 
correlation between severity of disease and extent of local neutrophilia. Certainly 
neutrophils are highly represented in cavitatory pulmonary tuberculosis [155, 156] and 
tuberculous cold abscesses (personal observations). Studies in genetically ‘susceptible’ as 
compared to ‘resistant’ mouse strains have linked neutrophilia with  poor disease outcome 
or survival [27, 28]. Abdul-Majid et al [157] also noted a more granulocytic response with 
virulent compared to attenuated organisms in a mouse model, correlating with the worse 
clinical outcome in these infections.  
There is evidence from animal studies to suggest that a polymorphonuclear response is the 
outcome of an exacerbated or inappropriately functioning immune system in the face of 
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established mycobacterial infection. Many murine studies involving susceptible mice on a 
particular genetic background and/or a disruption to immunological function resulting in 
exacerbated disease after mycobacterial challenge have demonstrated excessive neutrophil 
influx at the site of disease (Table 1.4).  
As can be seen, a diverse set of conditions all create the same outcome of marked 
neutrophil influx.  Occasional apparent inconsistency in the literature might reflect 
differences between organisms and disease sites. For example, TLR2-deficient mice 
demonstrated reduced hepatic neutrophil influx in response to systemic M.avium infection 
[48], but excessive pulmonary neutrophil influx in a study using airborne M.tuberculosis 
[95]. Murine T cells in peritoneal BCG or M.avium infection have been reported to drive 
neutrophil recruitment [133, 158], yet in T cell-deficient mice with respiratory tuberculosis 
excessive granulocyte influx is observed [159].  
Most authors recognise association between neutrophil influx and the extent of pathology: 
there is likely to be a ‘vicious circle’ in which tissue injury causes neutrophil attraction and 
the neutrophils themselves cause more damage through the release of their cytotoxic 
contents. There is also evidence that the endothelial mediators of neutrophil migration L-
Selectin, E-Selectin and ICAM-1 are up-regulated in active TB [160], which presumably 
contributes to this process. If the neutrophils cannot be cleared by mononuclear phagocytes 
following apoptosis then they will proceed to necrosis (so-called ‘secondary necrosis’) [137] 
with further inflammatory consequences. Of note, Cardona et al induced necrosis in the 
granulomas of mice with established infection by provoking neutrophil influx via nasal 
lipopolysaccharide administration [161]. 
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Table 1.4. Mouse models resulting in excessive neutrophilic influx in response to 
mycobacterial infection. 
Study Organism Intervention / Defect 
Cooper et al, 1993 [162] 
[see also [154, 163]] 
M.tuberculosis Interferon-γ gene disrupted mice 
Saunders et al, 1996 [25]
  
M.avium Beige mice (akin to human Chediak-Higashi 
syndrome) 
D’Souza et al, 1997 [164]
  
M.tuberculosis γδ T cell knockout [TCR C-δ gene mutant mice] 
Cooper et al, 2000 [165]
  
M.tuberculosis Impaired superoxide production by the NADPH 
oxidase [p47(phox) gene knockout] 
Peters et al, 2001 [166]
  
M.tuberculosis CCR2 knockout 
Abel et al, 2002 [167]
  
M.tuberculosis TLR-4 mutant [C3H/HeJ mouse] 
Kipnis et al, 2003 [168]
  
M.tuberculosis CD44 gene-disrupted [CD44 is an adhesion receptor 
involved in multiple
 
functions including tissue 
remodeling and T cell extravasation] 
Sugawara et al, 1993 [95]
  
M.tuberculosis TLR2-knockout  
Eruslanov et al, 2005 [27]
  
M.tuberculosis Polygenically ‘susceptible’ [I/StYCit mice] 
Feng et al, 2006 [159]
  
M.tuberculosis T cell deficient [RAG(-/-) mice] 
Keller et al, 2006 [28]
  
M.tuberculosis Polygenically ‘susceptible’ [CBA/J and DBA/2 mice] 
Maglione et al, 2007 [169]
  
M.tuberculosis B cell deficient [B cell(-/-) mice] 
Fremond et al, 2007 [170] 
[see also [171]] 
M.tuberculosis MyD88 deficient [MyD88(-/-) mice] and IL-1-R1 
deficient [IL-1-R1(-/-) mice] 
Beisiegel et al, 2009 [172]
  
M.tuberculosis iNOS defiency [iNOS(-/-) mice] 
Carlos et al, 2009 [173]
  
M.tuberculosis Histamine deficient [histidine decarboxylase knockout 
mice] 
Dorhoi et al, 2010 [135]  M.tuberculosis CARD9 deficient [CARD9(-/-) mice; CARD9 is an 
adaptor molecule regulating signals from pattern 
recognition receptors including Toll Like Receptors.] 
Lázár-Molnár et al, 2010 
[174] 
M.tuberculosis PD-1-deficient mice 
BCG = Bacille Calmette-Guerin; TLR = Toll Like Receptor; NADPH = nicotinamide adenine dinucleotide 
phosphate; iNOS = inducible Nitric Oxide Synthase; TCR = T cell Receptor; CCR = C-C chemokine receptor; IL-1-
R1 = Interleukin 1 Receptor 1; MyD88 = Myeloid differentiation primary response protein 88; CARD9 = Caspase 
recruitment domain containing protein 9. PD-1 = Programmed Death Ligand 1. 
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Despite this neutrophil-mediated damage, whether the overall net effect of neutrophils in 
established disease is positive or negative for the host has not been fully resolved. To 
address this question the granulocyte response was abrogated (using RB6-8C5) in anti-IFN-γ 
treated, T cell-deficient mice prior to, and during, M.tuberculosis infection. This resulted in 
more extensive infection and tissue destruction [159], suggesting that the neutrophils were 
in fact playing a protective, compensatory role - although since the intervention was prior to 
infection this could simply reflect an early mycobactericidal effect of neutrophils, as 
discussed earlier. Conversely, depletion of granulocytes (using the 1A8 antibody) in IFN-γR-/- 
mice with established M.tuberculosis infection extended survival [154]. Similarly, depletion 
(using RB6-8C5 or anti-G-CSF antiserum) in genetically ‘susceptible’ DBA/2 mice also 
extended survival when mice were subsequently challenged with a large inoculum of 
M.tuberculosis [28]. In fact the neutrophils in ‘susceptible’ mice may contribute to the 
establishment of infection: in one susceptible phenotype (I/StYCit) neutrophils demonstrate 
enhanced phagocytosis but impaired killing and delayed apoptosis [27], perhaps the ideal 
characteristics for ‘Trojan horses’. 
Dorhoi et al [135] also demonstrated improved survival after granulocyte depletion (via 
anti-Gr-1 or anti-G-CSF) in their CARD9-knockout mice challenged with airborne 
M.tuberculosis. Without depletion, these mice suffered an excessive granulocytic response 
and early death. Both “frustrated” neutrophils (releasing cytotoxic contents when unable to 
effectively clear pathogens) as well as a lack of regulatory IL-10 production were suggested 
as the cause of granulocyte-mediated pathology here. Neutrophil depletion (using MAb 
NIMP-R14) during chronic M.tuberculosis infection also reduced the CFU recovered from 
BALB/c mice [26], although in this study excess IL-10 from neutrophils was implicated. 
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Interpreting these data is difficult, especially since the neutrophils themselves may not 
behave ‘conventionally’ in gene-knockout animals. However, depleting neutrophils in the 
context of immune dysfunction and established tuberculosis infection does seem on balance 
to benefit the host.  
Although it is more difficult to study disease sites in humans, existing data from peripheral 
blood suggest that neutrophilia might also associate with poor prognosis in tuberculosis 
patients. One study has indicated that high neutrophil percentage at diagnosis predicts 
death or respiratory failure [175]; ‘leukocytosis’ has also been independently associated 
with mortality by others [176, 177]. Higher neutrophil counts at baseline have also been 
shown to predict slower sputum conversion to negative during anti-tuberculosis therapy in 
two separate studies [178, 179].  
Moreover, neutrophilia has been noted to be common in tuberculosis [180, 181]. Indeed, in 
studies I have identified that report both the prevalence of neutrophilia and abnormality of 
lymphocyte number (lymphocytosis or lymphopenia) in tuberculosis, neutrophilia was seen 
in between 25% and 57% of patients, and was the most common abnormal haematological 
finding reported (Table 1.5).  
Table 1.5. Reported prevalences of neutrophilia, lymphopenia and lymphocytosis in 
tuberculosis patients. 
Study Year Country No. of 
patients 
Tuberculosis 
disease site 
% of patients 
with 
neutrophilia 
% of patients 
with 
lymphopenia 
% of patients 
with 
lymphocytosis 
Morris et al [182] 1989 South Africa 265 Pulmonary 57 23 17 
Sharma et al [183] 1995 India 80 Miliary 25 3.8 NR 
Akintunde et al 
[184] 
1995 Nigeria 50 Pulmonary 40 46 6 
Wessels et al [185] 1999 South Africa 138 All sites 56 28 26 
Olaniyi et al [186] 2003 Nigeria 62 Pulmonary 45 5 8 
Hussain et al [176] 2004 India 110 Miliary 30 71 0 
 Weighted mean % 46.7 29.4 12.6 
Unweighted mean % 42.2 29.5 11.4 
NR = Not Recorded. 
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A neutrophil-driven IFN-inducible transcript signature has recently been described in the 
blood of patients with active TB [187] which correlates with lung radiographic disease 
severity, potentially implicating neutrophils directly in the pathogenesis of active TB. 
Programmed Death-1 (PD-1) ligand, predominantly expressed by neutrophils during TB 
disease, is a possible pathogenic factor [188]. The PD-1/PD-1 ligand axis has previously been 
demonstrated to inhibit T cell effector functions during tuberculosis infection [189]. 
However PD-1 or PD-1 ligand knockout mice show exaggerated pathology and paradoxically 
excess neutrophil influx to sites of disease (Table 1.4), perhaps due to loss of control of 
excessive inflammation [174]. It seems therefore that either PD-1 excess or deficiency may 
result in neutrophil-associated pathology, highlighting once again the fine balance that is 
required for an effective immune response.  
Of note, a proportion of people with latent tuberculosis infection demonstrated the same 
neutrophil-driven IFN-inducible blood transcript signature [187], suggesting that these may 
be the individuals more at risk from disease reactivation – although potential mechanisms 
for this remain unknown. 
The weight of evidence thus associates neutrophils with pathology and disease severity in 
active tuberculosis, although it remains unclear whether they are the cause, the effect or 
both. They may simply accumulate in response to uncontrolled inflammation and cause 
tissue damage via release of cytotoxic contents. However, it is also possible that given the 
appropriate signals they may specifically orchestrate the events required for disease 
progression. 
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1.8   The potential impact of HIV-1 on neutrophil anti-mycobacterial function 
HIV-1 and tuberculosis are inextricably entwined: the immune suppression and 
dysregulation of HIV-1 infection predisposes to an increased risk of TB and a more rapid and 
atypical clinical course, while TB hastens the progression of HIV-1 disease [190]. 
There is some existing evidence that although not directly infected, the functional capacity 
of neutrophils is compromised in people with HIV-1 infection. They have been described to 
exhibit decreased chemotaxis [191, 192], impaired fungicidal activity [191, 193, 194] and in 
vivo activation with dysfunctional responses to stimulation [194, 195]. HIV-1 infection also 
directly causes neutropenia in some cases [196], perhaps due to diminished G-CSF 
production [197] or an effect of viral ‘negative factor’ (Nef) on the bone marrow [198]. 
Accelerated apoptosis of peripheral blood neutrophils in HIV-1 patients has been described 
[199]: this appears to be both ‘spontaneous’ and Fas / Fas Ligand induced, the latter 
potentially a consequence of chronic immune activation. One can thus hypothesise that 
some of the increased susceptibility of HIV-1 infected patients to TB may be mediated by 
this impairment of both neutrophil number and function, factors which have been 
demonstrated to recover with treatment [191, 194, 200]. 
In one study, mycobacterial restriction by whole blood following initiation of antiretroviral 
therapy in children was demonstrated to improve, but restriction did not correlate well with 
CD4 count, or with supernatant interferon-γ or TNF concentrations [201].  Using the same 
model, neutrophils have been shown to be important mediators of mycobacterial control in 
blood [29] and hence one can postulate that improvement in neutrophil function was 
responsible for some of the observed effect of antiretrovirals.  
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1.9   Conclusions 
The ideas presented here form the basis for the work in this thesis. First, as no robust and 
reproducible assays existed to assess neutrophil-mediated restriction and phagocytosis of 
mycobacteria, it was necessary to develop these techniques. Subsequently I used these and 
other techniques to assess the effect of HIV-1 on neutrophil-mediated anti-tuberculous 
activity and cell death, and to determine whether anti-retroviral therapy improved any 
neutrophil dysfunction. I proceeded to investigate whether the neutrophil response against 
mycobacteria could be improved via the addition of micro-nutrients, or via the 
augmentation of neutrophil numbers in whole blood. I investigated the effect of live and 
dead neutrophils in modifying the acquired immune response in human whole blood, and 
the impact of neutrophils on BCG vaccination responses in a mouse model. Finally I analysed 
a cohort of tuberculosis patients to determine the determinants of neutrophilia and 
whether neutrophilia in active disease is an independent predictor of mortality. 
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2. Materials and Methods 
This chapter describes the materials and methods employed in this thesis. I was assisted in 
many experiments by Nonzwakazi Bangani. Others who assisted with this work are 
acknowledged where appropriate.  
 
2.1  Human Participants 
A brief overview of the cohorts of participants recruited for this thesis are presented in Figure 
2.1 HIV-1-infected patients for the cross-sectional and prospective South African studies were 
recruited from the Ubuntu HIV clinic, Site B Khayelitsha, Western Cape, South Africa. 
Asymptomatic patients eligible for antiretroviral therapy were identified by clinic counsellors 
and referred to study staff for assessment of eligibility.  
HIV-1-uninfected control patients for the cross-sectional study were recruited from the 
Khayelitsha Site B Youth Centre, following a negative HIV test result. Full inclusion and 
exclusion criteria for these participants are detailed in Table 2.1. These studies were approved 
by the University of Cape Town Research Ethics Committee (HREC 545/2010) and all 
participants provided written informed consent. 
All participants eligible for the study attended our laboratory site at the University of Cape 
Town to donate blood samples. On the first visit, details were taken on date of birth, country 
of birth, ethnicity, use of tobacco or alcohol, medical history (including history of tuberculosis), 
current medication and any current symptoms. Participant weight, temperature and pulse 
rate were measured, and the presence of a BCG scar was recorded.  
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Figure 2.1. Basic description of the cohorts of participants recruited for this thesis.
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Blood was taken by me or by Rene Goliath. In addition to experimental samples, we 
collected blood for full blood count, C-Reactive Protein (CRP) and, in HIV-1-infected patients, 
CD4 count and HIV-1 viral load measurement: these assays were performed by the National 
Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa.  
HIV-1-infected patients were invited to attend follow-up visits at 1, 3 and 6 months after 
commencement of antiretroviral therapy. At subsequent visits, participant weight, 
temperature and pulse rate were measured and details were collected on any current 
symptoms or new medication. Blood was collected for the same samples as detailed above. 
Participants for the United Kingdom (UK) cross-sectional ex vivo study were recruited from 
the tuberculosis contact clinic at Northwick Park Hospital, Harrow, UK. Contacts were 
identified by Tuberculosis specialist nurses at the time of Mantoux testing and referred to 
study staff. Participants were recruited when returning for the ‘reading’ of the Mantoux test 
after 48 hours. Inclusion and exclusion criteria are also detailed in Table 2.1. This study was 
approved by the Charing Cross Research Ethics Committee (REC 10/H0711/9) and all 
participants provided written informed consent. 
All participants were assessed for eligibility before taking blood samples. Details were taken 
on date of birth, country of birth, ethnicity, use of tobacco or alcohol, medical history 
(including history of tuberculosis), current medication, any current symptoms and the site of 
tuberculosis disease in their infected contact. The presence of a BCG scar was recorded and 
Mantoux induration was measured (defined as positive if ≥ 15mm with a history of BCG 
vaccination or ≥ 5mm in the absence of prior BCG vaccination). In addition to experimental 
samples, blood was also collected for full blood count, HIV testing and other tests as 
determined by the clinical services at Northwick Park Hospital (urea and electrolytes, liver 
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function tests, CRP): these assays were performed by the laboratories at Northwick Park 
Hospital. Participants underwent chest radiography if Mantoux testing was positive 
according to local clinical protocols. 
Tuberculosis patients analysed for determinants of neutrophilia and mortality were 
identified by retrospective review of databases and case-notes from the tuberculosis 
departments of Newham University Hospital Trust (NUHT) and King’s College Hospital (KCH), 
both in London, UK. This data extraction was performed by Dr Asela Bandara (analysis was 
performed by me). All patients diagnosed with active tuberculosis between 1999 and 2006 
were eligible for inclusion in the analysis of prevalence and determinants of neutrophilia at 
diagnosis; those who had a recorded outcome of either completing treatment or death 
were included in the analysis of determinants of mortality. Healthy contacts of tuberculosis 
cases were recruited from the same hospital sites; Dr Adrian Martineau recruited contacts 
at NUHT. The retrospective review of tuberculosis patient data and KCH contacts was 
approved by the Barking and Havering NHS Research Ethics Committee, London, UK (REC 
08/H0702/25). Written consent from participants was not required for this component of 
the study. The Newham healthy  contact study was approved by the North East London 
Research Ethics Committees, London, UK (REC P/02/146) and written informed consent was 
provided as previously described [202].  
Further experiments in this thesis were performed on healthy laboratory donors who 
provided verbal or written consent, as indicated in the relevant chapters.  
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Table 2.1. Inclusion and exclusion criteria for laboratory studies. 
 Inclusion criteria Exclusion criteria 
HIV-1-uninfected 
control patients 
(South Africa) 
HIV-1 uninfected 
No current symptoms of 
tuberculosis or bacterial 
infection 
Provides informed consent 
 
Age under 18 years 
Age over 70 years 
Known primary immunodeficiency / neutrophil disorder 
Current / recent (within last 3 months)  use of 
immunosuppressive drugs including corticosteroids 
Unable to satisfactorily retain and use information for 
decision-making  
Current symptoms of infection  
Currently taking antibiotics 
Known renal failure or hepatic impairment 
HIV-1-infected 
patients (South 
Africa) 
HIV-1 infected 
Agrees to start antiretroviral 
therapy and meets Site B 
antiretroviral clinic criteria for 
starting 
No current symptoms of 
tuberculosis or bacterial 
infection 
Provides informed consent 
 
Age under 18 years 
Age over 70 years 
Known primary immunodeficiency / neutrophil disorder 
Current / recent (within last 3 months)  use of 
immunosuppressive drugs including corticosteroids 
Unable to satisfactorily retain and use information for 
decision-making  
Known renal failure or hepatic impairment 
Any antimicrobial therapy other than antiretrovirals and co-
trimoxazole 
Tuberculosis 
contacts (United 
Kingdom) 
Contact of proven or treated 
case of tuberculosis identified 
by tracing exercise 
No current symptoms of 
tuberculosis or bacterial 
infection 
Having Mantoux test as part 
of NHS care 
Provides informed consent 
 
Age under 16 years 
Age over 70 years (possible immunosenescence) 
Pregnancy (possible immune dysregulation) 
HIV-1 positive (current test required) 
Significant abnormalities of white blood cell count (any 
lineage >10% outside reference range)  
Known primary immunodeficiency / neutrophil disorder 
Current / recent (within last 3 months)  use of 
immunosuppressive drugs including corticosteroids 
Unable to satisfactorily retain and use information for 
decision-making  
Current symptoms of active tuberculosis 
Current symptoms of other infection or currently taking 
antibiotics 
Known renal failure or hepatic impairment 
HIV = Human Immunodeficiency Virus; NHS = National Health Service. 
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2.2  Animals 
Six-to-eight-week–old specified pathogen-free (SPF) female C57BL/6 mice were used in all murine 
experiments. Animals were obtained from the University of Cape Town (UCT) Animal Breeding 
Facility. All procedures were performed in Bio-Safety Level-2 (BSL-2) animal facilities at the 
University of Cape Town (UCT). Procedures were approved by the UCT Laboratory Animal Ethics 
Board. 
 
2.3   Mycobacterial culture, preparation and storage 
Central to many of the experiments in this thesis are the plasmid-transformed luminescent 
organisms Mycobacterium bovis BCG-lux (BCG-lux) and Mycobacterium tuberculosis H37Rv-lux 
(M.tb-lux). These mycobacteria express the Vibrio harveyi luciferase enzyme, cloned from 
naturally luminescent sea-living Vibrio bacteria. In the presence of adenosine tri-phosphate (ATP) 
as a co-factor, luciferase catalyses the oxidation of reduced flavin mononucleotide (FMNH2) and N-
decyl aldehyde to produce FMN, H20 and light. The plasmid construction has been described 
previously [203]. The plasmid encodes the Lux A and B genes of Vibrio harveyi under the control of 
the hsp60 promoter. Some experiments also employed BCG-GFP-lux organisms, in which Green 
Fluorescent Protein (GFP) expression from the plasmid is under the control of the 19kDa protein 
promoter. Both promoters are constitutively expressed. The plasmid also encodes hygromycin 
resistance, allowing selection of plasmid-bearing organisms via the addition of hygromycin to 
liquid or solid culture media.  
BCG and M.tb are slow growing mycobacteria that require specific nutrient conditions. Liquid 7H9 
medium was prepared by dissolving 4.7g dried Difco Middlebrook 7H9 broth (Becton Dickinson 
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271310) in 900ml dH2O together with 4ml 50% glycerol (Sigma G5150) and 2.5ml 20% Tween 80 
(Sigma P5188). This was autoclaved in glass jars for 10 minutes at 15 lb/sq.in. and 121C. After 
cooling, 100ml ADC (albumin, dextrose, catalase) supplement (Becton Dickinson 212352) was 
added and the broth was stored in the fridge. Solid 7H11 medium was prepared by dissolving 21g 
dried Difco 7H11 agar (Becton Dickinson 283810) in 900ml dH2O with 10ml 50% glycerol. 
Autoclaving was performed for 15 minutes at the same pressure and temperature as for 7H9; after 
cooling the solution was enriched with 100ml OADC (oleic acid, albumin, dextrose, catalase; 
Becton Dickinson 212240) and 1ml hygromycin B (Roche diagnostics 843555) at 50mg/ml stock 
concentration. It was then poured under sterile conditions into 3-compartment petri dishes (VWR 
391-2030), 10ml per compartment, and allowed to set. Plates were stored in sealed bags at room 
temperature until use. 
Immediately before use of an aliquot of 7H9 broth, hygromycin B was added to give a final 
concentration of 50mcg/ml. Additional Tween 80 at this stage ensured that there was no clumping 
in the growth medium: optimal experimental volumes for my BCG-lux stock were 20ml 7H9, 20mcl 
hygromycin (50mg/ml stock concentration) and 150mcl 20% Tween 80; for M.tb-lux and BCG-GFP-
lux optimal volumes were 15ml 7H9, 15mcl hygromycin (50mg/ml stock concentration) and 
100mcl 20% Tween 80. A 1.5ml vial of BCG-lux or M.tb-lux was defrosted in a gloved hand and 
added to this medium in a 250ml Erlenmeyer flask (VWR 734-1886) and transferred to a shaking 
incubator at 100rpm and 37oC. 
Growth in 7H9 was monitored daily with luminescence readings as follows. 100mcl of the bacterial 
suspension was added to 900mcl Dulbecco’s Phosphate Buffered Saline (PBS; Invitrogen 14040-
174 or Sigma D8537) in a borosilicate glass luminometer tube (VWR 734-4222) or plastic 
luminometer tube (Greiner Bio-One 115101). This was briefly vortexed and then inserted into the 
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cassette of a Berthold Autolumat Plus LB953 Luminometer (for BCG) or a Berthold Sirius single-
tube luminometer (for M. tuberculosis, inside a Biosafety Cabinet) on. With appropriate 
instructions the luminometers inject 100mcl of 1% N-decyl-aldehyde (Sigma D7384) in ethanol 
(Sigma E7023) into the vial. Luminescence was measured and expressed in Relative Light Units 
(RLU). Measurements were always taken at least in duplicate.  
Colony Forming Units (CFU) were established by plating stock or experimental samples onto 7H11 
agar. 10mcl of bacterial suspension or sample was pipetted onto the agar and streaked with a 
sterile plastic loop spreader. Serial 10-fold dilutions using sterile PBS were also plated, taking at 
least two aliquots from each concentration. The plates were wrapped in ParaFilm or plastic bags 
(to prevent drying) and kept inverted inside an incubator at 37oC until CFU could be counted: 
usually two to three weeks from inoculation, when colonies were clearly visible but not yet 
confluent. When necessary, colonies were counted with the help of a magnifying glass and colony 
counter. 
Working stocks of all mycobacteria were derived from existing stocks stored at -80oC, kindly 
donated by Dr Beate Kampmann. Once the luminescence readings indicated that the mycobacteria 
had reached log phase growth, a further volume of 7H9/tween/hygromycin was added. Again 
growth was monitored daily, and stocks were made when the bacteria were in mid-log phase.  
BCG-GFP-lux was kindly donated by Dr Brian Robertson and Dr Nitya Krishnan. This was received 
as colonies on 7H11 agar: individual colonies were transferred with a loop spreader into 5ml 7H9 
each and dispersed. Suspensions were monitored daily by visual inspection and subsequently by 
luminescence readings once they began to appear dense. Broth volumes were incrementally 
increased whenever bacteria reached mid-log phase growth until sufficient quantity for stock 
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generation was reached. Candidate colonies whose growth faltered or which clumped in 
suspension were discarded.   
Preparation of stocks required the addition to bacterial suspensions of a sufficient volume of 
sterile 50% glycerol to give a final concentration of 15% glycerol. After thorough mixing 1.5ml 
aliquots were transferred into 2ml micro-tubes (Sarstedt 72.694006) and frozen at -80oC until use.  
 
2.4   Whole Blood Lux Assay 
The whole blood lux assay is designed to measure the total ability of the donor to control 
mycobacterial metabolism over 96 hours, in the presence of all cellular (neutrophil, lymphocyte, 
monocyte) and non-cellular components of host response.  
Mycobacteria must be in log phase to perform the experiment (48 to 72 hours growth, 
standardised for each series of experiments); the bacterial suspension was examined visually to 
ensure that it was not clumping and had its luminescence measured before proceeding with the 
assay. 
Blood was drawn from consenting donors into heparinised tubes (Bunzl Healthcare, 368480 or 
Greiner Bio-One 455051). It was diluted 1:1 with Roswell Park Memorial Institute-1640 (RPMI-
1640) (Invitrogen 21875034 or Sigma R8758) and 900mcl of diluted blood was aliquotted into each 
of the appropriate number of sterile 30ml Universal containers (VWR 215-0322) for baseline 
experiments or 7ml polystyrene bijou tubes (Medfor BTA0007G) for 96-hour time points. The 
assay required at least 3 aliquots for the baseline experiment (2 infected and 1 uninfected 
cytokine control), and at least 4 aliquots for the 96-hour time points (3 infected and 1 uninfected).  
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The mycobacterial stock was diluted with sterile PBS to reach a luminescence of approximately 1 x 
106 RLU per 100mcl; luminescence was measured as described above. 100mcl of this diluted stock 
was then inoculated into each of the blood samples labelled as ‘infected’. 2 further 100mcl 
aliquots of bacterial suspension per time point were added to 900mcl of 7H9: these served as a 
growth control. All vessels were re-capped, mixed gently, and those to be measured at later time 
points were placed in a 37oC incubator on a rocking plate set at 20 revolutions per minute. 
If baseline cytokine analysis was being performed, baseline samples were transferred to a 
centrifuge and spun at 2000 x g for 10 minutes. They were then removed, uncapped and 300mcl of 
supernatant was transferred from each sample to a 2ml microtube for freezing at -80oC until 
analysis. 300mcl PBS was added back to the blood samples to replace this aspirated volume 
(sterile if plating for CFU). The pellet was then resuspended via scraping and aspiration using a 
1000mcl filter tip on a Gilson pipette, and 10ml water (sterile if plating for CFU) was added.  
The samples were left to achieve cell lysis in the water for 10 minutes. They were then placed back 
in the centrifuge and spun at 2000 x g for 10 minutes. Supernatants were decanted into a waste 
vessel containing sufficient Surfanios (Anios 347036) to achieve a final concentration of 10% or 
ActiChlor (EcoLab HAS056.1P). Residual pellets were resuspended with 1ml PBS before vortexing. 
100mcl of the resultant suspension was added to 900mcl PBS in glass or plastic luminometer tubes 
and luminescence was measured as described previously. Samples were measured in at least 
duplicate for each sample and luminescence was taken as the median of these measurements. At 
later time points bijou tubes were removed from the rocking incubator and supernatants were 
removed as described above. Resuspended pellets were transferred to a 30ml Universal container, 
2ml water (sterile if plating for CFU) was added to each bijou and 8ml water was added to each 
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Universal. The bijous were vortexed to resuspend the last part of the pellet and this volume was 
added to the corresponding Universal. Luminescence was measured as described above. 
 
2.5   Cell depletion / CD15+ cell isolation using magnetic beads 
Magnetic MicroBeads (Miltenyi Biotec 130-048-001, 130-045-101, 130-045-201, 130-050-201, 
130-046-601) are approximately 50 nanometres in diameter and contain antibodies specific to 
certain cell surface antigens. When samples labelled with these beads are passed through a 
column containing a specialised matrix held in a magnetic field, the labelled cells are retained in 
the column. The ‘negative fraction’, depleted of the labelled cells, passes through and can be 
collected. If required, the retained cells can be eluted by removing the column from the magnet.  
Experiments were performed as follows. Blood was drawn into heparinised tubes as previously 
described. This was divided into the required number of aliquots, depending on how many 
depleted conditions were needed for the current protocol. A whole blood control condition was 
always included, to which Basic (unconjugated) MicroBeads were added. The correct amount of 
MicroBeads was pipetted into the sample which was then transferred to the fridge for incubation 
at 2-8oC. Volumes and incubation times were optimised for each antigen (see Table 2.2). 
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Table 2.2. Experimental conditions used for cell depletions. 
Depleted cell type MicroBead volume Incubation time 
CD4 100mcl per ml blood 30 minutes 
CD8 50mcl per ml blood 15 minutes 
CD14 100mcl per ml blood 30 minutes 
CD15 50mcl per ml blood 15 minutes 
Nil 
(Basic MicroBeads) 
50mcl per ml blood 15-30 minutes 
CD = Cluster of differentiation; mcl = microliters; ml = millilitres 
During incubation LS columns (Miltenyi Biotec 130-042-401) were ‘primed’ for use. This required 
running 3ml ‘MACS buffer’ (0.5% bovine serum albumin (Sigma A7030) and 2mM EDTA (Sigma 
E7889), prepared in advance and sterile filtered for use with a 0.22m filter unit (VWR 514-4126 
or Corning 430769)) through the column. 
After incubation the blood samples were diluted 1:1 with RPMI-1640, as required for the lux assay. 
Performing this step at this time point improved the flow of the samples through the columns. 
Diluted blood was then poured or pipetted into the top of LS columns while they rested in 
magnets (MidiMACS Separation Unit, Miltenyi Biotec 130-042-302). Samples depleted of target 
cell types were collected into Universal containers or 15ml Falcon tubes (VWR 7340451) and kept 
aside until all depletions were complete.  
6ml RPMI-1640 was added to the LS column containing CD15 MicroBeads to wash out residual 
erythrocytes and loosely adherent cells. The column was then removed from the magnet and 
placed into a 15 ml Falcon tube, 2 ml RPMI-1640 was added to the top and plunged briskly 
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through the column using the supplied syringe driver. The collected CD15+ cells were counted 
using a Beckman Coulter Ac.T Diff or a Drew Scientific HemaVet HV950 haematology analyzer (see 
below) and diluted if necessary with further RPMI-1640 to reach the required final concentration.  
 
2.6   Granulocyte isolation using Percoll and blood granulocyte augmentation 
Heparinised blood was taken from consenting donors, using a needle and syringe with only gentle 
back pressure. If blood granulocyte count was to be augmented, an appropriate volume (usually 
around 12ml) of blood was kept aside. The remaining volume was slowly decanted into a 50ml 
Falcon tube and 6% Dextran (Sigma 31392, prepared in advance and sterile filtered for use with a 
0.22m filter unit) was added at a quantity of 2.5ml per 20ml blood. The total volume was made 
up to 50ml with sterile 0.9% sodium chloride (Sigma 71382) warmed to 37oC in a water bath. After 
careful mixing the tube was left to sediment at room temperature for 20 to 30 minutes. 
At this time Percoll (GE Healthcare 17-0891-01) gradients were prepared at room temperature. 
‘Stock Percoll’ was generated by adding 3ml 10x PBS (Sigma D1408) to 27ml Percoll. This was then 
used to make aliquots of 81% Percoll (8.1ml ‘stock’ + 1.9ml 1x PBS), 70% Percoll and 55% Percoll.  
After the blood had sedimented, the leucocyte-rich upper layer was transferred to a fresh 50ml 
Falcon tube and topped up to a total volume of 50ml with warmed normal saline. This was 
centrifuged at 350 x g for 6 minutes. The supernatant was discarded and the cell pellet 
resuspended in 3ml 55% Percoll. To generate the gradient, 3ml 81% Percoll was carefully instilled 
at the base of a 15ml Falcon tube followed by 3ml 70% Percoll gently layered on top. The 55% 
Percoll containing leucocytes was then layered on top of this. The gradient was transferred to the 
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centrifuge and spun at 720 x g for 20 minutes with minimal acceleration and no deceleration. At 
the end of this spin the tube appearance was as shown in Figure 2.2. 
 
Figure 2.2. The Percoll gradient after centrifugation. 
 
The top layer of mononuclear cells was removed with a pipette and either discarded or donated to 
other researchers. The granulocytes were transferred via pipette to a new 15ml Falcon tube and 
washed twice with 10ml PBS (spun at 230 x g for 6 minutes). The granulocytes were resuspended 
in RPMI-1640 and counted (see below). If granulocyte augmentation of blood was required, the 
blood set aside at the beginning of the experiment was now prepared, usually into 3 x 4ml 
aliquots. Granulocytes in RPMI-1640 were added to blood requiring enrichment, and the volume 
topped up with neat RPMI-1640 to achieve a blood:RPMI ratio of 1:1 as required for the lux assay. 
The control ‘whole blood’ was diluted with RPMI-1640 alone. If required, half the granulocytes 
were rendered necrotic by heat shock at 60oC in a water bath for approximately 20 minutes (until 
Mononuclear cells 
Granulocytes 
Residual red cells 
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all cells were trypan blue (Sigma T8154) positive by microscopy) and, after cooling, these were 
added to an aliquot of blood in the same volume as viable granulocytes. 
For experiments on the effects of supplementary reagents on neutrophil antimycobacterial effects 
(Chapter 6), granulocytes were further purified as follows. 50mcl each of Magnetic MicroBeads 
(Miltenyi Biotec) conjugated to CD3, CD14 and CD19 were added to samples and they were 
incubated for 20 minutes. An LS column was ‘primed’ with MACS buffer during this time (see 
above) and the samples were run through the column; this additionally purified sample was then 
counted and used for experiments. 
 
2.7   Serum Generation, Heat Inactivation and Pre-opsonisation 
Freshly drawn non-anticoagulated blood was centrifuged in a 15 ml Falcon tube at 500 x g for 15 
minutes with minimal deceleration. Separated plasma was transferred to another Falcon tube and 
incubated in a water bath at 37oC. After the platelets had plugged serum was aspirated for use. 
Heat inactivation of serum (when required) was performed in a water bath at 56oC for 30 minutes 
or at 90oC for 2 minutes, as indicated in the relevant section. Heat-inactivated fetal calf serum was 
obtained from Biochrom AG (Berlin, Germany).  
For pre-opsonisation (Chapter 3), 200mcl BCG-lux suspension in 7H9 at a concentration of 5 
million RLU (1.7 million CFU) / 100 mcl was incubated at a 1:1 volume ratio with autologous serum 
for 20 minutes at 37oC. 
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2.8   Neutrophil Lux Assay 
The development and validation of this assay is described in detail in Chapter 3. Briefly, 
granulocytes were resuspended to an appropriate concentration (usually 1 x 106 cells / ml) in 
RPMI-1640. 400 mcl of cell suspension was pipetted into a 5 ml Falcon flow cytometry tube 
(Becton Dickinson). 50 mcl autologous serum was added (giving a final concentration of 10% 
serum) followed by 50 mcl organism suspension, appropriately diluted with sterile PBS to reach 
the required multiplicity of infection (MOI). The tubes were capped and then rolled to ensure that 
all organisms were mixed with the cell suspension before being incubated on their sides on a 
rocking plate (20 revolutions per minute (rpm)) at 37oC. After the required time had elapsed 
(usually 1 and 24 hours), samples were allowed to cool to room temperature for five minutes, 
briefly vortexed, caps were removed and the tubes were placed in a luminometer for 
measurement. Serum control samples were prepared with 400mcl RPMI-1640, 50mcl serum and 
50mcl organism suspension. 7H9 control samples were prepared with 450mcl 7H9 and 50mcl 
organism suspension. 
Additional reagents (Vitamin B12 (Sigma V6629), zinc chloride (Sigma 39059), L-Ascorbic Acid 
(Sigma A5960), N-Acetyl-L-cysteine (Sigma A7250), N-Acetyl-DL-serine (Sigma A2638), NG-
Monomethyl-L-Arginine (L-NMMA; Enzo Life Sciences ALX-106-001), 1,25-dihydroxycholecalciferol 
(Sigma D1530) and 25-dihydroxycholecalciferol (Sigma H4014) were added to the cell or serum 
samples prior to infection with mycobacteria in concentrations as indicated in Chapter 6. I was 
assisted in some of these experiments by Dr Meera Shah. 
While validating the assay cell lysis was undertaken on some samples. To achieve this, 1 ml 0.1% 
saponin (Becton Dickinson 554723) was added, samples were vortexed, incubated for 30 minutes 
and vortexed again. 1 ml PBS was added to control samples, which were otherwise treated 
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identically. Permeabilisation was confirmed by microscopy of cells stained with trypan blue and by 
flow cytometry after addition of propidium iodide (Becton Dickinson 556463): see Chapter 3. 
 
2.9   Flow cytometry of human blood 
200mcl of blood were transferred to 5ml flow cytometry tubes (Becton Dickinson 352003) and 
fluorochrome labelled antibodies were added in a quantity pre-determined by titration 
(fluorochromes used in this thesis with their volumes or concentrations are detailed in Table 2.3). 
The samples were incubated in the dark for 15 minutes before adding 2ml 1x BD FACS Lysing 
Solution (Becton Dickinson 349202), briefly vortexing and incubating for a further 10 minutes. 
Samples were then centrifuged at 500g for 5 minutes, supernatants were aspirated and pellets 
were resuspended in 2ml PBS. After a further centrifuge spin at the same settings, cells were 
resuspended in 500mcl 2% paraformaldehyde (Alfa Aesar 43368). Samples were processed on a 
BD FacsCanto II, BD FacsCalibur or BD Fortessa flow cytometer. Voltages and thresholds were 
determined on an unlabelled sample and appropriate single stained controls, either cells or 
CompBeads (anti-mouse Ig, κ/Negative, Becton Dickinson 552843), were always included for 
compensation. A minimum of 50,000 events was collected for each sample. Post-hoc analysis and 
compensation was performed using FlowJo software from Treestar. Specific gating strategies are 
described in the relevant Chapters. 
 
2.10   Neutrophil phagocytosis assay 
The development and validation of this assay is discussed in detail in Chapter 3. For Fluorescein 
isothiocyanate (FITC) labelling of mycobacteria, 5 ml of mid-log phase organisms in 7H9 were 
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centrifuged at 2000 x g for 5 minutes and resuspended in 1ml carbonate-bicarbonate buffer (pH 
9.6) (sodium hydrogen carbonate, Merck BB102474V) containing 0.05% Tween 80. 5 mcl of FITC 
stock (Sigma 46950), previously made to 100 mg/ml with Dimethyl sulfoxide (DMSO Calbiochem 
317275) and stored at -20oC until use, was added and the suspension was incubated at 37oC for 15 
minutes. The labelled organisms were spun in a micro-centrifuge at 4000 x g for 2 minutes, the 
supernatant was aspirated and the pellet was resuspended in 1ml PBS containing 0.05% Tween 80. 
This washing step was repeated twice and the organisms were then resuspended in 7H9. 
To perform the assay, 400mcl of CD15+ granulocytes in RPMI-1640 at a concentration of 1 x 
106/ml were aliquotted into sterile 5 ml flow cytometry tubes. 50mcl serum (or PBS in serum-free 
experiments) was then added, except when investigating pre-opsonisation of organisms (see 
Chapter 3). 50mcl of a suspension of organisms (or 100mcl of pre-opsonised suspension when 
appropriate) was added at the required concentration to reach the MOI for the experiment (see 
Chapter 3); for most experiments an MOI of 1 RLU:1 granulocyte was used.  
Samples were capped and then rolled to ensure that all organisms were mixed with the cell 
suspension before being incubated on their sides on a rocking plate (20 rpm) at 37oC for 30 
minutes. During this time the centrifuge was cooled to 0oC. After 30 minutes samples were placed 
immediately on ice for 5 minutes and then spun at 300 x g for 5 minutes in the pre-chilled 
centrifuge. Samples were returned to ice and supernatants were aspirated, leaving approximately 
100 mcl volume. 1 mcl eFluor450 Fixable Viability Dye (eBiosciences 65-0863-14) and 0.5 mcl 
Phycoerythrin (PE)-conjugated anti-CD66a,c,e antibody (BioLegend 342304) was added to the 
pellets and samples were incubated for 12 minutes. Subsequently 1 ml of ice-cold PBS and 12.5 
mcl of 0.2 micron syringe-filtered Trypan blue was added to the tubes and they were transferred 
back to the centrifuge at 0oC. (Note that syringe filtering of trypan blue is required because it 
71 
 
becomes highly particulate in suspension and can interfere with flow cytometry.) After a further 
centrifuge spin at 300 x g for 5 minutes, supernatants were aspirated and the pellets were 
resuspended in 500 mcl 2% paraformaldehyde (BCG) or 4% paraformaldehyde (M.tb). 
Compensation controls were prepared as follows. An identically processed aliquot of uninfected 
cells and serum was stained with CD66a,c,e-PE alone. Another aliquot of cells was divided into two 
and one half was heat-shocked at 60oC in a water bath for 20 minutes. The two halves were then 
recombined, mixed and separated into two again. One of these was labelled with eFluor450 
Fixable Viability Dye and the other with trypan blue. A further sample of granulocytes contained 
organisms only with no dyes or fluorochromes and a final control contained neither organisms nor 
fluorescent molecules. All samples were acquired on a Becton Dickinson Fortessa flow cytometer, 
immediately for BCG samples or after overnight fixation for samples containing M.tuberculosis. 
Gating is described in Chapter 3. 
When developing the assay, I also assessed clumping of mycobacteria. For this, samples were 
processed with identical volumes of serum and organisms but without human cells (500 mcl RPMI-
1640 was used instead of a granulocyte suspension). The samples were acquired on the flow 
cytometer for the maximum duration taken by a contemporaneous cell sample to reach 50,000 
events: see Chapter 3. 
 
2.11   pHrodo™ labelling 
Labelling of BCG-lux with the pH sensitive fluorophore pHrodo™ was performed at a concentration 
of 25mM according to the manufacturer’s instructions, except for omission of the 100% methanol 
step. 
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2.12   Neutrophil cell death assay and neutrophil supernatants 
400mcl granulocytes at a concentration of 1 x 106/ml in RPMI-1640 with 10% autologous serum, 
either infected with mycobacteria (50mcl suspension, at the same MOI as the restriction assay) or 
not, were incubated for at 37oC for 18 or 24 hours, as indicated. At this time samples were 
centrifuged at 500 x g for 6 minutes. The supernatants were removed and stored at -80oC until 
analysis; pellets were re-suspended in 500mcl Annexin V binding buffer (Becton Dickinson 
556454). 5mcl Annexin V-FITC (Becton Dickinson 556420), 0.5mcl CD66a,c,e-PE and 1mcl 
eFluor450 Viability Dye are added to each sample and they were incubated for 20 minutes. They 
were then washed in PBS and resuspended in 2% paraformaldehyde (BCG) or 4% 
paraformaldehyde (M.tb) for fixation before acquisition on a BD Fortessa flow cytometer. 
For gating, neutrophil surface marker positive events were gated amongst singlets using 
CD66a,c,e-PE versus side scatter (SSC). Alternatively, granulocytes were gated using Forward 
Scatter (FSC) versus SSC. These events are then divided into quadrants on the basis of Annexin V-
FITC and Viability Dye positivity (Figure 2.3). 
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Figure 2.3. Gating strategy for cell death assay. First, all doublet events were excluded on the basis of Forward Scatter 
Area (FSC-A) versus Forward Scatter Height (FSC-H). All singlet events were gated using FSC versus side scatter area 
(SSC-A) to define a ‘granulocytes’ gate or using SSC-A versus the neutrophil surface marker CD66a,c,e-PE to define a 
total ‘cells’ gate. These populations were then divided on the basis of eFluor450 Viability Dye (Pacific Blue channel) 
versus Annexin V-FITC (Alexa-Fluor 488 channel). Dual negative events were defined as viable, Annexin V-positive / 
Viability Dye negative events were defined as apoptotic, Viability Dye positive / Annexin V negative were defined as 
primary necrotic, and dual positive events were defined as late apoptotic/necrotic. 
 
2.13   Mouse air-pouch generation, neutrophil depletion, neutrophil recruitment, 
vaccination and sampling 
The influence of neutrophils on BCG vaccination responses was investigated in mice. Neutrophils 
were depleted systemically prior to BCG vaccination, additionally recruited to the vaccination site 
using prior treatment with the chemokine MIP-2, or not manipulated (in control animals). I was 
assisted in many murine experiments by Dr William Horsnell. 
In order to accurately target neutrophil recruitment to the vaccination site and sample the cells 
recruited after administration of BCG, air pouches were generated subcutaneously in mice. This 
 
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parallels the strategy used to study human BCG responses using a blister model [204]. 
Optimisation of this model is decribed in Chapter 7. 
The pouches must be epithelialized prior to use, which takes approximately 7 days. 
Correspondingly, 7 days prior to vaccination, 5ml sterile air was injected into the dorsal skin of the 
mice using a syringe attached to a 26G needle, under halothane anaesthesia. 3 days prior to 
vaccination, a further 2ml of air was injected into the pouch to maintain inflation. 24 hours before 
vaccination, neutrophil depletion was effected, if necessary, via an intra-peritoneal injection of 
500mcg 1A8 anti-Ly6G (lymphocyte antigen 6G) antibody (BioXCell BE0075-1) under halothane 
anaesthesia; control mice for the 1A8 experiments were injected with 500mcg 2A3 isotype control 
antibody (Bio XCell BE0089). If additional neutrophil recruitment was required, 50ng recombinant 
MIP-2 (R&D Systems 452-M2-050) was injected directly into the pouch 2 hours before vaccination. 
Vaccination was performed using freshly defrosted BCG, to parallel clinical practice in humans. 
Approximately 5 x 105 CFU BCG-GFP-Lux was administered into the pouch in a total volume of 1 ml 
Hanks’ Balanced Salt Solution (HBSS; Invitrogen Gibco 14025), under halothane anaesthesia. 2 
hours after vaccination, mice to be sampled were anaesthetised intra-peritoneally (prepared as 
1.2ml xylazine (100mg/ml; Sigma-Aldrich X1126) + 0.8ml 2% ketamine (Sigma-Aldrich K1884) + 8ml 
PBS, 100mcl administered per mouse). 1ml HBSS containing 5mM EDTA was instilled into the 
pouch and 500mcl was aspirated after 10 minutes with transfer to an EDTA blood tube (Becton 
Dickinson K3E Vacutainer 368860); both procedures utilised a 25G needle.  
Pouch aspirates were used for cell counting (HemaVet HV950 analyser), luminescence 
measurement (100mcl sample in 900mcl PBS, as described earlier) and flow cytometry. For flow 
cytometry, samples were centrifuged at 500 x g for 5 minutes, supernatants were discarded and 
25mcl of MACS buffer containing fluorochromes (anti-Gr1-PE, 1:320 concentration; anti-MHC II-
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APC, 1:1280 concentration; anti-F4/80-PECy5, 1:320 concentration) was added to each pellet. 
Samples were incubated for 20 minutes at 4oC, resuspended with 1ml PBS, centrifuged at 500 x g 
for 5 minutes and finally pellets were fixed in 500mcl 2% paraformaldehyde before acquisition on 
a BD Fortessa flow cytometer. Gating strategies are described in Chapter 7.  
 
2.14   Mouse spleen preparation and splenocyte restimulation 
Three weeks after vaccination mice were killed by halothane inhalation. Skin was sprayed with 
70% ethanol and spleens were removed aseptically via ventral incision. Spleens were weighed and 
then transported to the tissue culture laboratory in 2ml Iscove’s Modified Dulbecco’s Medium 
(IMDM; Invitrogen Gibco 12440) containing 10% normal rat serum (Animal Unit, University of Cape 
Town). Spleens were crushed through a 40 micron filter using the plunger of a 10ml syringe; the 
cell suspension was aspirated with a pipette, transferred to a 15ml Falcon tube and centrifuged at 
1200 rpm for 5 minutes. The supernatant was discarded and the pellet resuspended in 1ml Red 
Blood Cell Lysing Buffer (Sigma R7757). After 1 to 2 minutes the volume was topped up to 10ml 
with further IMDM and samples were centrifuged again at 1200 rpm for 5 minutes. Pellets were 
resuspended in 5ml IMDM containing 10% normal rat serum, 2.5ml 100x Penicillin G (10,000 U/ml) 
and Streptomycin (10,000 mcg/ml) (Gibco 15140122) and cells were counted on a 200mcl aliquot 
using a HemaVet HV950 Coulter counter. Volumes were adjusted to reach a final concentration of 
5 million cells/ml and 100mcl (i.e. 500,000 cells) was aliquotted into the wells of 3 round-bottom 
96-well culture plates. Samples were aliquotted in at least duplicate per spleen per re-stimulation 
condition and in triplicate per spleen for surface flow cytometry staining. I was assisted in some of 
these experiments by Sumaiyya Thawer. 
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For surface flow cytometry, one plate was centrifuged at 1200 rpm for 5 minutes, supernatants 
were removed and 25mcl MACS buffer containing one of the following fluorochrome 
combinations was added to each well, ensuring that each spleen was stained with each 
combination: ‘Phagocytes’ (CD11b, CD11c, MHC-II, Gr-1); ‘T-cells’ (CD3, CD4, CD8 +/- CD62L); ‘B-
cells’ (CD19, B220 +/- CD21/35). The specific combinations were chosen from the fluorochromes 
detailed in Table 2.3. Samples were incubated at 4oC for 20 minutes, washed with 200mcl PBS per 
well and resuspended in 200mcl 2% paraformaldehyde before acquisition on a BD Fortessa flow 
cytometer. Compensation controls were derived from Rat anti-rat Ig, κ/Negative CompBeads 
(Becton Dickinson 560499). 
Re-stimulation antigens were prepared as follows: anti-CD3 antibody (Clone 145-2C-11, Becton 
Dickinson 553058) was diluted with IMDM to reach a final concentration of 20mcg/ml, and BCG-
lux (freshly defrosted) was diluted with IMDM to reach a final concentration of approximately 
200,000 CFU/ml. 100mcl of diluted antigen was then added to each well of the 2 remaining plates 
(ensuring that each spleen was stimulated with each antigen in at least duplicate); final stimulant 
volumes were thus 2mcg for anti-CD3 and 20,000 CFU for BCG. Control samples (at least duplicate 
per spleen per plate) received 100mcl of medium alone. Plates were placed in an incubator at 
37oC. After 2 hours, monensin (Biolegend 420701, 1mM stock concentration) was added to each 
well of one plate to reach a final concentration of 2μM. 
The following day, the plate with monensin was removed. Replicates from the same spleen and 
stimulating antigen were pooled in 5ml flow cytometry tubes and centrifuged at 1200 rpm for 6 
minutes. Supernatants were discarded and 25mcl MACS buffer containing fluorochromes 
conjugated to anti-CD3, anti-CD4 (Table 2.3) and eFluor450 Viability Dye was added to each pellet. 
After 20 minutes incubation at 4oC, 1ml PBS was added, tubes were centrifuged at 1200 rpm for 6 
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minutes and supernatants discarded. Pellets were fixed with 500mcl 2% paraformaldehyde for 30 
minutes at 4oC and then centrifuged again at 1200 rpm for 6 minutes. After aspirating 
supernatants, 1ml 1x Perm/Wash (Becton Dickinson) was added and samples were incubated for 
another 30 minutes at 4oC. Following one more centrifuge spin (1200 rpm for 6 minutes), 25mcl 
Perm/Wash containing anti-TNF-PE (1:100 concentration) and anti-IFN-γ-APC (1:100 
concentration) was added to each pellet. Samples were incubated for a further 30 minutes at 4oC, 
then 1ml Perm/Wash was added, tubes were centrifuged again and resuspended in 500mcl 2% 
paraformaldehyde. 
72 hours after stimulating antigens were added, the remaining 96-well plate was centrifuged at 
1200 rpm for 10 minutes, supernatants were aspirated and stored at -20oC until analysis by ELISA 
(see below). 
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Table 2.3. Fluorochromes used in this thesis. 
Antibody Fluorophore Clone 
Working concentration 
or Volume per sample 
Manufacturer / 
Catalogue No. 
Human 
CD66a,c,e 
PE ASL32 0.5 – 2mcl / sample BioLegend 342304 
Human CD16 PerCP Cy5.5 3G8 4mcl / sample BD 560717 
Human CD11b PECy7 ICRF44 5mcl / sample BD 557743 
Human CD62L FITC DREG-56 15mcl / sample BD 555543 
Annexin V FITC - 5mcl / sample BD 556420 
eFluor450 
Viability Dye 
N/A - 1mcl / sample or 1/100 
eBiosciences 65-
0863-14 
Mouse CD3 AF700 500A2 1/320 BD557984 
Mouse CD4 PerCP RM4-5 1/640 BD553052 
Mouse CD8a V500 53-6.7 1/160 BD560776 
Mouse CD62L APC MEL-14 1/1280 BD553152 
Mouse B220 V500 RA3-6B2 1/320 BD561226 
Mouse CD19 PerCP-Cy 5.5 1D3 1/640 BD551001 
Mouse 
CD21/35 
APC 7G6 1/640 BD558658 
Mouse Gr-1 PE RB6-8C5 1/320 BD553128 
Mouse MHC II APC M5/114.15.2 1/1280 
eBiosciences 17-
5321-82 
Mouse MHC II FITC M5/114.15.2 1/640 
eBiosciences 11-
5321-82 
Mouse CD11b PerCP-Cy 5.5 M1/70 1/320 BD550993 
Mouse CD11c PE-Cy7 HL3 1/160 BD558079 
Mouse F4/80 PE-Cy5 BM8 1/640 
eBiosciences 15-
4801-82 
Mouse TNF PE MP6-XT22 1/100 BD554419 
Mouse IFN-γ APC XMG 1.2 1/100 BD554413 
 
CD = Cluster of Differentiation; MHC = Major Histocompatibility Complex; TNF = Tumour Necrosis Factor; IFN = 
Interferon; PE = Phycoerythrin; PerCP = Peridinin chlorophyll protein; Cy = Cyanin; FITC = Fluorescein isothiocyanate; 
AF = Alexa Fluor; APC = Allophycocyanin; mcl = microliters; No. = Number. 
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2.15   Enzyme Linked Immunosorbent Assays (ELISA) 
ELISA conducted on human samples in this thesis was performed using commercially available kits 
and processed according to manufacturer’s instructions. Standard curves were constructed from 
the provided standards. 
ELISA of mouse IFN-γ was performed with an in-house kit as follows. Flat bottom 96-well culture 
plates (Nunc MaxiSorp® 442404) were coated with 50mcl per well of Rat anti-mouse IFN-γ clone 
AN18KL6, stock concentration 2.67mg/ml diluted 1/500 in PBS, and incubated overnight at 4oC. 
The following day the plate was washed four times with 200mcl wash buffer (PBS containing 1% 
Tween 20) per well. Non-specific binding sites were then blocked with 200mcl 2% milk powder per 
well and incubated overnight at 4oC. Plates were washed 4 times as above and 50mcl samples 
were added to the appropriate wells, pre-diluted 1:3 or 1:4 with IMDM. A standard curve was 
generated from 3-fold dilutions of recombinant mouse IFN-γ with a maximum concentration of 
200ng/ml. 
Plates were incubated at 37oC for 3 hours, washed 4 times and then 50mcl biotin-labelled 
secondary antibody (Becton Dickinson BD554410), stock concentration 0.5mg/ml diluted 1/1000 
in PBS + 0.1% Bovine Serum Albumin (BSA), was added to each well. The plate was incubated for 3 
hours at 37oC and then washed 4 times as above. 50mcl alkaline phosphatase-labelled streptavidin 
(KPL 475-3000) diluted 1/1000 in PBS + 0.1% Bovine Serum Albumin (BSA) was then added to each 
well and the plate incubated at 37oC for 1 hour. After 4 more washes, 50mcl of the substrate P-
Nitrophenol-phosphate (PNP) at 1mg/ml concentration was added to each well. After the colour 
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developed, the plate was read with an ELISA reader (405nm filter) and results obtained using 
SoftMax Pro software. 
 
2.16   Luminex® 
Luminex technology allows measurement of multiple analytes in a single sample. Antibodies 
against molecules of interest are conjugated to 5.6 micron polystyrene beads rather than coated 
in the wells of a plate. These beads are internally dyed with red and infra-red fluorophores of 
differing intensities. This allows the detection system to differentiate one bead from another, 
dividing them into numbered ‘bead regions’ which correspond with individual target molecules. I 
was assisted in some experiments by Dr Anna Coussens. 
Supernatants from the whole blood lux assay were first centrifuged at at least 2000 x g for 5 
minutes to ensure that any cell debris was pelleted and aliquotted into 96 well plates. 
Supernatants from samples infected with M.tuberculosis were filtered twice through 0.22 micron 
filter plates (Merck Millipore MSGVS2210) with centrifugation at 3000 x g prior to removal from 
the BioSafety Level 3 laboratory. Final samples dilutions, based on preliminary experiments, were 
either 4-fold or 10-fold depending on experiment. In the Invitrogen 30-plex kit (Invitrogen LHC 
6003) standards were provided in two vials; each were reconstituted using 0.5ml Assay Diluent, 
and 300mcl of each were recombined to generate the universal high standard. This was then 
subject to serial two-fold dilution using Assay Diluent to create a standard curve. The procedure 
was followed according to manufacturer’s instructions, but I used a lower volume of beads: either 
12.5mcl or 8.4mcl, instead of 25mcl as suggested in the instructions. Plates were read on a 
calibrated Luminex 200™ reader and results calculated by the Luminex 200™ software. 
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2.17   Interferon-γ Release Assays 
Quantiferon Gold In-Tube assays (Cellestis T0590 0301) were performed on patients and healthy 
controls in Cape Town according to manufacturers’ instructions.  
 
2.18   Quantitative cell enumeration 
This was performed by Coulter counting. In the UK studies, Coulter counting was performed on 
diagnostic machines by the Department of Haematology, St Mary’s Hospital. In South Africa, either 
a Beckman Coulter Ac.T Diff or a Drew Scientific HemaVet HV950 was used. In both cases an 
aliquot of cells or blood (100 – 200mcl) was presented to the probe of the machine, which 
automatically aspirates 20mcl and provides automated counts.  
 
2.19   Confocal Microscopy 
Samples were incubated using the same reagent quantities as described for the neutrophil-lux 
assay in 8-chambered coverslips (Lab-Tek) and images were obtained on live cells using a Zeiss 
Axiovert LSM 510 Meta NLO Confocal Microscope. Nuclei were stained using the membrane 
permeable dye Hoechst 33342 (Anaspec Inc. 83218) at a 1mcg/ml concentration. Experiments 
were performed using FITC-labelled or GFP-expressing BCG. Image z-stacks were acquired using 
the 488 nm laser line at 5% transmission for excitation of GFP and differential interference 
contrast, and two-photon excitation of Hoechst 33342 with a Spectra-Physics MaiTai DeepSee 
laser set to 1% transmission at 750 nm. GFP/FITC fluorescence was detected using a 505-530 nm, 
and Hoechst 33342 with a 420-460 nm bandpass filter. Image z-stacks were rendered into 
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orthogonal projections to demonstrate internalization of BCG. I was supervised in all confocal 
microscopy by Dr Dirk Lang. 
 
2.20   Measurement of absorbance 
Single beam spectrophotometry measures the relative light intensity of a beam of light before and 
after a test sample is inserted in its path, or the difference in intensity reduction between a 
reference sample and a test sample. As the beam is scattered by a monochromator before 
reaching the sample then the intensity at individual wavelengths can be determined. 
A Cecil 2021 CE spectrophotometer was blanked (zeroed) to water at 490nm, the wavelength of 
maximal luminescence for Vibrio harveyi [205]. 100mcl of the fluid under investigation was added 
to 900mcl PBS (to match the composition of the samples inserted into the luminometer) in optical 
cuvettes. These were briefly vortexed, loaded into the spectrophotometer and digital absorbance 
readings taken.  
 
2.21   Analysis of causes of neutrophilia and mortality 
Demographic data on patient age, sex and ethnicity were extracted from the dataset used to 
investigate these phenomena. Ethnic origin was categorised as White, Indian/Sri Lankan, Pakistani, 
Bangladeshi, Black Caribbean, Black African, Black Other, Chinese or Other. Patients of Indian, Sri 
Lankan, Pakistani and Bangladeshi origin were grouped into a single category of ‘South Asian’ for 
analysis; patients of Black Caribbean, Black African and other black ethnic origin were grouped into 
a single category of ‘black’ for analysis. Clinical data were collected on co-morbidity (renal failure, 
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hepatic failure, previous ischaemic cardiovascular events, diabetes mellitus, hypertension, sickle 
cell disease, respiratory failure, arthritis (any type), inflammatory bowel disease, celiac disease, 
ankylosing spondylitis), use of immunosuppressive medication at time of diagnosis 
(corticosteroids, azathioprine or cyclosporin), HIV-1 status, and site of disease (pulmonary, 
peripheral lymph node, central nervous system, miliary or other extra-pulmonary site). The 
following laboratory data were also collected from the date of tuberculosis diagnosis: serum 
sodium concentration, bilirubin concentration and albumin concentration, peripheral blood 
haemoglobin concentration, peripheral blood neutrophil count, monocyte count, lymphocyte 
count and platelet count. Blood culture results were also recorded where performed. 
 
2.22   Statistical Methods 
Parametric data was analysed using Student’s t-tests for 2 groups (paired when appropriate) or 
one-way ANOVA for 3 or more groups with post-hoc correction. Non-parametric data was 
analysed using Mann-Whitney U-tests or Wilcoxon signed rank tests for 2 groups and Kruskal-
Wallis testing with post-hoc Dunn’s correction for 3 or more groups. Comparisons of proportions 
(eg sex, ethnicity, smoking status) were performed by chi-square tests. Confidence intervals for 
proportions were calculated by the adjusted Wald method.  
Multivariate analysis was conducted using linear regression if the dependent variable was 
continuously distributed or logistic regression if the dependent was binary. For investigation of the 
determinants of neutrophilia in tuberculosis patients (Chapter 8), neutrophil counts were treated 
as a binary categorical dependent variable: ≥7.5 x109/L or <7.5 x109/L, defined according to local 
reference ranges. Age was divided into strata pre-analysis (<20 years, 20–39 years, 40–59 years, 
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≥60 years). Categorical predictors with >25% missing values (HIV status and co-morbidity) were 
assigned a separate group of ‘unknown’ to enable inclusion of patients for whom these data were 
missing in multivariate analyses. Multivariate regression was subsequently performed using all 
significant (p<0.05) predictors from univariate analysis. Analysis of predictors of mortality was 
conducted similarly, with death/survival treated as a binary categorical dependent variable. 
Additional laboratory parameters were divided pre-analysis into strata: laboratory data were 
considered as categorical rather than continuous predictors because relationships were not 
anticipated to be linear and both high and low values of most variables were likely to be 
pathological. A distinction was made between pathological neutropenia (<1 x109/L) and mild, 
usually benign ethnic, neutropenia.  Bootstrapping analysis used simple (non-stratified) sample 
selection. 
A Receiver Operating Curve for mortality (Chapter 8) was generated by calculating the 
probabilities of death for each individual predicted by multivariate analysis, comparing to true 
outcome and plotting sensitivity versus (1-specificity), as per the statistical software’s 
methodology (SPSS Inc, Chicago, USA). To build a predictive model for mortality with high negative 
predictive value, candidate variables were chosen from the results of multivariate analysis. 
Inclusion of variables and cut-points were varied iteratively to maximise the common odds ratio 
for death, defined as: 
 
(probability of death if identified by model) x (1 – probability of death if not identified) 
(probability of death if not identified) x (1 – probability of death if identified by model) 
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Probabilities of 100% or 0% were adjusted by the LaPlace method to allow calculation [206]. The 
model was trained on the larger dataset from KCH and tested on the smaller dataset from NUHT.  
All statistical analyses in this section were performed using SPSS Version 18.0 (SPSS Inc, Chicago, 
USA) or GraphPad Prism version 4.0. All reported p-values are two-sided; p <0.05 was inferred as 
significant.  
 
2.23   Principal Component Analysis 
Principal component analysis and associated three-dimensional plots were generated using 
Qlucore™ Omics Explorer v2.3 software. Multi-group comparison was used to identify Luminex™-
measured cytokines or chemokines that significantly contributed to differentiation between the 
supernatants of three conditions (blood augmented with viable neutrophils, necrotic neutrophils 
or medium only). In general a p-value of 0.05 and q-value of 0.1 was used as the threshold (see 
Chapter 6). Individual points in the plots represented one donor in one augmentation condition 
and their position in the plot was determined by the combined effects of all parameters measured 
for the sample that significantly contributed to the overall between-group difference. The distance 
between sample points represented Euclidean distance and was calculated using all parameters 
that significantly contribute to the overall between-group difference. Component vectors are 
displayed, along with a percentage figure signifying the proportion of the variability in the data 
that each component accounts for. 
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3. Development and validation of assays
3.1   Introduction
Before commencing this work, techniques to assess growth restriction of mycobacteria by 
human neutrophils were not well established. Assessment of neutrophil antimycobacterial 
activity using a classical colony-forming unit (CFU) assay has multiple limitations. First, cell-
pathogen cultures are necessarily disturbed in the process of pathogen enumeration. Cell 
lysis to release organisms introduces new bio-active reagents and may be incomplete. Serial 
dilutions before plating CFU may be inaccurate, due to clumping and pipetting error, and 
the process is time-consuming. Furthermore, existing techniques for mycobacterial 
quantification (including radiometric assays such as Bactec) require prolonged culture of 
organisms in growth medium after the end of the restriction assay. This not only increases 
the risk of contamination but also deviates the in vitro assay further from in vivo reality, 
where organisms would not have the opportunity to recover and replicate in the absence of 
immune challenge. 
Another crucial aspect of neutrophil function in addition to killing is phagocytosis of 
mycobacteria: this may be either a prerequisite for elimination of the organisms or an 
essential stage in disseminating viable organisms to distant sites. However, assessment of 
this process is also challenging. Flow cytometric techniques [88, 111, 207-209] avoid labour-
intensive microscopy but suffer a number of potential pitfalls. Specifically, it has been little 
appreciated that vital dyes such as trypan blue, used to ‘quench’ extracellular fluorescence 
and to identify surface-bound organisms, also stain dead cells and will enter fixed cells 
[208]. Furthermore, mycobacterial clumping in culture can significantly interfere with flow 
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cytometry assays [111]. Although various techniques can minimise this at the point of 
inoculation, the organisms tend to re-aggregate during incubation [111]. 
I therefore established a neutrophil-mycobacterial restriction assay using the luminescent 
mycobacteria M.bovis BCG-lux and M.tuberculosis H37Rv-lux, and developed a phagocytosis 
assay which could be used contemporaneously. Of note, transformation with the lux-
bearing plasmids does not appear to negatively impact bacterial fitness or virulence, as 
previously demonstrated in an animal model [203]. 
This chapter summarises the development of these assays, as well as an investigation into 
the first stage of the whole blood mycobacterial restriction assay which modified my 
interpretation of the results. Methodologies are described in Chapter 2 and briefly 
summarised again here in Figure legends. 
 
3.2 Samples must be cooled to room temperature to enable accurate 
measurement of luminescence 
It had been reported that the luminescence of V.harveyi, a sea-living bacterium, was 
relatively inhibited at 37oC (human body temperature) which I proposed to use for 
incubation of samples [210]. To investigate this phenomenon, I prepared multiple aliquots 
of M.tuberculosis-lux in 7H9 broth and incubated them at 37oC for 1 hour before reading 
their luminescence sequentially, for 20 seconds per reading. Figure 3.1 details the results 
from a representative experiment; in all experiments, luminescence plateaued after 
approximately 200 seconds. I therefore left samples to cool for 5 minutes before 
measurement in the restriction assay.  
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Figure 3.1 Investigation of time out of incubator on mycobacterial luminescence. Samples of M.tuberculosis-
lux were prepared at approximately 100,000 RLU/100 mcl/20 seconds; 50mcl was added to serial aliquots of 
450mcl 7H9 broth and samples were incubated at 37
o
C for one hour. Tubes were then removed from 
incubator and luminescence measured sequentially, for 20 seconds per sample. One representative 
experiment. 
 
 
3.3 Neutrophils restrict bioluminescence of BCG-lux and M.tuberculosis-lux 
in a dose-dependent manner 
Isolated neutrophils from nine donors were infected with a fixed inoculum of M.bovis BCG-
lux across a variety of neutrophil numbers. Luminescence measured at one hour post-
inoculation showed a clear negative relationship with the number of neutrophils (Figure 
3.2A). I repeated the experiment using six separate donors and a higher ratio of neutrophils 
to organisms: this demonstrated a greater reduction in recovered luminescence than was 
seen previously (Figure 3.2B). The degree of suppression of bioluminescence using an MOI 
of 0.17 was similar for M. tb-lux (cell-containing samples exhibited mean 57.8% [range 
41.8% to 87.3%] luminescence of serum-only samples, see Figure 3.2C) and BCG-lux (cell-
containing samples exhibit mean 62.1% [range 32.7% to 105.4%] luminescence of serum-
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only samples, see Figure 3.2B). At 24 hours, the ability of cells to restrict mycobacterial 
luminescence versus serum was more significant than at one hour (Figure 3.2D), although 
interestingly there was relatively less effect at the highest MOI by this time point. On the 
basis of these results I concluded that an MOI of approximately 1 RLU to 1 – 2 neutrophils (1 
CFU to 3 – 6 neutrophils) was optimal to demonstrate an appreciable cell effect and yield 
inter-individual variability. Importantly, the addition of dead (heat-shocked) neutrophils to 
mycobacteria had no effect on mycobacterial bioluminescence at either 1 hour or 24 hours 
(Figures 3.2E and 3.2F). 
 
3.4   Lysis of neutrophils is not required in these experiments for accurate 
measurement of antimycobacterial effects 
Although the substrate for the lux construct is an aldehyde, which would be expected to 
diffuse freely through cell membrane [211], it could not be assumed that this would reach 
bacilli inside the phagosome of viable neutrophils. It was important to establish that the 
assay did indeed measure both intracellular and extracellular bacilli, since neutrophil killing 
may occur either inside or outside the cell. I thus proceeded to establish whether neutrophil 
lysis influenced measurement of mycobacterial bioluminescence, and hence accurate 
estimation of the antimycobacterial effect of neutrophils, in these experiments. Lysis using 
0.1% saponin solution in PBS, which permeabilised all human cells to propidium iodide 
(Figure 3.3A), did not have a different effect on mycobacterial luminescence to the addition 
of PBS vehicle alone (Figure 3.3B). An apparent increase in luminescence in both PBS and 
saponin-treated samples largely occurred immediately, most likely due to the increased 
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volume (which perhaps increased the amount of sample exposed to the luminometer’s light 
sensor). However, the ratio of luminescence in samples containing cells to that in samples 
containing serum alone was not influenced by the addition of saponin solution vs. PBS 
vehicle control (Figure 3.3C). I therefore maintained the assay volume at 500 mcl to ensure 
an adequate density of neutrophils in the assay, which may be limited depending on 
isolation method or blood volume.  
Plating for CFU of lysed samples also revealed the same pattern as RLU data (Figures 3.3D 
and E), suggesting that luminescence results indicating mycobacterial restriction by 
neutrophils are accurate. There was good correlation between RLU and CFU: at 1 hour 
Pearson r = 0.88 (95% CI 0.46 – 0.98, p = 0.004); at 24 hours Pearson r = 0.95 (95% CI 0.74 – 
0.99, p = 0.0003). 
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Figure 3.2. Restriction of mycobacterial luminescence by neutrophils is inversely proportional to 
multiplicity of infection and requires viable cells.  A. Luminescence of BCG-lux (Relative Light Units, RLU) at 
one hour post-inoculation according to MOI. Column heights represent the mean results from nine separate 
donors (neutrophils isolated by MicroBeads) performed in triplicate for each MOI; error bars indicate 
standard deviation (SD). The inoculum was standardised to 200,000 RLU (80,000 CFU) and the number of cells 
was varied as indicated. The serum control contained no neutrophils. Overall p-value for one-way ANOVA < 
0.0001. B. Luminescence of BCG-lux using higher ratio of neutrophils to organisms. Column heights represent 
the mean results from six different donors (neutrophils isolated by Percoll gradient) performed in triplicate 
for each donor; error bars indicate SD. Other experimental conditions as in (A). C. Luminescence of M. tb-lux 
using same MOI as in (B). Column heights represent mean results from four separate donors (neutrophils 
isolated by MicroBeads) performed in triplicate for each donor; error bars indicate SD. Other experimental 
conditions as in (A). D. 24-hour luminescence readings from same experiments presented in (A). Overall p-
value for one-way ANOVA < 0.0001. E. and F. Luminescence of BCG-lux (200,000 RLU / 80,000 CFU inoculum) 
incubated in RPMI-1640 with either 10% serum only (‘Serum’), serum plus viable neutrophils at MOI 0.17:1 
(‘Viable cells’) or serum plus neutrophils pre-heat-shocked at 60
o
C for 20 minutes at MOI 0.17:1 (‘Dead cells’); 
luminescence was measured at 1 hour (E) or 24 hours (F). 
 
I also investigated the time required to reach maximum luminescence in cell-containing and 
cell-free samples. There was a longer delay before peak luminescence in the cell samples, 
consistent with diffusion of the substrate across additional membranes (Figure 3.4A). 
Prolonged measurement times do not ‘close the gap’ between the cell samples and the 
serum-only samples, suggesting that there is not a slow or delayed diffusion of substrate to 
viable intra-cellular organisms (Figure 3.4B). I therefore concluded that 20 seconds was 
sufficient measurement time. 
Finally, the difference in luminescence between serum-only and cell-containing samples 
persisted to 24 hours (Figure 3.2D), a time point when most of the neutrophils have 
undergone cell death. In experiments using BCG-lux with MOI of 1 CFU:3 neutrophils, cell-
containing samples exhibited a mean of 81.6% (+/- 26.6%) of the luminescence of 
corresponding serum-only samples by one hour (across nine donors). At 24 hours this figure 
was 73.7% (+/- 28.5%), confirming that the bacteria do not recover after neutrophil death 
and hence that cell-mediated reduction in luminescence does not only reflect early 
phagocytosis (as noted earlier, dead cells do not directly impact upon mycobacterial 
luminescence). 
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Figure 3.3. Lysis or washing of cells results in artefactual increases in luminescence only. A. Saponin 
treatment permeabilises neutrophils. Samples of 400,000 neutrophils in 10% autologous serum were 
treated with 1ml 0.1% saponin (red line) or 1ml PBS (blue line) for 30 minutes and then incubated with 
5mcl propidium iodide for 20 minutes before acquisition on the flow cytometer. Figure shows granulocyte 
gate as set by forward and side scatter and propidium iodide signal (detected in PE-Cy7 channel). B. 
Saponin appears to increases luminescence in cell samples, but this effect is mediated by PBS alone. 
50mcl BCG-lux (400,000 RLU (150,000 CFU)) was inoculated into either 400mcl RPMI-1640 plus 50mcl 
autologous serum (‘serum’) or 400mcl neutrophil suspension (MOI = 1 CFU:3 neutrophils) in RPMI-1640 
plus 50mcl autologous serum (‘Cells’). After one hour’s incubation cell samples were allowed to cool and 
either vortexed and placed immediately in the luminometer (‘immediate’) or had 1ml 0.1% Saponin 
added, vortexed and incubated for 30 minutes before measurement in the luminometer (‘saponin’) or 
had 1ml PBS added, vortexed and incubated for 30 minutes before measurement in the luminometer 
(‘PBS’). Column heights represent mean values from four separate experiments, performed in triplicate at 
each occasion; error bars represent SD. p-values from paired t-tests. NS = Not Significant. C. Ratio of cell 
luminescence to serum luminescence does not change depending on condition. Ratio of cell:serum 
luminescence was calculated on samples from (b), also including measurements on serum and cell 
samples immediately after the addition of PBS or saponin. p > 0.05 across all conditions. Column heights 
represent means, error bars represent SD. D and E. CFU show similar pattern to RLU readings. RLU (left-
hand columns, small checks), and colony forming units (right-hand columns, large checks) in 500mcl 
samples containing 10% autologous serum and the number of neutrophils as indicated on the x-axis, 
initially inoculated with 200,000 RLU (80,000 CFU) BCG-lux. RLU and CFU were measured after one hour 
(d) or 24 hours (e) incubation at 37
o
C. Column heights represent means from two separate experiments, 
performed in triplicate for each condition; error bars represent SD. * = p < 0.05 versus serum control. 
Overall p-values for one-way ANOVA: 1 hour RLU, 0.019; 1 hour CFU, 0.019; 24 hour RLU, 0.027; 24 hour 
CFU, 0.010. Above each pair of columns is the mean RLU:CFU ratio for that MOI and time point. F. There is 
no greater residual luminescence in cell versus serum samples after replacing culture medium. Samples 
containing 200,000 RLU (80,000 CFU) BCG-lux, 10% autologous serum and either no neutrophils (‘Serum’) 
or 400,000 neutrophils (‘Cells’) were incubated at 37
o
C for one hour. Sample luminescence was either 
measured directly or culture medium was pipetted away and 500mcl fresh RPMI-1640 added before 
measurement (‘Serum pipetted’ and ‘Cells pipetted’). Results represent three separate experiments, 
performed in duplicate for each condition; p-values derived from paired t-tests. 
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Figure 3.4. ‘Time to peak’ and effect of reading time on measured luminescence in serum-only and neutrophil 
samples. A. Time to peak luminescence after addition of substrate was measured for M. tb-lux incubated for one hour 
in either 400mcl RPMI-1640 plus 50mcl serum (‘Serum’) or into 400mcl neutrophil suspension (at 1 x 10
6
 / ml) plus 
50mcl serum (‘Cells’). Column heights represent mean values from three separate donors; error bars represent SD. p = 
0.001 by two-tailed t-test. B. Total measured luminescence of BCG-lux according to time of measurement (one 
experiment). Triangles = serum only samples; squares = samples containing cells. Markers represent mean values from 
duplicate (serum) or triplicate (cell) readings.  
 
 
3.5   Neutrophils are not lost due to adherence to walls of luminometer tubes 
Incubating tubes with horizontal rocking, which is conventional for neutrophil antimicrobial assays 
[212] and for the whole blood lux assay [213], raised the concern that adherence of neutrophils to 
A 
B 
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the walls of the tubes during incubation could lead to cells ‘sequestering’ bacilli away from the 
light sensor in the luminometer. My colleague (Nonzwakazi Bangani), blinded to time point, 
measured total sample volume and performed microscopy with counting chambers on aliquots of 
vortexed samples before and after one hour’s incubation. Volumes did not decrease and, across a 
range of cell densities, we did not observe any significant reduction in the number of neutrophils 
counted by one hour (mean difference in cell count before and after incubation across four 
experiments = 0.4%; p = 0.96).  
I continued to investigate this potential issue by pipetting away the culture medium after one 
hour’s incubation and replacing with fresh medium. As demonstrated in Figure 3.3F, there was no 
greater residual luminescence in cell-containing samples vs. serum-only samples: again, this 
suggests that bacilli are not sequestered in adherent cells.  
 
3.6   The phagocytosis assay demonstrates clear populations of neutrophils 
defined by the presence and location of organisms  
Figures 3.5A to D demonstrate that when using BCG-lux, the phagocytosis assay clearly identifies 
cells with intracellular and extracellular organisms. FITC-positive, trypan blue-negative cells have 
internalised organisms only; FITC-positive, trypan blue-positive cells have both internal and 
external organisms; FITC-negative, trypan blue-positive cells only possess external organisms 
while dual negative cells are not associated with organisms.  
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3.7   Significant clumping of organisms does not occur at lower organism 
concentrations 
Since mycobacteria clump in culture, I investigated whether this phenomenon might have 
interfered with my experiments. Samples of FITC-labelled organisms with autologous serum in 
RPMI were processed identically to cell samples from six donors and then acquired on the flow 
cytometer for the maximum duration taken by a contemporaneous cell sample to reach 50,000 
events.  
Figure 3.6A shows that at high organism concentrations (5 x 106 RLU / 1.7 x 106 CFU in a 500mcl 
sample, the concentration used to create MOI 3 CFU:1 cell in these experiments), clumping can be 
significant and that organisms may mimic granulocytes by forward and side scatter. Although a cell 
surface marker may minimise this problem, Figure 3.6B shows how a clump of organisms attached 
to a cell (hence surface marker positive) may retain its green signal even after ‘quenching’ with 
trypan blue. However, at lower concentrations clumping of organisms is not a significant problem, 
with ‘granulocyte-mimicking’ organism events representing less than 0.1 percent of true cell 
events (Figure 3.6C). Confocal imaging confirmed that at lower MOIs most neutrophils contained 
only one or two bacilli (Figure 3.6D). I also confirmed that at this concentration of organisms 
trypan blue is able to quench FITC fluorescence and lend red fluorescence to organisms (Figure 
3.6E). 
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Figure 3.5. Gating strategy and interpretation for phagocytosis assay. A. First, doublet signals are excluded by 
plotting Forward Scatter Area versus Forward Scatter height. B. Dead cells are excluded on the basis of positivity for 
eFluor450 Fixable Viability Dye (signal seen in Pacific Blue channel); note that most dead cells are also positive for 
trypan blue (signal seen in APC channel). C. Neutrophils are defined as positive for PE-conjugated CD66a,c,e and high 
side scatter. D. Neutrophils are divided into quadrants on the basis of trypan blue signal (APC) and FITC signal (Alexa 
Fluor 488). Q1 (FITC positive, trypan blue negative): internalised organisms only; Q2 (FITC positive, trypan blue 
positive): internal and external organisms; Q3 (FITC negative, trypan blue positive): external organisms only; Q4: 
(FITC negative, trypan blue negative): not associated with organisms.  
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3.8   Internalisation increases with Multiplicty of Infection, but not in a linear 
fashion 
An analysis exploring the influence of multiplicity of infection on internalisation is shown in Figure 
3.7 and Table 3.1. As can be seen, there was an approximately linear increase in both 
internalisation and total percentage of cells which are ‘organism associated’ (i.e. those with both 
internalised and external bacteria) up to an MOI of 1 CFU:3 cells. After this the increase plateaus.  
At the lowest MOI (1 CFU:30 cells), there was less heterogeneity between donors and more 
external binding. At the highest MOI (3 CFU:1 cell) the forward and side scatter properties of the 
cells were altered and the number of viable neutrophils counted per 50,000 events was 
significantly reduced (22682 +/- 7844 vs 30077 +/- 7370 events, p = 0.037). Use of MOI of 3 CFU:1 
cell was also associated with a very high FITC median fluorescence intensity (MFI) which interfered 
with the PE signal of the neutrophil cell surface marker CD66a,c,e even after compensation (Figure 
3.7B and 3.7C. At lower MOI the CD66a,c,e expression, as indicated by PE MFI, was consistent for 
individual donors, suggesting that it may represent a useful indicator of activation or 
degranulation (Figure 3.7D). 
I therefore utilised an MOI of 1 CFU to to 3 – 6 cells for optimal results in terms of both minimising 
organism clumping (Figure 3.6) and easily measuring internalisation. These MOIs are also suitable 
for the restriction assay (see above). 
I was able to repeat the assay in three of the donors, maintaining MOI 1:3. The mean difference in 
percentage of neutrophils internalising mycobacteria between the first and second experiments 
was only 1.76%, suggesting good reproducibility of the method. 
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Figure 3.6. Assessment of clumping. A. A Forward Scatter 
versus Side Scatter plot of BCG-lux organisms (with 10% 
serum in RPMI-1640) demonstrates how organisms can 
mimic cells; the granulocyte gate was derived from a 
contemporaneous cell sample from the donor of the 
serum. B. Confocal microscopy image of a clump of BCG 
organisms attached to a neutrophil; note that the green 
fluorescence of individual external organisms has been 
‘quenched’ by trypan blue and they now fluoresce red 
(arrows), while the clump of organisms remains green. 
Nuclei are stained with Hoechst 33342. C. Samples of BCG-
lux at different concentrations in the presence of human 
serum in RPMI-1640 were processed identically to cell-
containing samples and results acquired on the flow 
cytometer. The number of events in these organism-only 
samples seen inside a granulocyte gate derived from a 
contemporaneous cell sample (on the basis of forward and 
A C 
B D 
E 
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side scatter) are here expressed as a percentage of the number of viable neutrophils in that cell sample; note the 
logarithmic y-axis and hence results are not shown if they are zero. Each marker represents one donor; lines represent 
medians. Overall p-value for Kruskal-Wallis test = 0.0028. D. Orthogonal Confocal microscopy images confirm in three 
dimensions that organisms (here GFP-expressing BCG-lux) are internalised and, as it typical at an MOI of 1 CFU:6 cells, 
most neutrophils only contain one or two organisms. Nuclei are stained with Hoechst 33342. E. Samples of 8 x10
4
 CFU 
FITC-labelled BCG-lux were prepared in 1ml PBS with 12.5mcl trypan blue (red line) or without trypan blue (blue line), 
centrifuged and fixed in 2% paraformaldehyde before acquisition on the flow cytometer. Signal in the FITC and APC 
(trypan blue) channels is represented for both samples; trypan blue treatment results in near-total loss of FITC signal and 
increase in APC signal.  
 
 
 
 
 
    Table 3.1. Results from the phagocytosis assay (six donors) according to multiplicity of infection. 
Multiplicity of 
infection 
(CFU:cells) 
A. Neutrophils 
with 
internalised 
organisms only 
(mean % +/- 
standard 
deviation) 
 
B. Neutrophils 
with both 
internalised 
and external 
organisms 
(mean % +/- 
standard 
deviation) 
C. Neutrophils 
with external 
organisms only 
(mean % +/- 
standard 
deviation) 
D. Total with 
internalised 
organisms  
(= A. + B.) 
(mean % +/- 
standard 
deviation) 
E. Total with 
external 
organisms 
(= B. + C.)  
(mean % +/- 
standard 
deviation) 
F. Neutrophils 
not associated 
with organisms 
(mean % +/- 
standard 
deviation) 
0.03:1 5.32 +/- 2.45 0.68 +/- 0.24 13.05 +/- 8.06 6.01 +/- 2.58 13.73 +/- 8.15 80.96 +/- 7.15 
0.15:1 20.82 +/- 11.63 1.77 +/- 0.65 7.17 +/- 3.58 22.59 +/- 12.15 8.94 +/- 3.20 70.25 +/- 8.85 
0.3:1 31.07 +/- 10.91 4.47 +/- 2.33 8.51 +/- 4.34 35.54 +/- 11.24 12.98 +/- 5.08 55.93 +/- 7.50 
3:1 56.42 +/- 15.11 20.05 +/- 15.85 3.98 +/- 2.61 76.47 +/- 14.62 24.03 +/- 16.50 19.57 +/- 13.54 
CFU = Colony forming units. 
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Figure 3.7. Determining optimal multiplicity of 
infection to demonstrate phagocytosis. A. Percentage 
of viable neutrophils with internalised organisms or 
‘organism associated’ (includes those cells with 
external organisms only) according to infecting 
inoculum of pre-opsonised FITC-labelled BCG-lux. The  
 
 
x-axis is a log10 scale, and inocula used for these 
experiments are indicated. Expressed as MOI 
(CFU:cells), 1.7 x 10
4
 CFU = 1:30; 8 x 10
4
 CFU = 1:6; 1.7 
x 10
5
 CFU = 1:3; 1.7 x 10
6
 RLU = 3:1. Markers represent 
mean of six experiments, error bars represent 
standard deviation. Neutrophils isolated by 
MicroBeads. B. FITC Median Fluorescence Intensity 
(MFI) of viable neutrophils according to multiplicity of 
infection (MOI). Points represent means of six donors, 
error bars represent standard error of the mean. C. PE 
MFI of viable neutrophils according to multiplicity of 
infection (MOI). Points represent means of all donors, 
error bars represent standard error of the mean. D. PE 
MFI for the three lower MOI (1 CFU:30 cells, 1 CFU:6 
cells, 1 CFU:3 cells) plotted according to donor. Lines 
represent means. 
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Figure 3.8. Phagocytosis is inhibited by ice. The phagocytosis assay was performed using an MOI of 1 RLU:1 cell 
(0.3 CFU:1 cell); samples were incubated for 30 minutes either at 37
o
C or on ice (0
o
C). The y-axis represents the 
total percentage of neutrophils with internalised organisms. 
 
3.9   Internalisation is inhibited by low temperature and results are comparable 
with those using acid-resistant fluorophores 
As a test of the reliability of the assay, I processed matched samples incubated at either 37oC or 
on ice (Figure 3.8). Ice inhibited internalisation significantly (using MOI 0.3 CFU:1 cell, mean 
percentage of neutrophils with internalised organisms at 37oC = 39.2% +/- 11.3%, mean 
percentage of neutrophils with internalised organisms at 0oC = 2.8% +/- 3.1%, p = 0.047). There 
was also a trend towards greater external binding when incubated on ice (using MOI 0.3 CFU:1 
cell, mean percentage of neutrophils with external binding at 37oC = 9.9% +/- 7.1%, mean 
percentage of neutrophils with external binding at 0oC = 19.4% +/- 13.0%). 
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Due to concerns regarding the acid resistance of FITC, I also compared the assay with 
experiments using the acid-resistant fluorophore pHrodo™ (Invitrogen): Figure 3.9 details the pH 
sensitivity and gating strategy (labelling is detailed in Chapter 2). The mean internalisation using 
BCG-lux and an MOI of 0.3 was 37.6% using pHrodo™ versus 35.5% for my assay, which I 
considered to be comparable. 
 
3.10   Trypan blue stains dead and fixed cells 
As mentioned above, trypan blue is commonly used in flow cytometry based phagocytosis assays 
to ‘quench’ extracellular fluorescence, and since it fluoresces itself in the red spectrum can be 
used to identify surface-bound organisms [207, 209]. However, trypan blue also enters dead cells 
and these could therefore be interpreted as organism-associated events. Indeed, samples 
processed without organisms showed good concordance between trypan blue and a Fixable 
Viability Dye (eFluor450) in identifying dead cells: see Figures 3.10A, B and C. 
Using a Viability Dye in my experimental samples excluded a mean of 1097 (+/- 407) events per 
sample, which represented 3.77% (+/- 0.11%) of viable neutrophils.  
I was also concerned that fixed cells would become positive for trypan blue signal. To investigate 
this, samples with a 1 CFU:3 cells MOI were processed again the following day. After this 
prolonged fixation (17 – 24 hours) nearly all events had become positive for trypan blue (see 
Figure 3.10D). However, there was only limited quenching of internalised signal: the mean 
percentage of FITC positive events on the following day was 95.7% that of the immediately 
acquired samples.  
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3.11   Non-heat inactivated autologous serum is optimal to demonstrate 
significant phagocytosis and mycobacterial restriction 
Phagocytosis of mycobacteria by neutrophils is likely to be influenced significantly by opsonisation 
[85] and I therefore investigated the need for pre-opsonisation and compared autologous and 
fetal calf serum as opsonins. 
Using an MOI of 1 CFU:3 cells I processed contemporaneous samples either pre-opsonised (20 
minutes incubation of organisms and serum), non-pre-opsonised but with serum added at the 
same time as organisms, or no serum at all. Results of internalisation and external binding for six 
donors are shown in Figure 3.11A. There was no significant difference between the percentages of 
neutrophils internalising organisms when pre-opsonised or when serum was added at the same 
time as mycobacteria. However, there was a highly significant difference (p < 0.001) between both 
these conditions and the percentage of neutrophils internalising organisms in the ‘no serum’ 
samples. There was a non-significant trend towards greater external binding in the absence of 
serum. 
Since the results of this assay reflect both the donor’s cellular phagocytic capability and the extent 
of opsonisation I repeated the assay, using an MOI of 1 CFU:3 cells, with stored serum from all six 
donors but a single neutrophil donor. In terms of total internalisation, the coefficient of variation 
between donors reduced from 30.5% when using autologous neutrophils to 12.5% when using a 
single neutrophil donor. 
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Figure 3.9.Use of pHrodo™ to evaluate neutrophil phagocytosis of mycobacteria. A. pH sensitivity of pHrodo-
labelled BCG. Approximately 100,000 CFU of pHrodo™-labelled BCG-lux were suspended in 500mcl buffer at 
pH 4, 7, 8 or 9.6. Samples were acquired on a BD Fortessa flow cytometer, and pHrodo fluorescence was 
measured in the PE-Texas Red channel. Green line – pH9.6, orange line – pH 8, blue line – pH 7, red line – pH 4. 
B. Gating strategy for pHrodo-based phagocytosis assay. First, singlet signals are gated (forward scatter area 
versus height). Subsequently, dead cells are excluded using eFluor450 Viability Dye versus side scatter. 
Neutrophils are gated via forward and side scatter characteristics. Finally, pHrodo signal is detected in the PE-
Texas Red channel versus APC (redundant channel). FSC = forward scatter, SSC = side scatter. 
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Figure 3.10. Trypan blue stains dead and prolonged fixed cells. A - C. Concordance of eFluor450 Fixable 
Viability Dye (fluorescence detected in the Pacific Blue channel) and trypan blue (fluorescence detected in APC 
channel). Samples of 400,000 neutrophils without organisms were stained with 12.5mcl trypan blue and 1mcl 
eFluor450 Fixable Viability Dye only; A – freshly isolated cells; B – cells heat-shocked at 60
o
C for 20 minutes; C 
– sample containing half freshly isolated and half heat-shocked cells. Plots include all singlet events. D. A 
sample of neutrophils containing FITC-labelled BCG organisms was acquired immediately (blue) and the 
following day (red); note the shift on the trypan blue axis (APC channel) but little change in the FITC (Alexa-
Fluor 488) axis.   
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Figure 3.11. Investigation of opsonisation. A. Internalisation and external binding of FITC-labelled BCG-lux by viable 
MicroBead-isolated neutrophils according to opsonisation.  All conditions performed with MOI 1 CFU:3 cells and 
incubated for 30 minutes. ‘Pre-opsonised’ – organisms were incubated with autologous serum for 20 minutes at 37
o
C 
before infection of cells. ‘Non-pre-opsonised’ – organisms and serum were added at the same time. ‘No serum’ – 
organisms were added without serum. Each marker represents one donor; lines represent means. Overall p-value for 
one-way ANOVA < 0.0001. B. Plot of FITC signal in viable neutrophils from one donor incubated (1 CFU:3 cells) with 
labelled organisms for 30 minutes. Blue line: organisms pre-opsonised for 20 minutes with autologous serum; Red 
line: organisms pre-opsonised for 20 minutes with heat inactivated Fetal Calf Serum (contemporaneous sample). 
FITC Signal 
B 
A 
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Heat inactivation of serum at 56oC reduced internalisation (by the same single donor’s 
neutrophils) significantly but not entirely: mean value reduced from 47.7% to 7.9% of 
neutrophils internalising. However, the coefficient of variation among the heat inactivated 
serum samples was higher than with intact serum, at 36.1%. Use of Heat inactivated Fetal 
Calf Serum yielded similar results to the ‘No serum’ condition (see Figure 3.11B), with 
internalisation less than 1%. 
Non-heat-inactivated serum was also optimal for sustaining mycobacterial luminescence in 
the restriction assay, and hence allowed maximum demonstration of neutrophil-mediated 
restriction. RPMI alone significantly reduced mycobacterial bioluminescence (see Figure 
3.12). Heat inactivation of serum at 56oC, and even more so at 90oC, reduced mycobacterial 
luminescence towards the level seen in RPMI alone, and this pattern was maintained to 24 
hours. The use of Hanks’ Balanced Salt Solution (HBSS) resulted in proportionally higher 
readings for all conditions but the same pattern of results was maintained.  
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Figure 3.12. Serum is required for mycobacterial viability. 50mcl BCG-lux was incubated into 400mcl RPMI-
1640 plus 50mcl serum pre-incubated at room temperature for 30 minutes (‘Room temp’), into 400mcl RPMI-
1640 plus 50mcl serum pre-incubated at 56
o
C for thirty minutes (‘56 degrees’), into 400mcl RPMI-1640 plus 
50mcl serum pre-incubated at 90 degrees for 2 minutes (‘90 degrees’), or into 450mcl RPMI-1640 without 
serum (‘RPMI only’). Luminescence was measured after one hour’s incubation. Markers represent the mean of 
duplicate results from eight separate donors (serum conditions) and three contemporaneous RPMI-only (no 
serum) experiments. 
 
 
3.12   Neutrophils are responsible for an early drop in luminescence in the 
whole blood lux assay 
Results in this chapter have demonstrated that neutrophils rapidly phagocytose and 
eliminate mycobacteria. I therefore investigated whether there was any effect of 
neutrophils during the initial experiment of the whole blood lux assay, since mycobacteria 
are usually inoculated into blood for several minutes before the initial centrifuge spin. These 
experiments were all standardised to 70 minutes duration. 
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There was a fall in recovered luminescence even in samples of BCG-lux processed in 7H9 
growth medium; however, there was a far greater reduction in blood samples (Figure 
3.13A). Adding 50% RPMI-1640 to the growth medium prior to the experiment did not affect 
the lux readings in this assay (percentage of inoculum recovered: 54.0 +/- 19.0% for 7H9 vs 
50.7 +/- 21.5% for 7H9/RPMI, p = 0.71; n = 15 for 7H9 samples, n = 8 for 7H9/RPMI 
samples), confirming that RPMI-mediated ‘toxicity’ did not explain the fall in luminescence 
in blood samples. The differential recovery was partially explained by a greater residual 
volume in the blood samples (1338 +/- 43 mcl vs 1060 +/- 20 mcl, p < 0.0001; n = 10 for 
blood samples, n = 8 for 7H9 samples) since luminescence is measured on only 100mcl in 
each instance. There was also an effect of ‘quenching’ of luminescence by residual 
haemoglobin in the blood samples: I investigated this by running samples of uninfected 
blood through the assay before inoculating BCG-lux and then immediately measuring 
luminescence. This quenching accounted for a 17.0 +/- 9.8% immediate fall in measured 
luminescence. Investigating quenching in a variety of fluids including blood at various 
dilutions, I observed an approximately linear relationship between fluid absorbance and 
reduction in luminescence with the exception of undiluted whole blood / 50% RPMI 
samples, which profoundly reduced measured lux (Figure 3.13B). This confirms that lysis is a 
necessary step in the whole blood lux assay. 
However, even after adjusting for volume and quenching effects, there was still a 
significantly greater fall in luminescence in blood samples versus 7H9 controls (Figure 
3.13A). This effect was abolished by depletion of CD15+ cells (granulocytes). Flow cytometry 
of post-assay samples confirmed that neutrophils are lysed by the 10 minute incubation 
with 10ml water (Figures 3.13C & 3.13D), confirming that the reduction in luminescence in 
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whole blood was not simply due to neutrophils ‘sequestering’ phagocytosed bacilli to 
reduce contact with substrate or to reduce emission of light. Quenching was similar in post-
assay CD15 deplete or non-depleted samples (18.7 +/- 11.4% vs 17.0 +/- 9.8% respectively, p 
= 0.81).  Furthermore, the same pattern of results was maintained when plating for CFU 
(Figure 3.13E) while the effect was reduced by incubating samples on ice, suggesting a 
cellular basis for the phenomenon (Figure 3.13F). 
Data from nine healthy tuberculosis contacts recruited at Northwick Park Hospital 
(characteristics summarised in Table 3.2) confirm that only CD15 depletion affects this early 
luminescence result, while CD4, CD8 or CD14 depletion have no significant effect (Figure 
3.14A). Note that data here were log-transformed to normalise. Indeed, there was a 
significant negative correlation between neutrophil count in the various depleted or 
undepleted samples and the early recovered luminescence (Figure 3.14B), while there was 
actually a weak positive correlation with lymphocyte count (Figure 3.14C). 
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Table 3.2. Characteristics of tuberculosis contacts recruited (n = 9). 
 
Age (years) Median 
Range 
36.0 
17 – 64  
 
Ethnicity Indian  
Pakistani    
Black African    
  
4 (44.4%) 
1 (11.1%) 
4 (44.4%) 
 
Sex Male    
Female    
4 (44.4%) 
5 (55.6%) 
 
Smoking Yes 
No 
 
1 (11.1%) 
8 (88.9%) 
Alcohol Yes 
No 
 
1 (11.1%) 
8 (88.9%) 
BCG Yes 
No 
Unsure / Unclear 
 
7 (77.8%) 
1 (11.1%) 
1 (11.1%) 
Mantoux induration 
(mm) 
Median 
Range 
 
18 
10 – 30  
Site of contact disease Pulmonary    
Miliary 
Joint (hip)
 
7 (77.8%) 
1 (11.1%) 
1 (11.1%) 
 
Co-morbidity 
a 
Absent    
Present   
 
6 (66.7%) 
3 (33.3%) 
 
HIV status Negative    
Positive    
 
9 (100%) 
0 (0%) 
 
Medication in previous 3 
months
 b 
Yes 
No 
 
5 (55.6%) 
4 (44.4%) 
Neutrophil count (x10
9
/L) Mean 
Range 
 
3.83 
1.87 – 5.79 
a
 Identified co-morbidities: hypertension, sickle cell trait. 
b 
Identified medications: paracetamol, ibuprofen, bendrofluazide, mebeverine.  
 
BCG = Mycobacterium bovis-BCG; mm = millimetres; HIV = human immunodeficiency virus. 
 
 
114 
 
7H9 Whole Blood CD15 deplete blood
0
10
20
30
40
50
60
70
80
90
p < 0.001 p < 0.05
NS
%
 o
f 
b
a
s
e
li
n
e
 l
u
m
in
e
s
c
e
n
c
e
re
c
o
v
e
re
d
 i
n
p
o
s
t-
a
s
s
a
y
 s
a
m
p
le
 
 
0 5 10 15 20
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
Other fluids
WB / 50% RPMI
Ratio of absorbance to 7H9 control
R
a
ti
o
 o
f 
lu
m
in
e
s
c
e
n
c
e
 t
o
 7
H
9
 c
o
n
tr
o
l
 
7H9 Whole BloodCD15 deplete blood
0
25000
50000
75000
100000
125000
p < 0.05 p < 0.05
C
F
U
NS
 
 
 
Room temp 37 degrees Ice
0
100000
200000
300000
L
u
m
in
e
s
c
e
n
c
e
 p
e
r 
1
0
0
m
c
l
m
e
a
s
u
re
d
 a
ft
e
r 
in
it
ia
l 
e
x
p
e
ri
m
e
n
t
p < 0.01
p < 0.01
Figure 3.13. Investigating the early fall in luminescence in the whole blood BCG-lux assay. A. Samples of 900mcl 7H9 
(‘7H9’), 450mcl blood + 450mcl RPMI (‘Whole Blood’) or 450mcl CD15-depleted blood + 450mcl RPMI (‘CD15 deplete 
blood) were infected with BCG-lux at several concentrations and processed through the baseline experiment of the 
whole blood lux assay. Results are presented as the percentage of luminescence recovered in 100mcl (derived from 
duplicate or triplicate readings in 900mcl PBS) versus the starting inoculum. Results take into account volume of the 
post-assay sample, and blood sample readings are also adjusted for ‘quenching’ (see text). Blood samples are all from 
a single donor; n=15 for 7H9, n=16 for Whole Blood, n=4 for CD15 deplete blood. B. BCG-lux was inoculated into 
A B 
C D 
E F 
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different fluids (900mcl 7H9; 450mcl 7H9 + 450mcl RPMI; 450mcl blood + 450mcl RPMI [either neat, diluted 1:10 or 
diluted 1:100]; and post-assay, previously uninfected blood samples. Luminescence and absorbance were measured 
on duplicate aliquots of 100mcl in 900mcl PBS, and are presented as ratios versus 7H9 controls in each instance. 
Undiluted blood + RPMI samples are represented by triangles, other samples by squares. C. The first experiment of the 
whole blood BCG-lux assay was run using BCG-GFP-Lux and the post-assay sample was processed on a BD FACS Canto 
II flow cytometer. This panel shows a representative forward and side scatter plot, demonstrating very few 
granulocytes. D. The same sample is gated on GFP (Alexa-Fluor-488) positive events, showing that only a very small 
percentage of organism events are associated with granulocytes. E. Samples were processed as in (A) but samples 
were plated for CFU; results are adjusted for total final volumes. n=7 for whole blood and CD15 deplete blood, n=4 for 
7H9. F. Matched blood + RPMI samples from four donors were infected with BCG-lux and then kept at room 
temperature, 37
o
C or on ice for one hour and during water lysis. Samples were then centrifuged, pellets resuspended 
and luminescence measured on triplicate samples of 100mcl in 900mcl PBS.  
 
 
CD4 deplete CD8 deplete CD14 deplete CD15 deplete Whole Blood
3.5
4.0
4.5
5.0 **
*
**
*
L
o
g
 (
lu
m
in
e
s
c
e
n
c
e
re
a
d
in
g
 i
n
 T
0
 e
x
p
e
ri
m
e
n
t)
 
 
0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25
0
5000
10000
15000
20000
25000
30000
35000
Neutrophil count (x10
9
/L)
L
u
m
in
e
s
c
e
n
c
e
 r
e
a
d
in
g
in
 T
0
 e
x
p
e
ri
m
e
n
t
p < 0.0001
 
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1
0
5000
10000
15000
20000
25000
30000
35000
p = 0.04
Lymphocyte count (x 10
9
/L)
L
u
m
in
e
s
c
e
n
c
e
 r
e
a
d
in
g
in
 T
0
 e
x
p
e
ri
m
e
n
t
 
Figure 3.14. The relative effect of different cell depletions on early measured mycobacterial luminescence. A. 
Blood from nine tuberculosis contacts was divided into aliquots which were then either depleted of the 
indicated cell type or left undepleted (Whole Blood) before infection with BCG-lux and processing through the 
first experiment of the whole blood lux assay. Log-transformed luminescence readings from duplicate aliquots 
of 100mcl post-assay sample in 900mcl PBS are plotted according to cell depletion. * = p<0.01, ** = p<0.001. B. 
Neutrophil counts from all depleted and undepleted samples are here plotted versus the luminescence 
reading obtained as in (A). C. Lymphocyte counts from all depleted and undepleted samples are here plotted 
versus the luminescence reading obtained as in (A). 
A 
B C 
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3.13   Discussion 
In this chapter I have first demonstrated a novel, simple technique to assess restriction of 
mycobacteria by human neutrophils, and subsequently presented an optimised 
phagocytosis assay which can be used contemporaneously. Finally I have explored the early 
effect of neutrophils in the whole blood lux assay. 
The restriction experiments were performed in single tubes without transferring or 
disturbing the medium during analysis; extensive evidence confirmed that lysis of human 
cells is not required. As expected, increasing the ratio of neutrophils to mycobacteria 
improves restriction on average, but there was considerable variability depending on donor 
– as previously reported [87]. This heterogeneity suggested that the technique may prove 
useful in detecting important inter-individual differences in innate immune function. 
Luminescent organisms carry a number of advantages for these assays: the ability to 
accurately standardise inocula (vital if performing cross-sectional inter-donor or prospective 
intra-donor analysis), the capacity to perform high throughput experiments with multiple 
replicates of experimental conditions, and instant results. It should be noted that the ‘read-
out’ in the restriction experiments is a marker of mycobacterial metabolism and, although 
there does appear to be good correlation with CFU results (Figures 3.3D and 3.3E), the assay 
does not directly measure bacterial numbers. Nevertheless, it is arguable that luminescence 
is a better marker of overall organism ‘fitness’ [203], and since there is no recovery of 
luminescence over 24 hours despite death of the granulocytes I concluded that the impact 
on bacillary fitness by neutrophils is long-lived. Neutrophils do not of course work in 
isolation in the body and, as ‘first responders’ before the arrival of other cells, a substantial 
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impact on mycobacterial metabolism, rendering organisms more susceptible to killing, may 
be as significant as killing itself. 
The phagocytosis assay presented here resolves a number of issues of particular concern for 
experiments using mycobacteria and neutrophils. First, if the density of organisms is too 
high then clumping can be significant enough to interfere with flow cytometric analysis and 
the fluorescence of organisms affects other cytometric channels. However, I discovered that 
at lower concentrations (below approximately 5 x 105 RLU, or 1-2 x 105 CFU, in 500mcl total 
volume) these issues were not significant. At lower MOI it is therefore not essential to use a 
cell surface marker to confirm that a ‘granulocyte’ event, as defined by forward and side 
scatter, is a mammalian cell. Nevertheless, I included CD66a,c,e-PE in my assay since it also 
served as a useful marker of neutrophil activation and degranulation (see Figure 3.7D and 
subsequent chapters). 
Conversely, too low a concentration of organisms (5 x 104 RLU, or 1.7 x 104 CFU incubated 
with 4 x 105 neutrophils in 500mcl volume) reduced inter-donor variability and appeared to 
increase external binding. This latter finding may relate to a ‘delay’ in the neutrophils 
encountering the organisms. 
I also investigated the correct usage of the quenching agent trypan blue in this assay. Since 
neutrophils die rapidly in vitro, a significant percentage of cell events may be due to dead 
cells and hence artefactually trypan blue positive: it was therefore essential to also use a 
viability dye. It should be noted that the emission spectrum of trypan blue is broad in the 
red and far-red spectrum. Indeed, I found similarly high MFI for trypan blue positive events 
among single-stained control samples in APC, Phycoerythrin-cyanin 5.5 (PE-Cy5.5), PE-Cy7 
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and Peridinin Chlorophyll Protein-Cyanin 5.5 (PerCP-Cy5.5). This necessarily limited the 
number of extra fluorochromes which can be added to the assay. 
Another important aspect was the need for prolonged fixation to ensure death of organisms 
when using virulent mycobacteria. As I have demonstrated, this permeabilises cells to 
trypan blue and as such the phagocytosis assay cannot be effectively used to resolve 
surface-bound organisms with M. tuberculosis. Importantly however, internalised signal 
does remain fairly reliable.  
Despite these issues, I still believe that use of a quenching agent is the best solution to 
prove internalisation compared to other strategies. Phagocytosis inhibitors (eg cytochalasin 
D) to create a ‘negative’ control [214] may not completely abolish internalisation and may 
result in greater relative surface adherence; incubating samples on ice appeared to induce 
the same phenomenon (Figure 3.8). Use of a secondary labelling antibody to identify 
mycobacteria on cell surfaces and removing these events [88] will also remove signals from 
cells which have both internalised and adherent organisms. Antibiotic elimination of 
extracellular organisms is unlikely to occur rapidly enough to allow processing of samples 
before neutrophil cell death, and fluorochrome labels can remain fluorescent on dead 
organisms. The pH-sensitive fluorochrome pHrodo™ (Invitrogen) only fluoresces strongly 
when the pH of its micro-environment falls, consistent with internalisation into the 
phagosome. However, this does not enable resolution of surface-bound organisms, and 
there is a risk of inaccuracy if virulent mycobacteria prevent acidification of the phagosome 
[215]. Finally, I found that the labelling procedure significantly affected viability resulting in 
difficulty with standardising inocula and consequent variability in the assay. 
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I also investigated the impact of opsonisation on neutrophil phagocytosis of mycobacteria. 
Although a separate period of pre-opsonisation was not required to permit phagocytosis, 
serum was clearly needed to permit internalisation (see Figure 3.11). Heat inactivation of 
serum significantly reduced the percentage of neutrophils internalising organisms, perhaps 
suggesting an important role for complement in this regard. It was interesting to note that 
the assay worked successfully using a single donor’s neutrophils but different donors’ 
serum, allowing me to directly compare the opsonic capacity of serum. Heat inactivation in 
this context significantly increased the coefficient of variation between the percentages of 
neutrophils internalising mycobacteria with different donors’ serum. This may represent the 
variable presence or activity of antibodies and could represent another measurable 
outcome. 
However, heat inactivation of serum also resulted in impaired mycobacterial metabolism in 
the restriction assay’s control condition (serum + medium only; see Figure 3.12). This effect, 
combined with reduced neutrophil phagocytosis, made it more difficult to identify the anti-
mycobacterial effect of the cells. Hence for the purposes of the restriction assay and to 
ensure measurement of appreciable internalisation in the phagocytosis assay, non-heat-
inactivated serum appeared preferable in most circumstances. 
The final section of this chapter demonstrated an early fall in mycobacterial luminescence 
(and CFU) in whole blood which was reduced by incubating blood on ice and abolished by 
depletion of CD15+ cells, but not by depletion of other cell types. Indeed, the early 
measured luminescence strongly negatively correlated with neutrophil count. The apparent 
positive correlation with lymphocyte count (Figure 3.14C) is probably explained by the fact 
that the neutrophil-deplete samples (with high luminescence readings) had relatively higher 
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lymphocyte counts while neutrophil-replete samples with lower luminescence included the 
CD4 and CD8-depleted samples and thus had lower lymphocyte counts. 
This phenomenon is important because it suggests that using the luminescence at the end 
of the baseline experiment as a denominator for calculating a mycobacterial growth ratio 
will underestimate the effect of neutrophils. It is thus more appropriate to use the initial 
infecting inoculum as the denominator for measuring growth.  
In summary, in this chapter I have demonstrated robust and easily used techniques to 
measure mycobacterial restriction and phagocytosis of mycobacteria by human neutrophils, 
and interrogated the whole blood lux assay in terms of early neutrophil-mediated effects. 
However, developing these methodologies also hinted at important biology – most 
importantly that neutrophils appear to rapidly phagocytose and eliminate mycobacteria, but 
only in the presence of opsonins. 
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4. The impact of HIV on neutrophil anti-mycobacterial function 
 
4.1   Introduction 
The previous chapter has established that neutrophils phagocytose mycobacteria and 
restrict their growth and metabolism. As discussed in Chapter 1, neutrophils are likely to be 
dysfunctional in people with HIV infection: their activation, respiratory burst, microbial 
killing capacity and cell death have all been described to be adversely affected in the context 
of HIV viremia [191, 193-195, 216]. However, despite the crucial role played by these cells in 
tuberculosis (as established both experimentally [29] and epidemiologically [175]), and 
despite the close inter-relation of the HIV and tuberculosis pandemics [190], no studies have 
previously investigated how HIV impacts upon neutrophil responses to mycobacteria. 
It seemed intuitive that the impact of HIV infection would be greatest in those who are 
naïve to antiretroviral treatment and who thus have the highest level of viremia. I therefore 
recruited patients from the Ubuntu HIV clinic in Site B, Khayelitsha, South Africa, who had 
been recently diagnosed with HIV and were due to start anti-retrovirals (CD4 count less than 
350 x 103/ml, according to current South African Ministry of Health criteria). This large 
township clinic administers ARV treatment to more than five thousand individuals, and new 
patients are diagnosed and commenced on treatment daily. Control patients were recruited 
from the same community, identified at Ubuntu or the Khayelitsha Youth Centre amongst 
people who had recently tested negative for HIV. 
At the baseline visit blood was collected for full blood count, C-Reactive Protein and 
Quantiferon™ Gold measurement, as well as CD4 count and HIV viral load in the HIV-
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infected patients. Neutrophils were isolated by Miltenyi MicroBeads (see Chapter 2) to be 
used for the M.tuberculosis restriction assay, phagocytosis assay and cell death assay 
(Sections 2.8, 2.10, 2.12). The negative fraction of blood after CD15 depletion was used for 
the whole blood lux assay (Section 2.4) in comparison to undepleted blood and blood 
depleted of CD4+, CD8+ or CD14+ cells. Supernatants from the blood lux assay were assayed 
for cytokines to assess the impact of cell depletions on the immune response, while 
supernatants from the cell death assay were measured for Human Neutrophil Peptide 1-3 
levels. A separate group of patients and controls were recruited to enable assessment of 
direct ex vivo cell activation by flow cytometry of cell surface markers. Note that in much of 
this chapter intra-donor ratios are provided in order to control for variability in 
M.tuberculosis-lux growth and behaviour.  
 
4.2   Patient characteristics and Exclusions 
23 HIV-infected and 21 HIV-uninfected people were identified by successful screening for 
the initial study; details of those participants recruited for investigation of neutrophil 
activation markers are reported later in this chapter. One HIV-uninfected and one HIV-
infected participant could not be bled. Two HIV-infected patients had a positive sputum 
culture for M.tuberculosis at study entry and all their results were thus excluded according 
to the study protocol. Baseline demographic and clinical characteristics of recruited HIV-
infected patients and HIV-uninfected controls are detailed in Table 4.1. All participants had a 
normal pulse rate and were apyrexial at the time of phlebotomy. The only difference 
between groups was in weight, with the HIV-uninfected participants being heavier than HIV-
infected (median weight 80.6kg vs. 65.4kg, p = 0.004). Identified co-morbidities and 
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medications are listed below Table 4.1; of note, the diet-controlled diabetic participant was 
in the HIV-uninfected group.  
 
Table 4.1. Participant characteristics at baseline enrolment. 
 HIV-infected  
(n = 20) 
HIV-uninfected 
(n = 20) 
p-value for 
comparison 
Age (years) Median 
Range 
30 
23 – 70  
24.5 
18 – 47  
0.343 
Ethnicity Xhosa 
Other Black African 
19 (95%) 
1 (5%) 
20 (100%) 
0 (0%) 
0.311 
Sex Male 
Female 
4 (20%) 
16 (80%) 
8 (40%) 
12 (60%) 
0.301 
Weight (kg) Median 
Range 
65.4 
50.1 – 82.7  
80.6 
51.5 – 121.1    
0.004 
Smoking Yes 
No 
1 (5%) 
19 (95%) 
4 (20%) 
16 (80%) 
0.151 
Regular Alcohol Yes  
No 
3 (15%) 
17 (85%) 
6 (30%) 
14 (70%) 
0.256 
BCG Yes 
No 
Unsure / Unclear 
15 (75%) 
0 (0%) 
5 (25%) 
12 (60%) 
5 (25%) 
3 (15%) 
0.054 
Co-morbidity 
a 
Yes 
No 
9 (45%) 
11 (55%) 
5 (25%) 
15 (75%) 
0.185 
Co-trimoxazole 
prophylaxis 
Yes 
No 
16 (80%) 
4 (20%) 
N/A  
Vitamin treatment Vitamin B Co-
Strong 
Vitamin C 
18 (90%) 
 
5 (25%) 
N/A  
Other medication in 
previous 3 months
 b 
Yes 
No 
6 (30%) 
14 (70%) 
3 (15%) 
17 (85%) 
0.256 
CD4 count (x10
6
/L) Median 
Range 
209.5 
22 – 498  
N/A  
Log [HIV viral load 
(copies/ml)] 
Median 
Range 
4.90 
3.45 – 6.06  
N/A 
  
 
Interferon-γ release 
assay result 
Positive 
Negative 
6 (30%) 
14 (70%) 
10 (50%) 
10 (50%) 
0.197 
Blood neutrophil 
count (x 10
9
/L) 
Median 
Range 
2.50 
1.05 – 5.73  
2.60 
1.40 – 5.01 
0.609 
Serum C-Reactive 
Protein 
Median 
Range 
2.0 
< 1 – 8.7 
1.75 
< 1 – 44.2 
0.497 
a 
Identified co-morbidities: chronic sinusitis, asthma, hypertension, diet-controlled diabetes mellitus, oral 
candidiasis, previous psychotic episode, chronic mildly increased alanine transaminase of uncertain cause, 
recent diarrhoea, anaemia, depression. 
b 
Identified medications: salbutamol inhaler, amitriptyline, ferrous sulphate, folic acid, loperamide, nystatin, 
hydrochlorothiazide, other antihypertensives (unknown classes). 
kg = kilogrammes; BCG = Mycobacterium bovis-BCG; CD4 = Cluster of Differentiation-4; HIV = Human 
Immunodeficiency Virus; N/A = Not Applicable. 
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4.3   HIV infection impairs the ability of neutrophils to control M.tuberculosis 
Isolated CD15+ cells from these donors were incubated with autologous serum and 
M.tuberculosis-lux for one hour and 24 hours before measurement of mycobacterial 
luminescence; serum-only and 7H9 samples served as controls (see Chapter 3 for the 
development of the assay). Table 4.2 details the effect of potential predictors in determining 
the one hour ratio of luminescence between neutrophil samples and serum controls. HIV 
infection had a significant negative impact (mean ratio of mycobacterial luminescence in 
neutrophil samples versus serum controls in HIV-infected patients 0.88, in HIV-uninfected 
patients 0.76; p-value adjusted for patient weight and use of alcohol = 0.019). Alcohol is 
included in the multivariate analysis because it closely approached the inclusion threshold 
(univariate p-value 0.1) and inclusion markedly improved the multivariate model (overall p-
value 0.015 versus 0.047). Regular alcohol consumption – which tended to be in the form of 
weekend ‘binge-drinking’ – was indeed an independent risk factor for poor restriction by 
neutrophils versus serum controls (mean ratio of mycobacterial luminescence in neutrophil 
samples versus serum controls in patients regularly ingesting alcohol 0.89, in patients not 
regularly ingesting alcohol 0.79; multivariate p = 0.039). 
Of note, the luminescence of one HIV-infected sample was measured before cooling to 
room temperature: this significantly confounds readings, as described in Chapter 3, and this 
unusual result (mycobacterial luminescence in neutrophil samples 27% higher than in 
serum-only samples) was therefore excluded. However, if included, the apparent effect of 
HIV appears even stronger than previously demonstrated and the associated univariate p-
value falls to 0.005.    
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Figure 4.1A presents the one-hour cell:serum mycobacterial luminescence ratio in HIV-
infected and HIV-uninfected participants. Poorer control of mycobacterial metabolism in 
HIV-infected participants also persisted to 24 hours (mean ratio of mycobacterial 
luminescence in neutrophil samples versus serum controls in HIV-infected patients 0.820, in 
HIV-uninfected patients 0.719; p = 0.022; Figure 4.1B). It was not explained by greater 
baseline restriction of mycobacteria by HIV-infected serum samples, since the mean ratio of 
mycobacterial luminescence in serum-only samples versus 7H9 controls was not different 
between HIV-infected participants and HIV-uninfected participants at one hour (median 
[IQR] 1.28 [0.87 – 1.52] vs 1.05 [0.92 – 1.27], p = 0.35; non-parametric data) and actually 
poorer by 24 hours (median [IQR] 0.80 [0.69 – 1.01] vs 0.62 [0.51 – 0.730, p = 0.001). 
The one-hour cell:serum luminescence ratio also correlated positively with log[HIV viral 
load] (Pearson r = 0.55, p = 0.015; Figure 4.1C), suggesting that the degree of neutrophil 
dysfunction is dependent on the level of viremia. At high viral loads there is no difference in 
mycobacterial luminescence between cell-containing samples and serum controls, implying 
that neutrophils are effectively contributing no killing activity. A slightly weaker inverse 
relationship was seen between CD4 count and one-hour cell:serum ratio (Pearson r = -0.47, 
p = 0.041). 
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4.4   Depletion of neutrophils from blood has a greater effect on restriction of 
mycobacteria than depletion of any other cell type, but the effect tends to be 
less in HIV infection and inversely correlates with viral load 
Aliquots of blood were depleted of CD4+, CD8+, CD14+ or CD15+ cells via Miltenyi MACS 
magnetic beads (see Section 2.5) or were incubated with non-conjugated beads as controls. 
This blood was then infected with M.tuberculosis-lux (triplicate per depletion condition) and 
incubated in rocking tubes for 96 hours, as per the previously described whole blood lux 
assay (Section 2.4). An uninfected blood sample per depletion condition served as a control 
for cytokine analysis of supernatants (see below). 
Overall lux ratios, calculated versus infecting inoculum (see Chapter 3) and corrected for 
M.tuberculosis growth in 7H9 broth, tended to be higher in HIV-infected patients than HIV-
uninfected (0.76 ± 0.77 vs 0.48 ± 0.44, p = 0.18). Figure 4.2A details the impact of cell 
depletion on the 96-hour luminescence of M.tuberculosis-lux, presented as a ratio versus 
the non-depleted condition. As can be seen, CD15 depletion had a greater effect than 
depletion of any other cell type on mycobacterial luminescence at 96 hours in both HIV-
infected and HIV-uninfected individuals. There was a trend towards a greater effect on 96-
hour luminescence readings of any depletion in the HIV-uninfected donors, although this 
was only significant for CD4 depletion. Of note, two HIV-infected donors had CD4 counts 
above 350 x 103/ml on repeat testing at the time of recruitment; if analysis is restricted to 
those with CD4 counts below this threshold (per protocol), the impact of CD15 depletion 
does demonstrate a significant difference in the extent of impairment of mycobacterial 
restriction between the groups (p < 0.05). Correspondingly, the impact of CD15 depletion 
correlated inversely with CD4 count (Pearson r = 0.51, p = 0.023). However, there was a 
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stronger, inverse relationship with log[HIV viral load] (Pearson r = -0.67, p = 0.001), implying 
that at high viral loads there was minimal impact of removing neutrophils on 96-hour 
mycobacterial luminescence (Figure 4.2B).  
Table 4.2. Potential predictors of neutrophil antimycobacterial activity. 
Predictor Mean ratio of 
luminescence in 
neutrophil samples versus 
serum controls at one 
hour 
 
Univariate 
p-value 
Multivariate 
p-value * 
Sex Male 
Female 
0.790 
0.825 
0.515  
BCG Yes 
No 
Unsure / unclear 
0.803 
0.879 
0.814 
0.590  
IGRA Positive 
Negative 
0.791 
0.831 
0.418  
Smoking Yes 
No 
0.748 
0.825 
0.285  
Regular alcohol Yes 
No 
0.885 
0.794 
0.106 0.039 
Comorbidity Yes 
No 
0.794 
0.825 
0.544  
HIV status Positive 
Negative 
0.876 
0.757 
0.010 0.019 
 Pearson r (correlation with 
ratio of luminescence in 
neutrophil samples versus 
serum controls at one 
hour  
  
Age 0.020 0.904  
Weight -0.328 0.041 0.788 
Serum C-Reactive Protein -0.275 0.090 0.568 
* Multivariate p-value adjusted for other potential predictors identified from univariate analysis. 
BCG = Bacille Calmette-Guèrin. IGRA = Interferon-γ release assay. HIV = Human Immunodeficiency Virus. 
4.5   Phagocytosis of M.tuberculosis by neutrophils is not affected by HIV 
infection 
Samples of 4 x 105 neutrophils from HIV-infected and HIV-uninfected donors were incubated 
with FITC-labelled M.tuberculosis to assess phagocytosis as described in Chapter 3. There 
was no difference between the groups, with 45.6 ± 13.5% of neutrophils in HIV-uninfected 
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donors versus 40.7 ± 22.7% of neutrophils in HIV-infected donors internalising mycobacteria 
by 30 minutes (multiplicity of infection 1 RLU: 1 neutrophil), p = 0.46. 
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Figure 4.1. The impact of HIV on the ability of neutrophils to control M.tuberculosis. A. 4 x 10
5
 CD15+ 
granulocytes in RPMI-1640 were incubated with 10% autologous serum and M.tuberculosis-lux (at multiplicity 
of infection approximately three granulocytes to one colony forming unit). Control samples comprised RPMI-
1640, 10% autologous serum and M.tuberculosis -lux only. Mycobacterial luminescence was measured for 20 
seconds after one hour’s incubation at 37
o
C, and the ratio of relative light units (RLU) in neutrophil samples 
versus serum controls is presented for 19 antiretroviral-naïve HIV-infected and 20 HIV-uninfected individuals. 
Lines represent means. B. Samples prepared identically to (A) were measured after 24 hours incubation at 
37
o
C. C. Data from the HIV-infected individuals in (A) are presented versus log[HIV viral load]. The dotted line 
represents a ratio of 1 (no impact of neutrophils versus serum controls). 
 
 
 
A B 
C 
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Figure 4.2. The impact of cell depletions on control of M.tuberculosis-lux in blood. A. Blood was taken from 
20 antiretroviral-naïve HIV-infected and 20 HIV-uninfected donors. 450mcl of blood depleted of CD4, CD8, 
CD14, CD15 or no cells (in triplicate per donor per condition) was diluted 1:1 with RPMI-1640 and infected with 
approximately 5 x 10
5
 CFU M.tuberculosis-lux in 100mcl PBS. Samples were incubated on a rocking plate 
(20rpm) at 37
o
C for 96 hours before removal of supernatants, lysis of red blood cells with water, resuspension 
in 1ml PBS and measurement of mycobacterial luminescence on at least two 100mcl aliquots. Results are 
presented as the ratio of mycobacterial luminescence in the various depleted conditions versus non-depleted 
controls. Solid lines represent means; the dotted line indicates a ratio of 1 (no impact of depletion). B. Results 
from the CD15-depleted condition in HIV-infected donors are presented versus log[HIV viral load]. The dotted 
line indicates a ratio of 1 (no impact of depletion). 
A 
B 
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4.6   Neutrophils from HIV-infected individuals demonstrate accelerated 
necrotic cell death when exposed to M.tuberculosis 
Samples of neutrophils from HIV-infected and HIV-uninfected donors were incubated with 
M.tuberculosis-lux for 24 hours under the same conditions as in the restriction assay 
(Section 4.3) and then assessed for cell death as previously described (Section 2.12). Results 
(Figure 4.3A) demonstrate a marked increase in the percentage of events identified as 
necrotic in HIV-infected patients compared to uninfected controls (85.3 ± 11.8% vs 57.9 ± 
22.4%, p < 0.0001 for Annexin V-positive necrotic events). There was a corresponding 
decrease in the percentage of apoptotic events (9.8 ± 2.2% vs 31.7 ± 4.5%, p = 0.0002) and 
viable events (2.1 ± 0.6% vs 8.7 ± 1.7%, p = 0.0014). Gating on ‘granulocytes’ as defined by 
Forward Scatter and Side Scatter revealed that cells in HIV-infected donors, although far 
fewer in number than in HIV-uninfected, were relatively more likely to be viable or necrotic 
and less likely to remain in apoptosis (for HIV-infected versus uninfected: viable events 33.6 
± 4.1% vs 20.1 ± 3.6%, p = 0.018; apoptotic events 23.0 ± 3.7% vs 63.6 ± 5.6%, p < 0.0001; 
Annexin V-positive necrotic events 34.4 ± 4.2% vs 14.3 ± 2.4%, p = 0.0005; primary necrotic 
events 9.0 ± 2.7% vs 2.1 ± 0.7%, p = 0.025; Figure 4.3B).  
Notably, the percentage of events excluded as dead cells in the phagocytosis assay (30 
minutes incubation) due to viability dye positivity was also significantly higher in the HIV-
infected donors (4.96 ± 1.78% in HIV-infected donors versus 3.17 ± 1.57% in HIV-uninfected 
donors, p = 0.0097).  
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Figure 4.3. Evaluation of cell death in neutrophils from HIV-infected and HIV-uninfected donors. A. 4 x 105 
CD15+ granulocytes in RPMI-1640 were incubated with 10% autologous serum and M.tuberculosis-lux (at 
multiplicity of infection approximately three granulocytes to one colony forming unit). After 24 hours 
incubation at 37
o
C samples were centrifuged, resuspended in Annexin V binding buffer and stained with 
Annexin V-FITC, eFluor450 Viability Dye and CD66a,c,e-PE for 15 minutes before washing, resuspension in 4% 
paraformaldehyde and subsequent acquisition on a BD Fortessa flow cytometer. Displayed are the 
percentages of total CD66a,c,e+ events for HIV-infected and HIV-uninfected donors classed as Viable (Annexin 
V negative, Viability Dye negative), Apoptotic (Annexin V positive, Viability Dye negative), Apoptotic & necrotic 
(Annexin V positive, Viability Dye positive) and Primary necrotic (Annexin V negative, Viability Dye positive). B. 
From the same samples as in (A), displayed are the percentages of granulocytes (as defined by forward and 
side scatter) for HIV-infected and HIV-uninfected donors classed as Viable, Apoptotic, Apoptotic & necrotic and 
Primary necrotic. 
A 
B 
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4.7   Neutrophils from HIV-infected individuals are hyper-activated  
The discovery that neutrophils from HIV-infected donors appear to die rapidly led me to 
consider their in vivo activation status. I therefore recruited a new group of HIV-infected and 
HIV-uninfected participants (detailed in Table 4.3) and immediately processed fresh blood 
to analyse surface markers of activation by flow cytometry. Results, including gating 
strategy, are represented in Figure 4.4: note that eosinophils are excluded here since they 
may be gated with neutrophils on the basis of CD66 or CD11b expression but are intrinsically 
CD16 negative, which would confound results. Analysis demonstrated that a higher 
percentage of neutrophils from HIV-infected patients had shed CD62L / L-Selectin (23.0% 
[IQR 14.8% – 33.8%] vs 8.5% [IQR 3.1% – 12.9%], p = 0.008) and CD16 (3.2 [IQR 1.7% – 
17.1%] vs 1.3% [IQR 1.1% – 6.2%], p = 0.03). There was a non-significant trend towards 
greater expression of CD11b on the neutrophils of HIV-infected donors (p = 0.13). 
 
4.8   Human Neutrophil Peptide 1-3 levels in supernatants are not affected by 
HIV infection 
Supernatants from M.tuberculosis-infected or uninfected neutrophils were aspirated at 24 
hours and stored at -80oC until analysis of Human Neutrophil Peptide 1-3 concentration by 
ELISA. There was no difference between HIV-infected and HIV-uninfected donors, although 
there was a trend towards lower concentrations in the former (1162 ± 726 pg/ml vs 1544 ± 
598 pg/ml, p = 0.13).  
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Figure 4.4. Activation status of neutrophils in HIV-infected and –uninfected individuals. A. 200mcl of blood 
were stained immediately after phlebotomy with fluorochromes, red cells were lysed and samples fixed before 
acquisition within 48 hours on a BD Fortessa flow cytometer. Singlet signals (derived from Forward Scatter 
(FSC) Area versus FSC Height, not shown) were first gated on eFluor450 Viability Dye versus Side Scatter (SSC) 
to exclude dead cells. Eosinophils, defined as CD16-negative with high SSC, are excluded and then neutrophils 
are defined as CD66a,c,e-PE positive events with high/intermediate SSC. B. Neutrophils thus defined are 
divided into quadrants on the basis of CD62L-FITC and CD16-PerCP Cy5.5. The contents of each quadrant are 
also shown on plots of FSC versus SSC, indicating that all quadrants resemble granulocytes. C. The Median 
Fluorescence Intensity of CD11b-PE Cy7 on neutrophils defined as in (A) is plotted for 11 HIV-infected and 6 
HIV-uninfected individuals. D. The percentage of neutrophils negative for CD62L, as defined in (A) and (B), is 
plotted for 11 HIV-infected and 6 HIV-uninfected individuals. E. The percentage of neutrophils 
negative/intermediate for CD16, as defined in (A) and (B), is plotted for 11 HIV-infected and 6 HIV-uninfected 
individuals. Lines in C – E represent medians and p-values derived from Mann-Whitney tests. 
  
A 
B 
C D E 
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Table 4.3. Participant characteristics at baseline enrolment for activation study. 
 HIV-infected  
(n = 11) 
HIV-uninfected 
(n = 6) 
p-value for 
comparison 
Age (years) Median 
Range 
33 
24 – 63  
37 
26 – 47  
0.513 
Ethnicity Xhosa 11 (100%) 6 (100%) N/A 
Sex Male 
Female 
3 (27.3%) 
8 (72.7%) 
2 (33.3%) 
4 (66.7%) 
0.793 
Smoking Yes 
No 
2 (18.2%) 
9 (81.8%) 
0 (0%) 
6 (100%) 
0.266 
Regular Alcohol Yes  
No 
1 (9.1%) 
10 (90.9%) 
1 (16.7%) 
5 (83.3%) 
0.643 
BCG Yes 
No 
Unsure / Unclear 
2 (18.2%) 
6 (54.5%) 
3 (27.3%) 
4 (66.7%) 
0 (25%) 
2 (33.3%) 
0.052 
Co-morbidity 
a 
Yes 
No 
6 (54.5%) 
5 (45.5%) 
2 (33.3%) 
4 (66.7%) 
0.402 
Co-trimoxazole 
prophylaxis 
Yes 
No 
9 (81.8%) 
2 (18.2%) 
N/A  
Vitamin treatment Vitamin B Co-
Strong 
Vitamin C 
8 (72.7%) 
 
5 (45.5%) 
N/A  
Other medication in 
previous 3 months
 b 
Yes 
No 
6 (54.5%) 
5 (45.5%) 
2 (33.3%) 
4 (66.7%) 
0.402 
CD4 count (x10
6
/L) 
[n = 10] 
Median 
Range 
170 
55 – 371  
N/A  
Log [HIV viral load 
(copies/ml)] 
Median 
Range 
5.14 
3.96 – 5.96  
N/A 
  
 
a 
Identified co-morbidities: epilepsy, oral candidiasis, recent finger infection, eczema, tinea cutis, shingles, 
chronic cough. 
b 
Identified medications: phenytoin, nystatin, ibuprofen, paracetamol, folic acid, acyclovir, antifungal creams, 
steroid creams. 
BCG = Mycobacterium bovis-BCG; CD4 = Cluster of Differentiation-4; HIV = Human Immunodeficiency Virus; 
N/A = Not Applicable. 
 
4.9   Blood supernatant cytokines are most affected by CD14 depletion and 
relatively little by CD15 depletion 
Results of Luminex™ analysis of cytokines and chemokines in the supernatants from 
depletion experiments (Section 4.4) are depicted in Figures 4.5 and 4.6. Only 18 of 30 
measured analytes had a median concentration greater than the lower limit of detection 
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(according to manufacturers’ criteria) across all M.tuberculosis-infected samples. Figure 4.5 
indicates analytes which were significantly affected by cell depletion, after correction for 
multiple comparisons by the Bonferroni methodology. Figure 4.6 presents the raw data 
from the supernatants of M.tuberculosis-infected samples. Uninfected control samples 
showed low or undetectable levels of most analytes. 
Supernatants from undepleted blood donated by HIV-infected individuals revealed a weaker 
inflammatory cytokine response to M.tuberculosis infection than in HIV-uninfected 
individuals. After correction for multiple comparisons, samples from HIV-infected individuals 
vs HIV-uninfected individuals contained significantly (p < 0.05) less detectable IL-1β (median 
[IQR] concentration 14.5 [4.5 – 30] ng/ml vs 51.5 [25.5 – 85.5] ng/ml), IL-8 (median [IQR] 
concentration 10,406 [6208 – 13190] ng/ml vs 21,442 [12920 – 31267] ng/ml) and CCL5 
(median [IQR] concentration 601.5 [355.5 – 858] ng/ml vs 1344 [702.5 – 1665] ng/ml). 
Depletion of CD8 cells had no effect on the cytokine profile of 96-hour blood supernatants 
in either HIV-infected or HIV-uninfected individuals, while the effect of depletion of CD4 
cells depended on HIV status. Sixteen cytokines and chemokines were significantly reduced 
by CD4 depletion in the HIV-uninfected donors, but only eight in the HIV-infected donors. 
Across all analytes, the median ratios of concentration in CD4-depleted blood versus 
undepleted blood were lower in HIV-uninfected participants than in HIV-infected 
participants (median [IQR] 0.51 [0.44 – 0.67] vs. 0.82 [0.72 – 0.96], p < 0.0001; see Figure 
4.5C). CD14 depletion markedly reduced the concentration of many mediators in both HIV-
infected and HIV-uninfected donors; there was no difference in the median ratios between 
the two groups (Figure 4.5C). 
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After correction for multiple comparisons, CD15 depletion significantly (p < 0.05) reduced 
CCL2 concentration versus undepleted blood in the HIV-uninfected group (median [IQR] 
concentration 1420 [807 – 1684] ng/ml in CD15 depleted blood supernatants vs 1903 [1084 
– 3386] ng/ml in undepleted blood supernatants). Conversely, in the HIV-infected group, 
CD15 depletion significantly increased the concentration of IL1β (median [IQR] 
concentration 33 [17 – 55] ng/ml in CD15 depleted blood supernatants vs 15 [5 – 30] ng/ml 
in undepleted blood supernatants) and Eotaxin (median [IQR] concentration 30 [21 – 51] 
ng/ml in CD15 depleted blood supernatants vs 18 [11 – 28] ng/ml in undepleted blood 
supernatants) versus the undepleted condition. 
 
4.10   Discussion 
This chapter has investigated the effect of HIV on neutrophil responses to mycobacteria. 
Importantly, I have discovered that neutrophils were less able to restrict M.tuberculosis in 
the context of HIV viremia, and that this impairment correlated inversely with HIV viral load. 
A similar result was replicated in the depletion experiments, where the impact of CD15 
depletion on mycobacterial bioluminescence also depended strongly on the HIV viral load: 
at the highest viral loads neutrophil depletion did not impair restriction of bacilli by whole 
blood. Although there was not an overall difference in the impact of CD15 depletion on 
control of mycobacteria between HIV-infected and HIV-uninfected donors, this may be 
confounded by the inclusion of two patients with relatively high CD4 counts in the HIV 
group (see above). 
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Figure 4.5. Cytokine and chemokine analysis of 96-hour supernatants of cell-depleted and undepleted blood 
infected with M.tuberculosis-lux. A. and B. Blood from 20 HIV-uninfected donors (A) and 20 HIV-infected donors (B), 
depleted of CD4+, CD8+, CD14+, CD15+ or no cells was infected with M.tuberculosis-lux for 96 hours; supernatants 
were aspirated and stored at -80
o
C until analysis by Luminex™ technology. Concentrations in the depleted conditions 
were compared with undepleted blood via Wilcoxon matched pairs tests. The figure shows those analytes which 
remain significantly (p < 0.05) different after adjustment for multiple comparisons via the Bonferroni methodology: 
green = significantly reduced, red = significantly increased. C. The median ratios of concentrations in CD4-depleted 
and CD14-depleted blood versus undepleted are shown for HIV-infected and HIV-uninfected donors: each dot 
represents one analyte. Lines represent medians.  
VEGF = Vascular endothelial growth factor; TNF = Tumour Necrosis Factor; IFN = Interferon; IL = Interleukin; IL-2R = 
Interleukin-2 Receptor; IL-1RA = Interleukine-1 Receptor antagonist; FGFb = Fibroblast growth factor basic; EGF = 
Epidermal growth factor; CXCL = C-X-C chemokine ligand; CCL = C-C chemokine ligand; CD = Cluster of differentiation. 
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Figure 4.6. Cytokine and chemokine raw results from 96-hour supernatants of cell-depleted and undepleted 
blood infected with M.tuberculosis-lux. A – R. Blood from 20 HIV-uninfected donors and 20 HIV-infected 
donors, depleted of CD4+, CD8+, CD14+, CD15+ or no cells was infected with M.tuberculosis-lux for 96 hours; 
supernatants were aspirated and stored at -80
o
C until analysis by Luminex™ technology. Box and whisker plots 
represent median, interquartile range, minimum and maximum values for each analyte; the first set of 
columns in each panel are from HIV-infected donors and the second set from HIV-uninfected donors. 
VEGF = Vascular endothelial growth factor; TNF = Tumour Necrosis Factor; IFN = Interferon; IL = Interleukin; IL-
2R = Interleukin-2 Receptor; IL-1RA = Interleukine-1 Receptor antagonist; FGFb = Fibroblast growth factor 
basic; EGF = Epidermal growth factor; CXCL = C-X-C chemokine ligand; CCL = C-C chemokine ligand; CD = 
Cluster of differentiation. 
 
 
 
The depletion experiments confirmed that neutrophils are the dominant cell responsible for 
M.tuberculosis control in blood, as previously demonstrated [29]. It is thus tempting to 
speculate that neutrophils may be responsible for preventing haematogenous dissemination 
of bacilli, and their poor restrictive ability in HIV-infected individuals may therefore help to 
explain the high rate of disseminated disease in this group [217]. It is interesting to note 
that CD15 depletion has relatively little effect on the cytokine and chemokine profile of 
M.tuberculosis-infected blood, confirming that the mechanism of restriction of 
mycobacterial growth by neutrophils is likely to be directly mycobactericidal. In fact, CD15 
depletion in the HIV-infected group actually increased the concentration of the Th1 cytokine 
IL1β. Depletion of CD14+ cells and, in HIV-uninfected individuals especially, CD4+ cells, 
significantly impaired the release of cytokines and chemokines, but the effect of these 
interventions on bacillary metabolism was still less than depletion of granulocytes. This 
suggests that direct killing of bacilli by neutrophils is more important than the activation of 
the acquired immune response for mycobacterial control, at least within peripheral blood. 
CD8 depletion also had relatively little effect on concentrations of soluble mediators in 
supernatants of M.tuberculosis-stimulated whole blood, suggesting that their modest effect 
on mycobacterial luminescence was also due to direct killing. 
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The exact mechanism by which neutrophil antimycobacterial function is compromised in 
HIV infection is not fully resolved, but the data presented here do reveal some important 
components. Notably, phagocytosis of mycobacteria is not impaired in HIV-infected donors, 
suggesting that the HIV-associated impairment of killing of M.tuberculosis by neutrophils is 
likely to be intracellular. Supernatant HNP concentrations were also not different between 
HIV-infected and HIV-uninfected donors. However, it is difficult to interpret this result, since 
supernatant concentrations will reflect the extent of extracellular release during neutrophil 
activation and the extent of cell death (at which point all intracellular contents are released 
into the supernatant). Indeed, a trend towards lower concentration in the HIV-infected 
samples despite more necrotic cell death may hint at a lower ‘per cell’ HNP concentration. 
Accelerated cell death was one of the most marked findings in the neutrophils from HIV-
infected individuals. Gating on all CD66a,c,e-positive events revealed a far higher 
percentage of necrotic events by 24 hours in the HIV samples vs. non-HIV samples, while 
gating on ‘granulocytes’ suggested that cells may be rapidly progressing through apoptosis 
to necrosis. This result, corresponding with previous findings in other contexts [216], is likely 
to relate to HIV-associated excessive activation of neutrophils in vivo before they even 
encounter pathogens. However, this activation may not be typical: when staining for 
neutrophil surface activation markers in fresh blood, the predominant finding was loss of 
CD62L (L-Selectin) and CD16 on the neutrophils from HIV-infected people. These markers 
are preferentially lost as neutrophils progress towards death [218]; thus the pattern of 
neutrophil activation in HIV appears to be in the direction of cell death. In contrast the 
activation marker CD11b did not in fact demonstrate a significant difference in median 
fluorescence intensity between the HIV-infected and –uninfected groups. It thus seems 
likely that neutrophils from HIV-infected individuals are already beyond optimum activation 
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by the time they encounter bacilli, are less able to eliminate pathogens and instead die in 
situ with rapid progression to necrosis. 
The studies reported here have some limitations. HIV-infected and –uninfected participants 
differed in terms of weight, which correlated inversely with the ability of neutrophils to 
control M.tuberculosis at one hour, but this was controlled for in analysis. HIV-infected 
patients also tended to be on co-trimoxazole or vitamin supplements. However, it is 
reported that co-trimoxazole has no effect on neutrophil function at in vivo concentrations 
[219]. While there may be an in vitro effect of high concentration co-trimoxazole on 
M.tuberculosis [220], in my study restriction of mycobacteria by serum (versus 7H9 controls) 
was actually poorer in HIV-infected individuals than in HIV-uninfected, especially by 24 
hours, suggesting that prophylactic drug treatment was not a significant confounder. 
Vitamin B12 and Vitamin C are both investigated in Chapter 6: at physiological 
concentration, Vitamin B12 does not improve cellular function or direct control of bacilli 
and, at one hour, while Vitamin C does not affect these functions even at high 
concentration. Many of the results acquired here required analysis as ratios to control for 
differences in growth and behaviour of M.tuberculosis-lux (despite using a single stock 
throughout). However, many of the important findings are based on intra-donor comparison 
of conditions and thus ratios are appropriate. 
This chapter also yielded some other interesting results. First, regular alcohol ingestion – 
usually as weekend ‘binges’ – was found to be an independent risk factor for poor 
neutrophil antimycobacterial function. Alcohol has previously been shown to have 
detrimental effects on neutrophil function, including impairment of chemotaxis and 
respiratory burst [221], and this result has public health significance for South Africa, 
especially if poor neutrophil function in those who drink regular alcohol extends to defence 
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against other pathogens. I have also delineated the cells responsible for cytokine and 
chemokine production upon exposure to M.tuberculosis (see above), finding that CD14+ 
cells (predominantly monocytes in blood) represent by far the most dominant source. CD4+ 
cells are also important, especially in HIV-uninfected people, as would be expected. Overall, 
HIV-uninfected donors mounted a more robust response to mycobacterial challenge, 
consistent with previous reports [222, 223] and presumably secondary to a higher number 
of functional CD4+ cells. 
In summary, neutrophils from HIV-infected, antiretroviral-naïve people are hyperactivated 
and approaching cell death even in circulating blood; they are able to phagocytose 
M.tuberculosis but restrict bacilli poorly and die rapidly. These functional impairments may 
help to explain some of the vulnerability of HIV-infected people to both infection with, and 
dissemination of, M.tuberculosis. 
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5. The effect of antiretroviral therapy on neutrophil anti-mycobacterial 
function 
 
5.1   Introduction 
The previous chapter has established that HIV renders neutrophils hyper-activated and 
compromises their anti-mycobacterial function in terms of impaired direct restriction of 
bacilli and accelerated cell death. Antiretroviral therapy (ART) has been shown to improve 
neutrophil number and antimicrobial function against other pathogens [191, 194, 200], and 
I thus hypothesised that the same may occur with neutrophil responses to M.tuberculosis. 
The first cohort described in the previous chapter was followed for 6 months of 
antiretroviral therapy with blood taken at 1 month, 3 months and 6 months. At the two 
interim time points neutrophils were isolated for restriction experiments, cell death 
assessment and supernatant HNP concentrations in addition to testing for full blood count, 
CD4 count, viral load and serum C-Reactive Protein. At six months, phagocytosis, 
comparative depletion experiments and interferon-γ release assays were also performed. 
Participants were assessed for new symptoms or diagnoses and had clinical observations 
taken at each visit (see Table 5.1).  
 
Table 5.1. Summary of experiments performed at each visit 
 Clinical 
assessment 
FBC, CRP, 
CD4, HIV VL 
Neutrophil 
lux assay 
Whole 
blood (+ 
depletions) 
lux assay 
Phagocytosis 
assay 
Cell 
death 
assay 
HNP 
concentration 
IGRA 
Baseline X X X X X X X X 
1 month X X X   X X  
3 months X X X   X X  
6 months X X X X X X X X 
FBC = Full blood count; CRP = C-Reactive protein; CD4 = Cluster of differentiation 4; HIV = Human 
immunodeficiency virus; VL = viral load; HNP = Human neutrophil peptide; IGRA = Interferon-γ release assay. 
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5.2   HIV-infected adults had robust virological and immunological response 
to antiretroviral therapy 
Of the twenty participants who commenced the study, one was lost to follow-up after the 
first visit and one was lost to follow-up after the 3-month visit (as he moved away from the 
Western Cape province). The remaining 18 patients attended all visits. As shown in Figure 
5.1A, most patients had suppressed viral replication by 6 months such that HIV was below 
the limit of detection (40 copies/ml) in blood. One patient had not reached suppression but 
the level was declining (111 copies/ml); another patient achieved suppression by 3 months 
but then lost control due to confusion with medication (an issue resolved at the 6-month 
visit). Immunological response was also encouraging (Figures 5.1B and C) with the median 
(IQR) CD4 count improving from 209.5 (125.5 – 295.5) x 103/ml to 322.5 (203.5 – 483.5) x 
103/ml (p = 0.002) and the median (IQR) CD4 percentage improving from 14.0% (9.3% - 
18.4%) to 24.7% (15.5% - 30.8%), p = 0.0002. Interferon-γ release assay readings showed 
that 11 baseline negative results remained negative and 5 positive results remained 
positive, while a further 2 patients with baseline negative results converted to positive by 6 
months. 
 
5.3   Direct restriction of M.tuberculosis-lux by neutrophils isolated from HIV-
infected patients improves over 6 months of antiretroviral therapy 
There was an improvement in the ability of neutrophils to restrict M.tuberculosis-lux versus 
serum control samples at one hour’s incubation across the studied time period, with a 
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significant linear trend in results (p = 0.03; Figure 5.2A). Pairwise comparisons revealed a 
significant difference between baseline and 6-month results in HIV-infected participants 
(mean ratio of luminescence in neutrophil versus serum samples at one hour = 0.88 ± 0.14 
at baseline versus 0.78 ± 0.11 at 6 months, p = 0.024) and no difference between HIV-
infected participants after 6 months’ ART and HIV-uninfected donors’ results (mean ratio of 
luminescence in neutrophil versus serum samples at one hour = 0.78 in HIV-infected donors 
at 6 months versus 0.76 in HIV-uninfected donors, p = 0.59). This suggests that neutrophil 
anti-mycobacterial function improves to the level of HIV-uninfected donors over this time 
period. 24-hour luminescence ratios also declined over time, such that there was no longer 
a significant difference between HIV-infected and HIV-uninfected donors at 6 months (mean 
ratio of luminescence in neutrophil versus serum samples at 24 hours = 0.77 ± 0.16 in HIV-
infected donors at 6 months versus 0.72 ± 0.13 in HIV-uninfected donors, p = 0.27). 
Although there was not an overall significant improvement in neutrophil anti-mycobacterial 
restriction by one month, this may be confounded by patients with an inflammatory 
response. Patients with a significant rise in C-Reactive Protein (>20 mg/L) or symptoms of 
night sweats, fever or cough (all had active tuberculosis excluded) experienced deterioration 
in the ratio of luminescence in neutrophil samples versus serum samples at one hour, while 
asymptomatic patients with normal CRP broadly improved control (Figures 5.2B and C). 
The previous finding of poorer control in serum versus 7H9 controls by 24 hours in the HIV-
infected donors vs. uninfected donors (median ratio of luminescence in serum vs 7H9 in 
HIV-infected donors = 0.80; in HIV-uninfected donors = 0.62 (non-parametric data)) 
disappeared by three months (median ratio of luminescence in serum vs 7H9 = 0.77 at one 
month, 0.55 at 3 months and 0.58 at six months). Correspondingly, the overall extent of 
restriction in cell + serum samples versus 7H9 controls by 24 hours also reached the level of 
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HIV-uninfected participants by 3 months (median ratio of luminescence in cell + serum 
samples versus 7H9 controls at 24 hours = 0.65 at baseline, 0.61 at 1 month, 0.45 at 3 
months, 0.46 at 6 months and 0.45 in HIV-uninfected – see Figure 5.2D). 
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Figure 5.1. Virological and immunological response to antiretroviral therapy. 20 HIV-infected patients were 
recruited before commencing antiretroviral therapy and followed for 6 months of therapy. Blood was taken at 
1 month, 3 months and 6 months for HIV viral load (A) and CD4 count (B) and percentage (C). ** p < 0.01 
(Wilcoxon signed rank test versus baseline). *** p < 0.001 (Wilcoxon signed rank test versus baseline). 
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Figure 5.2. Improvement in neutrophil antimycobacterial activity over 6 months of anti-retroviral therapy. A. 
4 x 10
5
 CD15+ granulocytes in RPMI-1640 were incubated with 10% autologous serum and M.tuberculosis-lux 
(at multiplicity of infection approximately three granulocytes to one colony forming unit). Control samples 
comprised RPMI-1640, 10% autologous serum and M.tuberculosis-lux only. Mycobacterial luminescence was 
measured for 20 seconds after one hour’s incubation at 37
o
C, and the ratio of relative light units (RLU) in 
neutrophil samples versus serum controls is presented for HIV-infected donors at the indicated intervals over 6 
months of antiretroviral therapy and for HIV-uninfected individuals. Lines represent means; dotted red line 
indicates ratio of 1 (no impact of neutrophils versus serum controls). B. Baseline and 1-month samples from (A) 
are plotted for those who experienced symptoms or rise in C-reactive protein >20mg/L at the 1-month visit. C. 
Baseline and 1-month samples from (A) are plotted for those who experienced no symptoms or significant rise 
in C-reactive protein at the 1-month visit. D. The ratio of mycobacterial luminescence (relative light units 
(RLU)) in neutrophil + serum samples versus 7H9 controls after 24 hours incubation at 37
o
C is presented for 
HIV-infected donors at the indicated intervals over 6 months of antiretroviral therapy and for HIV-uninfected 
individuals.  
A 
B C 
D 
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5.4   The impact of neutrophil depletion on the control of M.tuberculosis-lux 
by whole blood of HIV-infected people after 6 months antiretroviral therapy 
returns to that seen in HIV-uninfected people  
Comparative depletion experiments were performed after six months of ART as described in 
Chapter 4; results are shown in Figure 5.3. The overall mean ratio of luminescence in CD15-
depleted blood versus undepleted controls tended to increase from the baseline visit (from 
1.48 ± 0.54 to 1.64 ± 0.42, p = 0.33) becoming relatively more similar to that in HIV-
uninfected donors (1.70 ± 0.41, p = 0.62). The effect of depletion of other cell populations 
on 96-hour M.tuberculosis-lux bioluminescence did not change over time: in particular there 
remained a significant difference between the effect of CD4 depletion in HIV-uninfected 
donors and the effect of CD4 depletion in HIV-infected donors at 6 months (ratio to 
undepleted blood 1.17 ± 0.29 vs. 0.94 ± 0.15 respectively, p = 0.004). Overall lux ratios 
calculated versus infecting inoculum (see Chapter 3) and corrected for M.tuberculosis 
growth in 7H9 broth, tended to be lower by 6 months than at baseline (0.64 ± 0.42 vs 0.76 ± 
0.77, p = 0.56), but still tended to be higher than in HIV-uninfected donors (0.64 ± 0.42 vs 
0.48 ± 0.44, p = 0.26). However, there were large standard deviations in these data and no 
comparisons actually reached significance. 
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Figure 5.3. The impact of cell depletions on control of M.tuberculosis-lux in blood after 6 months of 
antiretroviral therapy. Blood was taken from 18 HIV-infected donors after 6 months of antiretroviral therapy. 
450mcl of blood depleted of CD4+, CD8+, CD14+, CD15+ or no cells (in triplicate per donor per condition) was 
diluted 1:1 with RPMI-1640 and infected with approximately 5 x 10
5
 CFU M.tuberculosis-lux in 100mcl PBS. 
Samples were incubated on a rocking plate (20rpm) at 37
o
C for 96 hours before removal of supernatants, lysis 
of red blood cells with water, resuspension in 1ml PBS and measurement of mycobacterial luminescence on at 
least two 100mcl aliquots. Results are presented as the ratio of mycobacterial luminescence in the various 
depleted conditions versus non-depleted controls. Solid lines represent means; the dotted line indicates a ratio 
of 1 (no impact of depletion).  
 
5.5   Phagocytosis of M.tuberculosis does not change over 6 months of 
antiretroviral therapy 
Samples of 4 x 105 neutrophils from HIV-infected donors were incubated with FITC-labelled 
M.tuberculosis to assess phagocytosis (as described in Chapter 3) after 6 months of 
antiretroviral therapy. There was no difference between the baseline and 6-month results, 
with 40.7 ± 22.7% of neutrophils in HIV-infected donors at baseline versus 35.5 ± 22.9% of 
neutrophils at 6 months internalising mycobacteria by 30 minutes (multiplicity of infection 1 
RLU: 1 neutrophil), p = 0.16. 
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5.6   The risk of accelerated neutrophil cell death on exposure to 
M.tuberculosis in HIV infection declines over 6 months of antiretroviral 
therapy 
Neutrophils from HIV-infected donors were incubated with M.tuberculosis-lux for 24 hours 
and assessed for cell death, as described in Section 4.6, at each visit during the six months of 
antiretroviral therapy. Results analysing all CD66a,c,e-positive events (Figure 5.4A) showed 
that there was a decrease in necrotic events (p-value for linear trend = 0.008) and 
corresponding increase in apoptotic events (p-value for linear trend = 0.004) over the 
studied period. By 6 months results in HIV-infected participants more closely resembled 
those seen in HIV-uninfected participants, except that viable events remained lower (viable 
events 2.6% vs 8.7% respectively, p = 0.002; apoptotic events 24.5% vs 31.7% respectively, p 
= 0.28; apoptotic / necrotic events 71.8% vs 57.9% respectively, p = 0.07; primary necrotic 
events 1.1% vs 1.7% respectively, p = 0.15) 
Gating on granulocytes (defined by forward and side scatter) also revealed a progressive 
change in the pattern of cell death (p-value for linear trend in apoptotic events < 0.0001; p-
value for linear trend in necrotic events = 0.003). By 6 months results in HIV-infected 
participants resembled those seen in HIV-uninfected participants (viable events 26.4% vs 
20.0% respectively, p = 0.20; apoptotic events 53.7% vs 63.6% respectively, p = 0.18; 
apoptotic / necrotic events 17.4% vs 14.3% respectively, p = 0.39; primary necrotic events 
2.6% vs 2.1% respectively, p = 0.57).  
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5.7   The risk of neutrophil hyperactivation declines over 6 months of 
antiretroviral therapy 
The group of HIV-infected individuals recruited to assess surface markers of activation was 
not followed prospectively. However, I also analysed the expression of CD66a,c,e on 
neutrophils in the phagocytosis assay (perfomed on all patients at baseline and in HIV-
infected donors after 6 months of antiretroviral therapy) via measurement of median 
fluorescence intensity; this marker has previously been shown to be indicative of neutrophil 
activation and degranulation [224]. Median [IQR] MFI in HIV-infected individuals at baseline 
was 5344 [3829 – 7265] versus 3032 [2540 – 4624] after 6 months of ART and 3241 [2282 – 
4570] in HIV-uninfected donors. There was a significant difference (p < 0.05) between 
results from the HIV-infected group at baseline and those from the same cohort after 6 
months ART or the HIV-uninfected participants (Mann-Whitney with Dunn’s Multiple 
Comparison test). 
 
5.8   Human Neutrophil Peptide 1-3 levels in supernatants of neutrophils 
cultured in presence of M.tuberculosis are not significantly affected by 
antiretroviral therapy 
Supernatants from M.tuberculosis-infected or uninfected neutrophils were aspirated at 24 
hours and stored at -80oC until analysis of Human Neutrophil Peptide 1-3 concentration by 
ELISA. There was no difference between results from baseline and after 6 months ART (1162 
± 726 pg/ml vs 1247 ± 816 pg/ml, p = 0.75).  
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Linear trend in necrotic events, p = 0.008 
Linear trend in apoptotic events, p = 0.004 
Linear trend in necrotic events, p = 0.002 
Linear trend in apoptotic events, p < 0.0001 
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Figure 5.4. Evaluation of cell death in neutrophils from HIV-infected donors over 6 months of antiretroviral 
therapy. A. 4 x 105 CD15+ granulocytes in RPMI-1640 were incubated with 10% autologous serum and 
M.tuberculosis-lux (at multiplicity of infection approximately three granulocytes to one colony forming unit). 
After 24 hours incubation at 37
o
C samples were centrifuged, resuspended in Annexin V binding buffer and 
stained with Annexin V-FITC, eFluor450 Viability Dye and CD66a,c,e-PE for 15 minutes before washing, 
resuspension in 4% paraformaldehyde and subsequent acquisition on a BD Fortessa flow cytometer. Displayed 
are the mean (SD) percentages of total CD66a,c,e+ events for HIV-infected donors at baseline and after 1, 3 or 
6 months of antiretroviral therapy classed as Viable (Annexin V negative, Viability Dye negative; white 
columns), Apoptotic (Annexin V positive, Viability Dye negative; green columns), Apoptotic & necrotic (Annexin 
V positive, Viability Dye positive; red columns) and Primary necrotic (Annexin V negative, Viability Dye positive; 
black columns); data from HIV-uninfected donors are shown for comparison. B. From the same samples as in 
(A), displayed are the mean (SD) percentages of granulocytes (as defined by forward and side scatter) for HIV-
infected donors at baseline and after 1, 3 or 6 months of antiretroviral therapy classed as Viable (white 
columns), Apoptotic (green columns), Apoptotic & necrotic (red columns) and Primary necrotic (black 
columns); again, data from HIV-uninfected donors are shown for comparison.  
A 
B 
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5.9   The effect of cell depletion on blood supernatant cytokine release 
remains similar to baseline after 6 months of antiretroviral therapy, although 
CD4 cell depletion has more impact on analyte profile 
Luminex™ analysis of cytokines and chemokines in the blood supernatants from depletion 
experiments is depicted in Figures 5.5 and 5.6. Compared to baseline, there was a broadly 
stronger immune response to mycobacterial challenge after 6 months of ART (Figure 5.5). In 
particular, after correction for multiple comparisons, by there was significantly (p < 0.05) 
more detectable CCL5 (median [IQR] concentration 1168 [983 – 1521] ng/ml vs 601.5 [355.5 
– 858] ng/ml) and Eotaxin (median [IQR] concentration 30 [20 – 51] ng/ml vs 18 [10.5 – 28] 
ng/ml) at 6 months. 
The effect of CD4 depletion was also more pronounced than at baseline, with fourteen 
mediators being significantly reduced in concentration (Figure 5.5) versus eight at baseline. 
Across all analytes, the median ratios of concentration in CD4-depleted blood versus 
undepleted blood were lower at 6 months than at baseline (median [IQR] 0.65 [0.58 – 0.78] 
vs. 0.82 [0.72 – 0.96], p = 0.002). However, these ratios were still not as low as in HIV-
uninfected participants (median [IQR] 0.65 [0.58 – 0.78] vs. 0.51 [0.44 – 0.67], p = 0.026). 
As before, CD14 depletion had the most profound effect on release of measured analytes, 
with overall median [IQR] ratio of luminescence vs undepleted blood across all analytes of 
0.13 [0.04 – 0.54], while CD8 depletion had no significant impact. CD15 depletion resulted in 
a significant (p < 0.05 after correction for multiple comparisons by Bonferroni methodology) 
reduction in IL-8 concentration versus undepleted blood (median [IQR] 9171 [5048 – 16208] 
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ng/ml vs 14943 [12364 – 22493] ng/ml) and a significant increase in Eotaxin concentration 
versus undepleted blood (median [IQR] 30 [20 – 51] ng/ml vs 48.5 [20 – 74.5] ng/ml). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. Cytokine and chemokine analysis of 96-hour supernatants of cell-depleted and undepleted blood 
infected with M.tuberculosis-lux. Blood from 18 HIV-uninfected donors (on antiretrovirals for 6 months) 
depleted of CD4+, CD8+, CD14+, CD15+ or no cells was infected with M.tuberculosis-lux for 96 hours; 
supernatants were aspirated and stored at -80
o
C until analysis by Luminex™ technology. Concentrations in the 
depleted conditions were compared with undepleted blood via Wilcoxon matched pairs tests. The figure 
shows those analytes which remain significantly (p < 0.05) different after adjustment for multiple comparisons 
via the Bonferroni methodology: green = significantly reduced, red = significantly increased. 
VEGF = Vascular endothelial growth factor; TNF = Tumour Necrosis Factor; IFN = Interferon; IL = Interleukin; IL-
2R = Interleukin-2 Receptor; IL-1RA = Interleukine-1 Receptor antagonist; FGFb = Fibroblast growth factor 
basic; EGF = Epidermal growth factor; CXCL = C-X-C chemokine ligand; CCL = C-C chemokine ligand; CD = 
Cluster of differentiation. 
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Figure 5.6. Cytokine and chemokine raw results from 96-hour supernatants of cell-depleted and undepleted 
blood infected with M.tuberculosis-lux. A – R. Blood from 20 HIV-uninfected donors (on antiretrovirals for 6 
months) depleted of CD4+, CD8+, CD14+, CD15+ or no cells was infected with M.tuberculosis-lux for 96 hours; 
supernatants were aspirated and stored at -80
o
C until analysis by Luminex™ technology. Box and whisker plots 
represent median, interquartile range, minimum and maximum values for each analyte. 
VEGF = Vascular endothelial growth factor; TNF = Tumour Necrosis Factor; IFN = Interferon; IL = Interleukin; IL-
2R = Interleukin-2 Receptor; IL-1RA = Interleukine-1 Receptor antagonist; FGFb = Fibroblast growth factor 
basic; EGF = Epidermal growth factor; CXCL = C-X-C chemokine ligand; CCL = C-C chemokine ligand; CD = 
Cluster of differentiation. 
 
 
5.10   Discussion 
This chapter has explored the ability of antiretroviral therapy to restore neutrophil anti-
mycobacterial function. Fortunately loss to follow-up over six months of treatment was 
lower than anticipated, and both virological suppression and significant improvement of 
CD4 count were achieved by most participants.  
Direct restriction of M.tuberculosis-lux by neutrophils improved over the follow-up period. 
However, an interesting phenomenon was observed after one month of ART, wherein those 
people with symptoms or significant rise in inflammatory markers (perhaps suggesting an 
immune reconstitution inflammatory syndrome (IRIS)-like reaction) experienced 
deterioration in mycobacterial restrictive ability, while other patients’ results broadly 
improved. Whether this relates simply to inflammation or whether this is peculiar to ART-
induced IRIS is currently unknown, but it would first be important to replicate the result in 
larger numbers. Nevertheless, it is interesting to note that neutrophils have been 
increasingly implicated in the pathogenesis of IRIS [225]. 
By three months the restrictive ability of both neutrophils and serum had recovered such 
that restriction of M.tuberculosis-lux bioluminescence versus 7H9 controls at 24 hours post-
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infection in HIV-infected participants was indistinguishable from that seen in HIV-uninfected 
individuals (Figure 5.2D). Notably, this was the time point at which HIV viral load fell below 
approximately 1000 copies/ml for all donors; I thus hypothesise that neutrophil function 
and any innate components in serum responsible for mycobacterial restriction are restored 
below this level of viremia.  
This improvement in anti-mycobacterial restriction was accompanied by a progressive 
change in the pattern of cell death towards that seen in HIV-uninfected individuals. Most 
notably, necrotic events reduced in frequency while more granulocytes remained in 
apoptosis until 24 hours incubation. This may reflect a reduction in neutrophil 
hyperactivation, a theory supported by a reduction in surface CD66a,c,e, expression by 6 
months of ART (as measured during the phagocytosis assay). While this marker may be 
indicative of degranulation [224], which intuitively should lead to enhanced delivery of 
antimicrobial substances to pathogens, high expression may also reflect baseline hyper-
activation rendering cells refractory to further up-regulation on stimulation [226]. Certainly 
differences in expression did not translate into differences in supernatant HNP 
concentration between baseline and 6 months. Similarly, phagocytosis did not appear to be 
affected (in fact tending towards a decrease over the period of antiretrovirals) suggesting 
that changes in antimycobacterial function are occurring at an intracellular level.  
In contrast to neutrophils, cellular function in the acquired immune system may take longer 
to recover in blood. While the effect of CD15 depletion on 96-hour mycobacterial 
luminescence after 6 months’ ART closely paralleled that seen in HIV-uninfected individuals 
(mycobacterial control impaired by 64% versus 70% after depletion, p = 0.62), the effect of 
depleting CD4+, CD8+ or CD14+ cells on luminescence was still modest. CD4 depletion was 
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particularly interesting, since although the effect on cytokine and chemokine response was 
more profound than at baseline (Figures 5.5 and 5.6 versus Figures 4.5 and 4.6) this did not 
translate into an effect on mycobacterial restriction (Figure 5.3).  
In a large prospective multicohort study (more than 30,000 individuals) [227] the incidence 
of tuberculosis fell markedly from the period 0-3 months after commencement of 
antiretrovirals (13 per 100 person years) to the period 3-5 months after commencement of 
antiretrovirals (6 per 100 person years). My results would suggest that restoration of 
neutrophil function (and innate serum components) might plausibly explain this early 
protection rather than reconstitution of the mycobactericidal functions of the acquired 
immune system. A more cautious interpretation restricts this hypothesis at least as far as 
circulating blood (as this was used for the experiments), a conclusion supported by a 
progressive decrease in the relative proportion of extra-pulmonary tuberculosis over the 
first year of ART [227]. In body tissues, the overall more robust release of soluble mediators 
in response to M.tuberculosis (Figure 5.6), presumably largely secondary to reconstituted 
CD4 cells, is likely to also have an impact on protection against tuberculosis. 
In summary, the data in this chapter support the hypothesis that administration of ART is 
associated with improvements in neutrophil antimycobacterial function. Since the 
neutrophil functional impairment seems to relate most closely to HIV viral load (Chapter 4), 
my results would support the initiation of ART as a protective intervention against 
tuberculosis on the basis of viral load as much as CD4 count.  
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6. The effect of manipulating neutrophil function or number on 
antimycobacterial activity, cell death and cytokine profile 
 
6.1   Introduction 
Thus far I have established that neutrophils rapidly phagocytose mycobacteria, but that 
elimination is variable and host-dependent. Neutrophils also die rapidly after interaction 
with mycobacteria, especially in HIV-infected individuals. In this chapter I attempt to explore 
whether restriction of mycobacteria by neutrophils can be enhanced or inhibited in vitro, or 
whether the rapid necrosis in association with HIV can be mitigated. I also explore whether 
large numbers of additional necrotic neutrophils, as may be seen at sites of disease in HIV, 
impacts upon the control of M.tb by blood and subsequent cytokine response; this is 
compared with the addition of viable neutrophils or no neutrophils. 
The inhibitors of neutrophil antimicrobial effector mechanisms I chose to investigate are 
antioxidants (N-acetylcysteine and Vitamin C) and the Nitric oxide synthase inhibitor L-
NMMA [228, 229]. As mentioned in Chapter 1, both reactive oxygen and nitrogen 
intermediates have been suggested to contribute to the control of mycobacteria. There is 
no available inhibitor of human neutrophil peptides – the most implicated molecules for 
anti-mycobacterial activity – except a neutralising antibody which is unlikely to reach the 
primary granules without significant disruption of cellular function. Potential stimulators of 
mycobacterial restriction studied were 1,25(OH)2-Vitamin D, Vitamin B12 and zinc chloride. 
1,25(OH)2-Vitamin D has been shown to induce autophagy and enhance production of 
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cathelicidin in macrophages [124], thereby enhancing elimination of mycobacteria, and thus 
a similar effect may be observed in neutrophils. Vitamin B12 [230, 231] and zinc [232, 233] 
have been described to enhance neutrophil activity in other systems. Zinc has also been 
shown to enhance killing of M.tuberculosis in macrophages [234], and to reduce cell death 
of neutrophils [235] and other cell types [236] which may be of particular importance in 
HIV-infected people. 
 
6.2   Inhibitors of reactive oxygen and reactive nitrogen intermediates do not 
influence the ability of neutrophils to restrict mycobacterial luminescence 
Samples of Percoll-isolated neutrophils in RPMI-1640 and 10% autologous serum or serum-
only controls from six donors were supplemented with either N-acetylcysteine (NAC), L-
NMMA, L-ascorbic acid (Vitamin C) or water (vehicle) alone; final concentrations were 
10mM for NAC and L-ascorbic acid and 2mM for L-NMMA. These samples were infected 
with BCG-lux, as per the neutrophil mycobacteria restriction assay described in detail in 
Chapter 3, but with a slightly higher MOI (approximately 8 cells: 1 CFU); luminescence was 
measured at 1 hour, 4 hours and 24 hours. Initial experiments suggested a large effect of 
NAC and a further condition was thus introduced of the inactive control N-acetlyserine 
(NAS).  
Results (Figure 6.1) demonstrate a cell-independent effect of Vitamin C on mycobacterial 
luminescence, which was decreased by 24 hours with this treatment. Conversely, NAC 
supplementation resulted in a trend towards increased mycobacterial luminescence by 24 
hours. Curiously in these experiments the luminescence was higher in cell than serum-only 
samples at later time points: this may relate to the MOI and is discussed at the end of this 
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chapter. Nevertheless, the ratio of cell to serum luminescence was unaffected by anti-
oxidants (Table 6.1) and the effect of NAC in increasing luminescence was also seen with 
NAS (Figure 6.1). These direct effects were not explained by pH, since both Vitamin C and 
NAC reduced pH similarly at early time points (Figure 6.1D) despite opposite effects on 
luminescence. Furthermore, at 24 hours, there was more sustained reduction in pH with 
Vitamin C (median 6.99 vs 8.53 for ‘no reagent’ control, p < 0.05 by Friedman test with post-
hoc Dunn’s correction), but not to a lower level than at baseline (where the effect of 
Vitamin C on luminescence was insignificant). NAC did not significantly affect pH at this later 
time point, despite the trend towards markedly increased luminescence. L-NMMA did not 
affect measured luminescence, the ratio of cell to serum luminescence or the pH of 
incubation medium (Figure 6.1 and Table 6.1). 
Table 6.1. Ratio of luminescence of BCG-lux in cell-containing samples vs serum-only 
samples at various time points (6 donors). 
 Median (IQR) ratio of 
BCG-lux RLU in cell-
containing samples vs 
serum-only samples at 1 
hour 
  
Median (IQR) ratio of 
BCG-lux RLU in cell-
containing samples vs 
serum-only samples at 4 
hours 
 
Median (IQR) ratio of 
BCG-lux RLU in cell-
containing samples vs 
serum-only samples at 
24 hours 
 
No reagent 0.46 (0.36 – 1.05) 1.08 (0.83 – 1.88) 1.26 (1.03 – 1.62)  
Zinc chloride 0.48 (0.41 – 0.66) 0.69 (0.47 – 1.04) 0.56 (0.35 – 1.21) * 
Vitamin B12  0.35 (0.30 – 0.54) * 1.01 (0.59 – 1.10) 1.06 (1.00 – 1.31)  
1,25-OH Vitamin D 0.50 (0.35 – 0.77) 0.90 (0.66 – 1.21) 1.21 (0.90 – 1.39)  
Vitamin C 0.78 (0.51 – 1.05) 0.89 (0.86 – 1.06) 0.97 (0.35 – 2.72)  
NAC 0.49 (0.39 – 0.84) 1.01 (0.87 – 1.12) 1.53 (0.92 – 2.05)  
L-NMMA 0.38 (0.29 – 0.81) 0.88 (0.60 – 0.99) 1.14 (0.79 – 1.72)  
IQR = interquartile range; RLU, Relative Light Units; NAC = N-acetylcysteine; L-NMMA = NG-Monomethyl-L-
Arginine;; vs = versus; BCG = Mycobacterium bovis-BCG.  *p < 0.05 for pairwise comparison vs ‘No reagent’ 
control (Wilcoxon signed-rank test] 
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6.3   Zinc, Vitamin B12 and Vitamin D have variable direct effects on 
mycobacterial luminescence but only zinc improves proportional restriction 
versus vehicle alone 
Experiments were performed as in the previous section; final concentrations of potential 
neutrophil stimulants were 1mM for Vitamin B12, 2mM for zinc chloride and 10nM for 
1,25(OH)2-Vitamin D. Vitamin B12 directly reduced luminescence of BCG-lux by one hour 
(Figure 6.1), and, at least by pairwise comparison with the ‘No reagent’ control, also slightly 
reduced the ratio of cell to serum luminescence (Median 0.35 vs 0.46, p < 0.05, Table 6.1). 
However, while the direct effect on luminescence was sustained to later time points, the 
relative improvement in cellular function was not. In three further experiments at 
physiological concentrations (1nM), Vitamin B12 did not directly affect luminescence (p = 
0.92) or reduce the cell to serum ratio (p = 0.26). 
 Zinc chloride elicited a non-significant reduction in luminescence versus ‘no reagent’ 
controls in serum-only samples, but a significant reduction in cell samples from 4 hours 
onwards (Figure 6.1). This was manifested by an improvement in the ratio of cell to serum 
luminescence by 24 hours (median 0.56 vs 1.26, p < 0.05 by pairwise comparison; Table 6.1). 
In fact this was the only condition where a restrictive effect of cells was maintained at later 
time points in these experiments. 1,25(OH)2Vitamin D did not result in a cell-independent 
effect on luminescence or alter the ratio of cell to serum luminescence at any time point. 
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Figure 6.1. Investigation of potential modifiers of 
neutrophil-mediated control of BCG-lux. A. 150,000 RLU of 
BCG-lux (in 50mcl PBS) were added to 390,000 neutrophils 
(390mcl) in RPMI-1640 (‘Cells’) or to 390mcl RPMI-1640 
(‘Serum’ controls) in the presence of 10% autologous serum 
(50mcl), and supplemented with 10mcl of specified 
reagents in water. The ‘No reagent’ control contained 
vehicle (water) only. Final concentrations were 2mM for 
zinc chloride (ZnCl2), 10nM for 1,25-OH Vitamin D, 1mM for 
Vitamin B12, 2mM for NG-Monomethyl-L-Arginine (L-
NMMA), 10mM for Vitamin C and 10mM for N-
acetylcysteine (NAC). Luminescence was measured at one 
hour on duplicate (Serum) or triplicate (Cells) samples. 
Column heights (error bars) represent medians (IQR) from 
six donors processed in independent experiments (four 
donors only for NAS). B. Luminescence of samples prepared 
as in A. was measured at four hours. C. Luminescence of 
samples prepared as in A. was measured at 24 hours. D. 
Aliquots of 390mcl RPMI-1640, 50mcl PBS, 50mcl freshly 
defrosted healthy donor serum and 10mcl reagents (in 
concentrations as described above) were measured for pH 
immediately (green line), after 20 minutes (blue line) or the 
next day, at approximately 24 hours (red line). Markers 
(error bars) represent median (interquartile range) of three 
independent experiments. 
For A – C: * p < 0.05  ** p < 0.01, derived from Friedman 
test with post-hoc Dunn’s testing of each reagent 
(excluding NAS) versus ‘No reagent’ control.  
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6.4   Vitamin B12 does not affect neutrophil cell death but N-acetylcysteine and 
especially zinc chloride reduce neutrophil cell death 
Samples were processed as in the previous sections, supplemented with those reagents which had 
the greatest effects on mycobacterial luminescence: NAC, Vitamin B12 or zinc chloride. They were 
stained for the cell death assay described in Chapter 2 after 24 hours’ incubation. Analysis with one-
way ANOVA and post-hoc Bonferroni correction revealed a significant reduction in the frequency of 
CD66-positive events in the necrotic population with NAC treatment (p < 0.05) versus the ‘No 
reagent’ condition, while Vitamin B12 did not affect the percentage of events in any state of cell 
death (mean ± SD percentages for 4 donors – Viable: No reagent 10.1% ± 9.25%, NAC 13.1% ± 5.6%, 
B12 8.5% ± 11.2%; Apoptotic: No reagent 43.8% ± 15.8%, NAC 55.1% ± 18.7%, B12 51.7% ± 14.0%; 
Necrotic: No reagent 46.1% ± 16.7%, NAC 31.9% ± 14.8%, B12 39.8% ± 12.8%). Together with the 
trend towards more viable events in the NAC group, this is consistent with slightly delayed 
apoptosis – and subsequent progression to necrosis – with inhibition of reactive oxygen 
intermediates, as previously described (see Chapter 1).  
Zinc chloride markedly reduced cell death in these assays (Figure 6.2). Across three donors the 
percentage of viable events increased from 4.6% (4.0% - 9.2%) to 40.5% (35.6% - 47.0%).  
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6.5   Zinc chloride at physiological doses may reduce neutrophil cell death in HIV-
infected people, although results are inconsistent 
In the previous chapter, I reported that HIV-infected patients’ neutrophils demonstrate a 
propensity to undergo rapid necrotic cell death. Since zinc reduced cell death in my experiments, 
consistent with other literature [235], I therefore investigated whether zinc could mitigate against 
this phenomenon in ART-naïve HIV-infected people. I also investigated the effect of zinc 
supplementation of medium on the killing ability of patients’ neutrophils. To maintain in vivo 
relevance, I predominantly focussed on achievable physiological concentrations of zinc. 
These experiments were conducted in two sets, the first using only a single concentration of zinc 
(final concentration of 20μM) and the second using a range of concentrations. Unfortunately there 
is a high probability that the blood tubes used for the second group were contaminated by 
lipopolysaccharide (discussed below). Table 6.2 details the participant characteristics for these 
studies. Results from the restriction assay are shown in Table 6.3, and show that zinc chloride did 
not improve the ability of neutrophils to control mycobacterial metabolism at either one hour or 24 
hours: in fact there was a significant increase in cell-associated luminescence and the ratio versus 
serum control with the highest zinc dose (500μM) in the second group. 
Figure 6.3 details the results of the cell death assay, in this instance performed at 18 hours due to 
the high percentage of necrotic events seen previously in HIV-infected donors (Chapter 4). In the 
first group, a significant effect of zinc chloride was seen in M.tuberculosis-infected samples, 
wherein the overall percentage of necrotic events was reduced but events remaining in apoptosis 
increased in the zinc-treated samples (mean percentage of Viability Dye-positive events in vehicle 
only samples 51.0 ± 18.1% vs zinc-treated samples 41.8 ± 15.8%, p = 0.02; mean percentage of 
apoptotic events in vehicle only samples 40.4 ± 15.7% vs zinc-treated samples 48.1 ± 13.7%, p = 
0.004). There was a corresponding trend towards a higher percentage of singlet events being gated 
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as neutrophils by forward and side scatter (29.1 ± 22.1% vs 17.8 ± 16.1%, p = 0.10). However, as 
also represented in Figure 6.3, the same results were not replicated in the second group, where 
none of the zinc concentrations used appeared to impact upon neutrophil cell death.  
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Figure 6.2. Effect of high dose zinc chloride on neutrophil cell death in the presence of BCG. A. 3.9 x 10
5 
neutrophils 
were incubated with 50mcl serum, 50mcl BCG-lux (2 x 10
5
 RLU) and 10mcl of water (‘No reagent’) or 10mcl of zinc 
chloride to reach a final concentration of 2mM. After 24 hours, samples were centrifuged at 500 x g for 6 minutes, 
resuspended in 500mcl Annexin V binding buffer and stained with CD66a,c,e-PE, Annexin-V FITC and eFluor450 Viability 
dye. After 20 minutes, samples were centrifuged, washed with PBS and resuspended in 2% paraformaldehyde before 
acquisition in a BD Fortessa flow cytometer. Shown are the percentage of singlet CD66a,c,e-positive events defined as 
viable (Annexin V and Viability dye negative). Three separate donors in two independent experiments. B. For the same 
samples as (A), shown are the percentage of singlet CD66a,c,e-positive events defined as apoptotic (Annexin V positive, 
Viability dye negative). C. Representative Annexin V vs Viability dye flow cytometry plots and adjunctive histograms 
from one donor showing singlet CD66a,c,e positive events either with (blue) or without (red) zinc chloride treatment.   
A B 
C 
Viable events Apoptotic events 
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Table 6.2. Participant characteristics for ex vivo zinc supplementation studies. 
 Group 1 (n = 10) Group 2 (n = 8) 
Age (years) Median 
Range 
36.5 
24 – 44  
35 
24 – 63  
Ethnicity Xhosa 10 (100%) 8 (100%) 
Sex Male 
Female 
7 (70%) 
3 (30%) 
3 (37.5%) 
5 (62.5%) 
Smoking Yes 
No 
Ex 
Unknown 
5 (50%) 
2 (20%) 
2 (20%) 
1 (10%) 
2 (25%) 
4 (50%) 
2 (25%) 
0 (0%) 
Regular Alcohol Yes 
No 
Unknown 
2 (20%) 
7 (70%) 
1 (10%) 
1 (12.5%) 
7 (87.5%) 
0 (0%) 
BCG Yes 
No 
Unsure / Unclear 
5 (50%) 
0 (0%) 
5 (50%) 
1 (12.5%) 
4 (50%) 
3 (37.5%) 
Co-morbidity 
a 
Yes 
No 
4 (40%) 
6 (60%) 
2 (25%) 
6 (75%) 
Co-trimoxazole 
prophylaxis 
Yes 
No 
4 (40%) 
6 (60%) 
6 (75%) 
2 (25%) 
Vitamin treatment Vitamin B Co-Strong 
Vitamin C 
4 (40%) 
1 (10%) 
5 (62.5%) 
4 (50%) 
Other medication in 
previous 3 months
 b 
Yes 
No 
4 (40%) 
6 (60%) 
5 (62.5%) 
3 (37.5%) 
Current symptoms 
c 
Yes 
No 
2 (10%) 
8 (90%) 
3 (37.5%) 
5 (62.5%) 
CD4 count (x10
6
/L) Median 
Range 
311   [n = 9] 
26 – 432  
151 
55 – 371  
Log [HIV viral load 
(copies/ml)] 
Median 
Range 
4.57 
2.26 – 5.79  
5.37 
3.96 – 5.96  
Weight (kg) Median 
Range 
68.5   [n = 7] 
56.8 – 100.2  
68.3   [n = 4] 
53.6 – 86.5 
a 
Identified co-morbidities: epilepsy, hypertension, chronic back pain, depression, shingles. 
b 
Identified medications: sodium valproate, phenytoin, anti-hypertensives (unknown class), amitriptyline, folic acid, 
acyclovir, paracetamol, nystatin. 
c
 Identified symptoms: back pain, shingles, oral candidiasis. 
BCG = Mycobacterium bovis-BCG; CD4 = Cluster of Differentiation-4; HIV = Human Immunodeficiency Virus; kg = 
kilogrammes. 
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Figure 6.3. Investigating the ex vivo effect of zinc on cell death of HIV-infected patients’ neutrophils. A. 3.9 x 105 
neutrophils were incubated with 50mcl serum, 50mcl TB-lux (2 x 10
5
 RLU) and 10mcl of water (-) or 10mcl of zinc 
chloride to reach a final concentration of 20μM (+). After 18 hours, samples were centrifuged at 500 x g for 6 minutes, 
resuspended in 500mcl Annexin V binding buffer and stained with CD66a,c,e-PE, Annexin-V FITC and eFluor450 Viability 
dye. After 20 minutes, samples were centrifuged, washed with PBS and resuspended in 4% paraformaldehyde for 
overnight fixation before acquisition in a BD Fortessa flow cytometer. Shown are the percentage of singlet CD66a,c,e-
positive events defined as necrotic (Viability Dye+), Apoptotic (AnnV+, Viability Dye-) and Viable (AnnV-, Viability Dye-). 
Column heights (error bars) represent mean (SD) from 10 donors. p-values derived from paired t-tests. B. Experiments 
were performed as in A, but zinc chloride was added to reach the final concentrations (in μM) as indicated after ‘+’. 
Column heights (error bars) represent mean (SD) from 8 donors. No statistically significant differences in any group. 
A 
B 
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Table 6.3. Results from luminescence readings in ex vivo zinc supplementation experiments. 
 Group 1 (n = 10) Group 2 (n = 8) 
No zinc 20μM 
ZnCl2  
p-value 
(paired t-
test) 
No zinc 20μM 
ZnCl2 
100μM 
ZnCl2 
500μM 
ZnCl2 
p-value (one-
way ANOVA 
[Bonferroni]) 
Luminescence 
in serum 
samples at 1 
hour (Mean ± 
SD) 
19612 ± 
6924 
20062 ± 
5597 
0.639 57832 ± 
12285 
56569 ± 
11179 
59737 ± 
13928 
59522 ± 
10989 
0.570 
Luminescence 
in neutrophil 
samples at 1 
hour (Mean ± 
SD) 
15738 ± 
5876 
15806 ± 
5903 
0.924 47244 ± 
12204 
47494 ± 
11828 
49092 ± 
14327 
53190 ± 
13134 
0.006  
[p<0.05 for 
500μM ZnCl2 
vs No zinc] 
Cell/Serum 
ratio at 1 
hour (Mean ± 
SD) 
0.795 ± 
0.118 
0.769 ± 
0.147 
0.332 0.819 ± 
0.110 
0.840 ± 
0.130 
0.816 ± 
0.111 
0.888 ± 
0.105 
0.017  
[p<0.05 for 
500μM ZnCl2 
vs No zinc] 
Luminescence 
in serum 
samples at 24 
hours (Mean 
± SD) 
12956 ± 
5467 
12456 ± 
5266 
0.469 29072 ± 
7381 
27474 ± 
7665 
27614 ± 
6894 
26740 ± 
6752 
0.405 
Luminescence 
in neutrophil 
samples at 24 
hours (Mean 
± SD) 
11177 ± 
6312 
10797 ± 
6286 
0.596 28330 ± 
9214 
26990 ± 
8549 
25986 ± 
8844 
28966 ± 
10632 
0.299 
Cell/Serum 
ratio at 24 
hours (Mean 
± SD) 
0.828 ± 
0.317 
0.821 ± 
0.259 
0.896 0.975 ± 
0.195 
1.012 ± 
0.255 
0.933 ± 
0.138 
1.070 ± 
0.244 
0.298 
μM = micromolar; ZnCl2 = zinc chloride; ANOVA = Analysis of variance; SD = standard deviation. 
 
6.6   The addition of live neutrophils improves, while the addition of necrotic 
neutrophils impairs, control of M.tuberculosis in whole blood 
I have previously established that the depletion of neutrophils significantly impairs the control of 
M.tuberculosis by human whole blood (Chapters 4 and 5). I therefore hypothesised that the 
addition of neutrophils to whole blood would improve mycobacterial control. However, at sites of 
disease neutrophils die rapidly, and this process may be accelerated in people with HIV infection. I 
therefore also investigated the addition of necrotic (heat-shocked) neutrophils to human whole 
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blood. These experiments were performed in ten healthy donors; neutrophils were isolated by the 
Percoll methodology and divided into two equal aliquots. One half was heat-shocked at 60oC (and 
subsequently cooled). I then added 450mcl of viable neutrophils, necrotic neutrophils or RPMI-1640 
only to 450mcl aliquots of the same donor’s blood (kept aside at the time of venepuncture). The 
whole blood lux assay was conducted in the standard manner (Chapter 2) with the exception that 
the entire experiment was performed in 15ml Falcon tubes and thus sample transfer was not 
required before water lysis. One sample was contaminated, as evidenced by very high levels of 
inflammatory cytokines in the uninfected control samples (in many cases higher than in the M.tb-
infected samples): this was a similar pattern to a preliminary series of contaminated experiments in 
which the contaminant was found to be lipopolysaccharide present in sodium-heparin blood tubes. 
All results from this experiment were discarded. 
Overall neutrophil purity assessed by Coulter counting was 97.79 ± 1.16%. The non-augmented 
mean ± SD neutrophil count was 2.10 ± 0.75 x 109 / L versus 9.00 ± 3.30 x 109 / L in those samples 
augmented with viable neutrophils (p < 0.0001). Lymphocyte counts were not significantly 
different: 1.18 ± 0.53 x 109/L in non-augmented versus 1.30 ± 0.59 x 109/L (p = 0.09) in neutrophil-
augmented blood.   
Luminescence readings per 100mcl of 96-hour sample (performed in at least duplicate per donor 
per condition) were 9379 ± 4888 RLU for non-augmented blood. Luminescence was significantly 
decreased in samples augmented with viable neutrophils (2766 ± 1672 RLU, p < 0.001), and 96-hour 
luminescence correlated inversely with the number of neutrophils using all data from non-
augmented or viable-augmented samples (p = 0.0003). Conversely, augmentation with necrotic 
neutrophils increased mean luminescence at 96 hours to 11722 ± 6132 RLU, p = 0.013 versus no 
augmentation (Figure 6.4). 
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Figure 6.4. Luminescence of M.tuberculosis-lux after incubation in whole blood augmented with viable, necrotic or no 
neutrophils. A. 100,000 RLU of M.tuberculosis-lux in 100mcl PBS was inoculated into samples of 450mcl whole blood 
plus either 450mcl Percoll-isolated autologous neutrophils in RPMI-1640 heat-shocked at 60
o
C for 20 minutes and 
allowed to cool (‘+ Necrotic Neut’), 450mcl RPMI-1640 only (‘+ Nil’), or 450mcl room temperature Percoll-isolated 
autologous neutrophils in RPMI-1640 (‘+Viable Neut’). After 96 hours’ incubation samples were centrifuged at 2000 x g 
for 10 minutes, supernatants were aspirated and pellets were resuspended in 10ml water for 10 minutes. After further 
centrifugation pellets were resuspended in 1ml PBS and 100mcl aliquots were added to 900mcl PBS for measurement 
of luminescence in a Berthold Sirius single tube luminometer (at least duplicate readings per condition). Results are 
shown from 9 independent donors. B. Results from non-augmented and viable neutrophil-augmented samples in (A) 
are here plotted versus neutrophil count as established by Coulter counting. R
2
 for exponential relationship = 0.778; 
linear correlation R
2
 = 0.563 (p = 0.0003).  
B 
A 
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6.7   The addition of either live or necrotic neutrophils to M.tuberculosis-infected 
whole blood significantly affects supernatant immune responses 
Supernatants from these experiments were assayed by Luminex™ 30-plex technology, as previously 
described. In total 26 cytokines or chemokines were detectable with acceptable standard curves 
and a median value greater than the lower limit of detection. In order to differentiate between the 
three conditions (non-augmented, viable neutrophil-augmented or necrotic neutrophil-augmented) 
I employed Qlucore™ Omics Explorer v2.3 to perform principal component analysis. Initial 
exploration of data suggested that neutrophil manipulation by itself had a significant effect on 
cytokine and chemokine responses; subtracting baseline values from uninfected controls therefore 
removes much of the biological effect of the manipulation: I therefore present analysis on this raw 
data. 
Principal component analysis showed clear distinction between the non-augmented, viable 
neutrophil-augmented and necrotic neutrophil-augmented conditions (Figure 6.5; Table 6.4 details 
p- and q-values). This analysis required a slightly more stringent q-value than the usual cut-off of 
0.1 to ensure that p-values also fell below 0.05. However, the separation of groups was clear at any 
stringency. Figure 6.6 presents analyte values as box-and-whiskers plots and displays results from 
one-way ANOVA analysis for each cytokine or chemokine found to contribute to the separation of 
groups in principal component analysis. This allows determination of the direction of differences 
between groups for each analyte. 
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Table 6.4. p- and q-values for Principal component Analysis of raw Luminex™ data from 
augmentation experiments. 
Analyte p-value q-value 
CCL2 0.0061 0.0132 
CCL3 0.000769 0.00399 
CCL5 0.00103 0.00399 
CXCL10 0.00799 0.016 
Eotaxin 0.000387 0.00251 
FGFb 0.00222 0.00641 
G-CSF 0.00451 0.0107 
GM-CSF 0.00107 0.00399 
HGF 7.029 x 10-6 0.000116 
IL-1β 8.932 x 10-6 0.000116 
IL-10 0.00138 0.0045 
IL-12p40p70 0.00247 0.00641 
IL-2R 0.000257 0.00223 
IL-7 0.0199 0.0345 
TNF 0.00962 0.0179 
CCL = C-C chemokine ligand; CXCL = C-X-C chemokine ligand; FGFb = fibroblast growth factor-basic; G-CSF = 
Granulocyte-colony stimulating factor; GM-CSF = Granulocyte Macrophage-Colony Stimulating Factor; HGF = 
hepatocyte growth factor; IL = Interleukin; IL-2R = Interleukin-2 Receptor; TNF = Tumour Necrosis Factor. 
 
 Figure 6.5. Principal Component Analysis of cytokine response in augmentation experiments. Three dimensional 
principal component analysis plots generated using cytokine/chemokines that significantly contribute to 
differentiation between supernatants of augmentation conditions (calculated using multi-group comparison; 
purple = non-augmented, blue = necrotic neutrophil-augmented, yellow = viable neutrophil-augmented). 
Individual points represent one donor in one augmentation condition and their position in the plot is determined 
by the combined effects of all parameters measured for the sample that significantly contribute to the overall 
between-group difference. The distance between sample points represents Euclidean distance and is calculated 
using all parameters that significantly contribute to the overall between-group difference. Component vectors are 
displayed, along with a percentage figure signifying the proportion of the variability in the data that each 
component accounts for. Analysis is presented using raw values from infected supernatants.  
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Figure 6.6. Raw Luminex™ data from neutrophil augmentation experiments. A – O. Cytokines and 
chemokines were measured in 96-hour supernatants of M.tuberculosis-infected blood which had been 
augmented with necrotic autologous neutrophils (‘+ Necrotic’), with medium only (‘+ Nil’), or with viable 
autologous neutrophils (‘+ Viable’). Box and whisker plots represent median, interquartile range, minimum and 
maximum values for each analyte found to be significant in Principal Component Analysis. Presented are p-
values from one-way ANOVA with Bonferroni correction comparing both augmented conditions with the 
medium-only control: * p < 0.05, ** p < 0.01, *** p < 0.001. Data are from 9 separate donors in four 
independent experiments. IL = Interleukin, TNF = Tumour Necrosis Factor, FGFb = Fibroblast Growth Factor 
basic, G-CSF = Granulocyte-Colony Stimulating Factor, GM-CSF = Granulocyte Macrophage-Colony Stimulating 
Factor, CCL = C-C motif ligand, CXCL – C-X-C motif ligand, IL-2R = Interleukin-2 Receptor, HGF = Hepatocyte 
Growth Factor.  
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6.8   Discussion 
In this chapter I have explored the impact of various manipulations of neutrophil function or 
number on the response to mycobacterial challenge. Experiments investigating potential 
inhibitors or stimulators of neutrophil-mediated mycobacterial restriction were more 
difficult to interpret than anticipated due to direct effects of the mediators on 
mycobacterial luminescence and a generally poor ability of neutrophils to control 
mycobacterial metabolism versus serum controls in these assays. The direct effects on 
mycobacteria may well be interesting to pursue, especially for those agents which appear to 
have a restrictive effect (Vitamin B12, zinc chloride and Vitamin C), but these are beyond the 
scope of this thesis. Data recently published confirms a direct effect of Vitamin C [237], but 
in those experiments, as in mine, vitamin concentrations were far greater than those found 
in vivo in humans. It is worth noting that neither Vitamin B12 at physiological concentrations 
(1nM) nor Vitamin C even at high concentration affected neutrophil antimycobacterial 
activity at one hour: this suggests that these agents were not responsible for the effect of 
HIV demonstrated in Chapter 4 (where most HIV-infected patients were taking vitamin 
supplements). The apparent effect of N-acetylcysteine in increasing BCG luminescence is 
also interesting (as mentioned earlier, this does not appear to be simply a pH phenomenon). 
However, the inclusion of both cell-free and inactive controls (N-acetylserine) confirms that 
the effect is not dependent on the presence of neutrophils. 
The higher luminescence in neutrophil samples compared to serum samples at later time 
points in these experiments was unusual and remains unexplained. As mentioned above, a 
higher MOI was used for these experiments in order to maximise any effect of the 
neutrophil modulating agents. However, as reported in the initial MOI experiments in 
Chapter 3, there was a suggestion by 24 hours of a ‘U-shaped curve’ when plotting 
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mycobacterial luminescence versus neutrophil concentration. It may be that high numbers 
of neutrophils contribute to increased mycobacterial survival, perhaps via extracellular 
products from cell death. Indeed, the only condition which maintained suppression versus 
serum to 24 hours was zinc chloride supplementation, which also significantly arrested cell 
death. It is tempting to speculate that there may be biological significance to this 
phenomenon, since neutrophilia in tuberculosis predicts poor prognosis (see Chapters 1 and 
8); and necrotic neutrophils also enhance growth of M.tuberculosis in blood (Figure 6.4A 
and discussed below). 
Notwithstanding these caveats, I can draw some conclusions from these experiments. 
Inhibitors of reactive oxygen intermediates (NAC and Vitamin C) and reactive nitrogen 
intermediates (L-NMMA) did not impact on the relative ratio of luminescence in neutrophil 
samples versus serum controls (Table 6.1), suggesting that these mechanisms are not of 
fundamental importance in control of mycobacteria by neutrophils: this is consistent with 
previous literature [87, 106]. Although N-acetylcysteine may delay cell death, this in itself 
does not appear to improve control of mycobacterial luminescence. It therefore seems likely 
that antimicrobial peptides such as HNP are of more importance in killing of mycobacteria 
(as discussed in Chapter 1). 
1,25(OH)2Vitamin D also did not have any significant effect on control of mycobacteria, 
despite previous promising findings in macrophages [124]. Vitamin B12 – at very high 
concentration – possibly effected an early improvement in control in addition to its direct 
effects on mycobacterial health, but this was not sustained (Table 6.1). However, zinc 
chloride, despite also having direct effects on BCG luminescence, did appear to elicit a 
sustained improvement in the relative effect of neutrophils versus serum; this was 
accompanied, at this high concentration, by an apparently marked reduction in cell death 
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(Figure 6.2). I am somewhat cautious in my interpretation of this result, since the binding of 
Annexin V in the assay is calcium-dependent and zinc may block this as a competing divalent 
cation. However, calcium competition may in fact be the mechanism by which zinc can delay 
neutrophil death [238]. Furthermore, the appearance of the flow cytometry plots also 
suggested more viable neutrophils in the treated group (i.e. more events in the granulocyte 
region of the FSC vs SSC plot), and this result is consistent with other published data [235].  
Similar results of delayed cell death were replicated in the first group of HIV-infected 
patients where I used only physiological doses of zinc (20μM – see Figure 6.3A): in this case 
a significant reduction in necrotic events was seen. Unfortunately these results were not 
seen in the second group, across a range of zinc concentrations (Figure 6.3B). However, it is 
possible that these latter experiments were contaminated by lipopolysaccharide in the 
sodium-heparin blood tubes used to take patient samples. Although supernatants of these 
samples were not assayed, this manufacturing error is known to have affected other 
samples taken at a similar time and from the same batches of tubes (specifically, a 
preliminary series of neutrophil augmentation experiments and an investigation into the 
effect of G-CSF stimulation on mycobacterial restriction: all these results were discarded). It 
is therefore difficult to draw firm conclusions at this stage on the effect of zinc on mitigating 
cell death in HIV-infected patients’ neutrophils, and further investigation is required. 
However, my results in healthy donors and the weight of literature suggest that zinc can 
improve cell viability [235, 236, 238]. Zinc supplementation has also been shown to improve 
neutrophil function in terms of degranulation and killing [232] and improves outcomes in 
sepsis [239] – albeit results in active tuberculosis infection have been inconclusive [240]. Of 
note, although high concentration zinc chloride appeared to improve restriction of BCG by 
healthy donors’ neutrophils, consistent with published literature on macrophages [234], I 
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did not detect an improvement in direct restriction of M.tuberculosis by neutrophils in any 
of the experiments on HIV-infected patients. 
Aside from attempting to modulate neutrophil function, I also explored the effect of 
modifying neutrophil number and viability status in whole blood. The addition of autologous 
viable neutrophils universally and markedly improved control of M.tuberculosis 
luminescence. This is compatible with previous results demonstrating the significant 
negative effect of depleting neutrophils (Chapters 4 and 5) and the direct control of 
mycobacteria by neutrophils (Chapters 3 and 4). It thus seems unequivocal that viable 
neutrophils are of prime importance in the control of mycobacteria in blood, and may 
therefore be essential in controlling or preventing dissemination of infection. In contrast, 
the addition of necrotic neutrophils to blood resulted in significantly increased 
luminescence by 96 hours. 
Intriguingly, cytokine analysis of supernatants – which very clearly separated viable 
neutrophil-augmented, necrotic neutrophil-augmented and non-augmented blood from one 
another (Figure 6.5) – revealed that maximal Th1 cytokine responses were seen in the non-
augmented blood. Despite their reputation as inflammatory cells, viable neutrophil 
augmentation was in fact broadly anti-inflammatory, reducing many inflammatory cytokines 
and chemokines with the exception of Hepatocyte Growth Factor (HGF) which was 
increased (Figure 6.6). There are two plausible explanations for this: first, that neutrophils 
kill many bacilli early and thus less activation of the acquired immune response is required; 
second, that neutrophils die by apoptosis which generally elicits an anti-inflammatory 
response in phagocytosing mononuclear cells (see Chapter 1). 
The addition of necrotic cells to blood also suppressed Th1 responses, but in this case in the 
context of impaired mycobacterial control. Furthermore, necrotic neutrophil augmentation 
179 
 
provoked an increase in IL-10, which would be expected to actively suppress protective 
immune responses [241]. Several other mediators were also increased with the addition of 
necrotic cells, most notably G-CSF and GM-CSF but also the chemokine CCL2. Although 
favourable roles have been suggested for some of these molecules in mycobacterial 
infection, for example GM-CSF [242], their predominant role at sites of inflammation is to 
attract more cells – especially more neutrophils. One can thus hypothesise that in the 
context of active tuberculosis with necrotic neutrophilic inflammation, as may be seen in 
HIV infection, patients will suffer from impaired mycobacterial control, suppression of Th1 
but enhancement of Th2 immune responses, and an ongoing influx of neutrophils to 
perpetuate this pathological cycle. Poor control of infection and aberrant immune responses 
might also contribute to dissemination of bacilli in the blood of HIV-infected people if, as 
previous results suggest (Chapter 4), neutrophils are rapidly undergoing cell death. 
Interestingly, HIV-infected people tend to be zinc deficient [243, 244], and if zinc can rescue 
neutrophils from cell death then supplementation may reduce the negative impact of 
necrotic neutrophils, especially in ART-naïve individuals. This question requires further 
research. 
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7. The influence of neutrophil augmentation or depletion prior to BCG 
vaccination on the development of an acquired immune response in the 
mouse  
 
7.1   Introduction 
As discussed in Chapter 1, and demonstrated ex vivo in Chapter 6, neutrophils have been 
shown to influence the development of adaptive immune responses. In relation to BCG 
vaccination, it has been noted that neutrophils ingest the instilled bacilli in mice and traffic 
them to lymph nodes [147], and that dendritic cells interacting with neutrophils in these 
experiments elicit greater T-cell responses. Recently, it has been confirmed that neutrophils 
are also the dominant cells attracted to the site of BCG instillation in humans [204].  
Murine neutrophil depletion pre-vaccination has been shown to impair restimulated IFN-γ 
responses from lymph node T-cells harvested after 3 days [40]. Conversely, the neutrophil 
product lactoferrin has been used successfully as an adjunct in BCG vaccination [150], 
improving T-cell IFN-γ responses and survival from subsequent M.tuberculosis infection. 
Thus the majority of available evidence from animal studies suggests that neutrophils may 
contribute positively to the development of adaptive immune responses to BCG vaccination.  
However, no published work to date has investigated the effect of directly enhancing the 
neutrophil response to vaccination, and nor had the downstream, systemic effects of 
neutrophil manipulation at the time of vaccination been described. I therefore used a 
mouse model to investigate augmentation or depletion of neutrophils at the site of BCG 
vaccination, with my primary readout as the IFN-γ response in splenocytes upon BCG re-
stimulation three weeks after vaccination. My hypothesis was that manipulation of 
181 
 
neutrophil number at the vaccination site would significantly affect the response of the 
acquired immune system to re-challenge after a three week interval. 
A subcutaneous air-pouch system was used in all but one experiment (see below) to enable 
accurate recruitment of neutrophils to the vaccination site, accurate delivery of vaccination 
and easy sampling of recruited cells. Experiments either compared responses in control 
animals to neutrophil-depleted mice or compared controls to mice with additional 
neutrophils recruited to the vaccination site. Neutrophil depletion was effected by the anti-
Ly6G 1A8 antibody, administered subcutaneously one day before vaccination; the isotype 
control antibody 2A3 was administered to control animals. Additional recruitment of 
neutrophils to the pouch was achieved using MIP-2 (CXCL2), which is structurally related 
and functionally similar to human IL-8. This was administered directly into the pouch two 
hours before vaccination; control animals received no treatment. 
I chose to use BCG-GFP-Lux organisms as the vaccination strain for these experiments: these 
enabled measurement of bacillary load in the pouch (via luminescence readings on 
aspirates) and identification of which cells were associated with organisms (via flow 
cytometry of aspirates).  
Three weeks after vaccination, mice were killed and spleens were removed. Spleens were 
analysed by weight, cell number (Coulter counting), flow cytometric determination of cell 
proportions and response to BCG re-challenge via intracellular cytokine measurement (flow 
cytometry) and supernatant IFN-γ measurement (ELISA). Figure 7.1 summarises the basic 
experimental system.  
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Figure 7.1. Summary of system and timescale for murine experiments into neutrophil effect on BCG efficacy. 
 
7.2   Optimising the pouch model 
I first needed to define the optimal sampling time of air pouches after vaccination to record 
the peak cellular response. I therefore sampled pouches in a small number of untreated 
mice 1, 2 or 4 hours after instillation of either BCG-lux or HBSS vehicle alone. As 
demonstrated in Figure 7.2A, the response to BCG vaccination appeared to peak at 2 hours. 
By 4 hours, counts had fallen significantly. Organism luminescence (Figure 7.2B) was seen 
until 2 hours and then fell significantly. I therefore concluded that 2 hours after vaccination 
would be the optimal sampling time to enable assessment of mycobacterial burden and 
host cellular response. These experiments were performed with a low vaccine inoculum 
(approx. 1 x 105 CFU). 
In order to improve recovered luminescence and cell counts I then investigated alternative 
doses between 1 x 105 CFU and 1 x 106 CFU (Figure 7.2C). The recovered cell counts 
appeared to plateau at approximately 5 x 105 CFU, and I therefore used this dose for further 
experiments. 
Inject 5ml air 
to form pouch 
Top up pouch  
with 3ml air 
1A8 or 2A3 Ab 
by IP injection 
(if required)  
MIP-2 injected  
into pouch 
(if required) 
BCG vaccination Pouch lavaged  
and sampled  
Mouse sacrificed, 
spleen removed 
and processed  
T – 7 days T – 3 days T – 1 day T – 2 hours T0 T + 2 hours T + 3 weeks 
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Figure 7.2. Optimising the pouch model. A. Mouse pouches were injected with 1ml HBSS containing 1 x 10
5
 
CFU BCG-lux (‘BCG’) or 1ml HBSS alone (‘HBSS’). After the indicated number of hours, 1ml HBSS + 5mM EDTA 
was injected into the pouch and, after 10 minutes, 500mcl aspirated; Coulter counts (HemaVet HV950) were 
performed on aspirated samples. n=3 or 4 per group per time point. Column heights represent mean, error 
bars represent SD. B. Luminescence measurements on BCG-infected samples from A, performed in duplicate 
on 100mcl samples per mouse per time point (n=4 per time point). Column heights represent mean, error bars 
represent SD. C. Mouse pouches (n = 4) were infected with the indicated number of BCG-lux CFU and sampled 
after 2 hours. Cell counts and luminescence measurement were performed as described above. Each point 
represents duplicate readings from 1 mouse. 
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7.3   1A8 treatment reduces the proportion of granulocytes at the site of 
vaccination but does not affect organism burden 
Pouches were generated in two out of the three depletion experiments performed in total; 
in the final experiment BCG was injected intra-dermally to ensure that the results were 
reproducible in the absence of an artificial pouch vaccination site. Coulter counts performed 
on pouch aspirates suggested a trend towards reduced cell recovery with 1A8 treatment 
compared to 2A3 controls (0.43 +/- 0.24 x 106 cells/ml vs 0.86 +/- 0.66 x 106 cells/ml, p = 
0.060). There was no difference in immediate recoverable organism burden after neutrophil 
depletion (1A8, 19760 +/- 17545 RLU/100mcl/20secs vs 2A3, 22347 +/- 13843 
RLU/100mcl/20secs, p = 0.80).  
Figure 7.3A details the gating strategy employed to analyse flow cytometric data from the 
pouches. First, singlet events were defined (FSC-A vs FSC-H), then eosinophils were removed 
(due to their high autofluorescence in the FITC channel, and variable number between 
experiments): these are defined as Gr-1 mid-to-low cells with high side scatter. 
Subsequently I gated on Gr-1 versus MHC-II to identify neutrophils and antigen-presenting 
cells. Gating on GFP signal (lower panels) allowed me to assess which cells were associated 
with organisms, in addition to measuring overall proportions. Figure 7.3B shows that 
strongly positive Gr-1 cells were F4/80 negative, suggesting that they are neutrophils and 
not inflammatory monocytes (which appear to have intermediate Gr-1 signal, as indicated, 
and consistent with existing literature [245]). Figures 7.3C and 7.3D demonstrates the loss of 
neutrophil population with 1A8 treatment but preservation of other populations. 
Total cell and organism-associated proportions of Gr-1+ and MHC-II+ events are shown in 
Figure 7.4. 1A8 treatment resulted in a significant decrease in the percentage of neutrophils 
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overall (20.41 +/- 11.06% vs 48.94 +/- 21.16%, p = 0.0014) and the percentage associating 
with organisms (15.12 +/- 13.71% vs 44.24 +/- 13.32%, p = 0.0001), while there was a higher 
proportion of MHC-II expressing cells overall (23.37 +/- 7.89% vs 13.85 +/- 9.26%, p = 0.024) 
and associating with organisms (51.76 +/- 14.79% vs 36.63 +/- 16.09%, p = 0.042). Note 
however that 1A8 treatment did not completely eliminate all neutrophils.  
 
7.4   1A8 treatment does not affect spleen cellularity or lymphocyte 
proportions at 3 weeks but may increase the proportions of neutrophils and 
eosinophils 
3 weeks after vaccination, mice were killed and spleens processed as detailed in Materials 
and Methods (Chapter 2). Total spleen cellularity was calculated from Coulter counting; 
spleen proportions were calculated from flow cytometric analysis of single cell splenocyte 
suspensions: gating strategies are demonstrated in Figure 7.5A, B and C. 
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Figure 7.3. Flow cytometry gating strategies for pouch aspirates from BCG-vaccinated mice. A. Gating 
strategy to analyse cell proportions. First, singlet events are defined by gating on FSC-Area vs FSC-Height. Next, 
eosinophils (high SSC, Gr-1-PE mid-to-low cells) are excluded. Total proportions of MHC-II+ (APC) and Gr-1+ 
(PE) cells are then defined (top panel). Organism-associated, GFP-positive events (seen in Alexa-Fluor 488 
channel) are gated to assess proportions of MHC-II expressing cells and neutrophils associating with BCG. B. 
Events which are strongly positive for Gr-1-PE (R4) are negative for F4/80-PE-Cy5, suggesting they are 
neutrophils. Inflammatory monocytes (F4/80-mid, Gr-1-mid) are seen in R3, ‘resident’ monocytes (F4/80-mid, 
Gr-1-neg) are seen in R2, and macrophages (F4/80-hi, Gr-1-mid-to-low) are seen in R1. C. and D. Untreated 
mice (C) show a significant neutrophil population in R2, but this is not present after 1A8 treatment (D). 
Eosinophils (R1), mononuclear phagocytes (R3) and lymphocytes (R4) are unaffected or relatively increased by 
1A8 treatment. 
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Figure 7.4. Results from flow cytometry of pouch aspirates on 1A8-treated and 2A3 control mice. A. Overall 
cell proportions of strongly Gr-1 positive events in control mice and 1A8-treated mice. Results are from 2 
independent experiments combined. Lines represent means; p-values are from unpaired t-tests. B. Overall cell 
proportions of MHC-II positive events in control mice and 1A8-treated mice. Results are from 2 experiments 
combined. Lines represent means; p-values are from unpaired t-tests. C and D. Organism-associated cell 
proportions from the same experiments. Lines represent means; p-values are from unpaired t-tests. 
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Figure 7.5. Gating strategy to determine splenocyte cell populations. A. Gating strategy to analyse B-cell 
proportions. First, singlet events are gated using FSC-area vs FSC-height. Lymphocytes are gated using FSC vs 
SSC, and then B-cells are defined as CD19-PerCPCy5.5+ and B220-Horizon V500+. B. Gating strategy to analyse 
T-cell proportions. Singlets and lymphocytes are gated as in A. T-cells are defined as CD3-Alexa Fluor 
700+/CD4-PerCPCy5.5+ or CD3-Alexa-Fluor700+/CD8-Horizon V500+. C. Gating strategy to analyse phagocyte 
proportions. Singlet events are gated as in A. Debris is gated out (R1), then events positive for MHC II-FITC and 
strongly positive for CD11c-PECy7 (R2) are defined as dendritic cells. A gate positive for MHC II-FITC (R6) is also 
created. Events positive for CD11b-PerCPCy5.5 (R3) are further divided on the basis of Gr-1 and SSC properties 
into neutrophils (R4): strongly Gr-1 positive, mid-to-high SSC, and eosinophils (R5): mid-to-low Gr-1, high SSC. 
Remaining CD11b positive events are gated for MHC II expression using R6; these CD11b+ MHC II+ events are 
defined as non-dendritic cell antigen-presenting mononuclear phagocytes. 
 
Results of these analyses are shown in Figure 7.6. There was no difference in total 
splenocyte numbers between conditions, nor was there any difference in B-cell, T-cell, 
dendritic cell, total CD11b+ or dual CD11b+/MHC II+ cell proportions between treated and 
control mice. Where measured, there was also no difference in the proportion of 
CD3+/CD4+ cells expressing CD62L or the proportion of CD19+/B220+ cells expressing 
CD21/35. By pairwise analysis (without correction for multiple comparisons) there was a 
higher percentage of neutrophils and eosinophils in 1A8-treated mice (neutrophils 1.16 +/- 
0.21% vs 0.62 +/- 0.12%, p = 0.038; eosinophils 0.72 +/- 0.06% vs 0.57 +/- 0.03%, p = 0.039). 
Of CD11b+ cells, neutrophils represented a higher percentage in 1A8 vs 2A3 mice (19.8 +/- 
10.7% vs 11.2 +/- 6.0%, p=0.030), and MHC II+ cells a lower percentage in 1A8 vs 2A3 mice 
(15.1 +/- 3.5% vs 18.9 +/- 3.0%, p = 0.012).  
 
7.5   1A8 treatment does not affect the percentage of TNF-secreting CD4+ 
cells upon restimulation 3 weeks after vaccination 
Splenocytes were restimulated with antigens as described in Materials and Methods 
(Chapter 2). Intracellular cytokine production was assessed by flow cytometry: Figure 7.7A 
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details the gating strategy. Note that CD3 was not used as a T-cell marker because the 
positive control (anti-CD3 ligation) blocked this site for fluorophore binding.  
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Figure 7.6. Total cell counts and sub-population proportions of splenocytes in 1A8-treated and 2A3 control 
mice. A. Cell counts (millions) in spleens harvested from 1A8-treated and 2A3 control mice. B – D. Proportions 
of lymphocytes, CD3+/CD4+ (B), CD3+/CD8+ (C), B220+/CD19+ (D). E – I. Proportions of cells, MHC II+/CD11++ 
(dendritic cells, E), in neutrophil gate (F), in eosinophil gate (G), CD11b+ (H) and CD11b+/MHC II+ (I). All graphs 
represent results from two experiments, except total cells (three experiments) and CD3+/CD8+ cell 
proportions (1 experiment), n = at least 5 per group per experiment.     * Significant comparison (p < 0.05) by 
unpaired t-test. 
Unfortunately, there were very few events seen in the IFN-γ channel with BCG antigen 
stimulation, making this analysis impossible to perform accurately: IFN-γ release was 
assessed by ELISA, as described below. Unstimulated controls had very few positive events: 
these were treated as ‘background’ and subtracted from the same animal’s PPD- or anti-
CD3-stimulated results. Figure 7.7B shows the results: there was no significant difference 
between treated and control mice either with BCG or anti-CD3 restimulation, although the 
A C B 
D E F 
G H I 
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trend was towards lower values in 1A8-treated mice (with BCG stimulation, 1A8 median 
(IQR) 0.41% (0.30%–0.60%), 2A3 median (IQR) 0.57% (0.40%-0.69%), p = 0.16).
 
1A8 BCG 2A3 BCG 1A8 CD3 2A3 CD3
0
1
2
p = 0.27 p = 0.69
%
 o
f 
C
D
4
+
 c
e
ll
s
 s
e
c
re
ti
n
g
 T
N
F
 
 
Figure 7.7. Gating strategy and results of intracellular cytokine analysis on BCG-restimulated splenocytes from 
1A8-treated and 2A3 control mice. A. Gating strategy for intracellular cytokine analysis (anti-CD3 stimulated 
sample). First, singlet events are defined (FSC-A vs FSC-H), then dead cells are excluded (defined as positive for 
eFluor450 Viability Dye, detected in Pacific Blue channel). Lymphocytes are gated by FSC and SSC, then CD4+ 
cells are identified (CD4-PerCPCy5.5+). Finally, CD4 cells are defined into quadrants on the basis of staining for 
TNF-PE or IFN-γ-APC. B. Percentage of CD4+ lymphocytes staining for TNF in spleens from 1A8- or 2A3 (control)-
treated mice after restimulation with PPD or anti-CD3 antibody (αCD3). Data from two independent 
experiments, n = at least 5 per group per experiment. Column heights represent medians, error bars represent 
interquartile range. p-values derived from Mann-Whitney tests. 
 
A 
B 
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7.6   1A8 treatment reduces IFN-γ release upon splenocyte restimulation 3 
weeks after vaccination 
Restimulated splenocytes were assessed for IFN-γ release in 72-hour supernatants by ELISA, 
as detailed in Chapter 2. Figure 7.8 shows the results of this analysis. There was a significant 
decrease in IFN-γ release from the splenocytes of 1A8-treated mice in response to BCG: 
12.45 +/- 14.65 ng/ml in 1A8 treated mice vs 28.86 +/- 25.02 ng/ml in 2A3 controls, p = 
0.014). Responses to anti-CD3 showed a similar trend (113.8 +/- 50.33 ng/ml in 1A8 treated 
mice vs 132.2 +/- 45.19 ng/ml in 2A3 controls, p = 0.25), but many results were at the 
maximum limit for the ELISA and this result is thus less accurate. Unstimulated control 
samples did not release detectable amounts of IFN-γ. There was no difference between 
matched animals from a single experiment whose pouches were sampled and those which 
were not sampled (n = 5 per group; p = 0.41). There was also no difference between animals 
with pouches and without pouches (p = 0.20) and the same pattern of results was 
maintained.  
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Figure 7.8. Results of IFN-γ ELISA on supernatants of BCG-restimulated splenocytes from 1A8-treated and 
2A3 control mice. Splenocytes (5 x 10
5
 / well) harvested 3 weeks after BCG vaccination from 1A8- or 2A3 
control-treated mice were restimulated with 20,000 CFU BCG-lux for 72 hours. IFN-γ was measured in 
supernatants by ELISA. Data from three independent experiments, n = at least 5 per group per experiment. 
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Column heights represent means, error bars represent standard deviation; p-value derived from unpaired t-
test. 
 
7.7   MIP-2 treatment increases cell counts and proportion of granulocytes at 
the site of vaccination but does not affect organism burden 
A sample of mouse pouches was aspirated in two out of the three MIP-2 neutrophil 
augmentation experiments performed in total. Compared to controls, MIP-2 treatment 
tended to increase overall recovered cell numbers (2.36 +/- 1.77 x 106 cells/ml vs 1.19 +/- 
0.90 x 106 cells/ml, p = 0.054). There was no difference in immediate recoverable organism 
burden after treatment (25697 +/- 11779 RLU/100mcl/20secs vs 47086 +/- 37178 
RLU/100mcl/20secs, p = 0.20). 
Total cell and organism-associated proportions of Gr-1+ and MHC-II+ events are shown in 
Figure 7.9. MIP-2 treatment resulted in a significant increase in the percentage of 
neutrophils overall (65.32 +/- 11.39% vs 42.23 +/- 21.78%, p = 0.009) and the percentage 
associating with organisms (64.32 +/- 15.84% vs 44.08 +/- 14.23%, p = 0.005), while there 
was a trend towards a lower proportion of MHC-II expressing cells overall (6.87 +/- 5.60% vs 
13.88 +/- 10.10%, p = 0.074) and significantly less associating with organisms (20.45 +/- 
11.43% vs 34.45 +/- 14.34%, p = 0.024).  
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7.8   MIP-2 treatment does not affect spleen cellularity or cell proportions at 
3 weeks restimulation 3 weeks after vaccination 
As with depletion experiments, mice were killed 3 weeks after vaccination and spleens 
removed for further analysis. Overall cellularity and cell proportions did not differ between 
MIP-2-treated and control mice (Figure 7.10). Where measured, there was also no 
difference in the proportion of CD3+/CD4+ cells expressing CD62L or the proportion of 
CD19+/B220+ cells expressing CD21/35. 
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Figure 7.9. Results from flow cytometry on pouch aspirates of MIP-2-treated and control mice. A. Overall cell 
proportions of strongly Gr-1 positive events in control mice and MIP-2-treated mice. Results are from 2 
independent experiments combined. Lines represent means; p-values are from unpaired t-tests. B. Overall cell 
proportions of MHC-II positive events in control mice and MIP-2-treated mice. Results are from 2 experiments 
combined. Lines represent means; p-values are from unpaired t-tests. C and D. Organism-associated cell 
proportions from the same experiments. Lines represent means; p-values are from unpaired t-tests. 
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Figure 7.10. Total cell counts and sub-population proportions of splenocytes in MIP-2-treated and control 
mice. A. Cell counts (millions) in spleens harvested from 1A8-treated and 2A3 control mice. B – D. Proportions 
of lymphocytes, CD3+/CD4+ (B), CD3+/CD8+ (C), B220+/CD19+ (D). E – I. Proportions of cells, MHC II+/CD11++ 
(dendritic cells, E), in neutrophil gate (F), in eosinophil gate (G), CD11b+ (H) and CD11b+/MHC II+ (I). All graphs 
represent results from two experiments, except total cells (three experiments) and CD3+/CD8+ cell 
proportions (1 experiment), n = at least 5 per group per experiment. No statistically significant differences 
were seen between groups. 
 
7.9   MIP-2 treatment increases the percentage of TNF-secreting CD4+ cells 
upon restimulation 3 weeks after vaccination 
Spleens were processed 3 weeks after vaccination, as for depletion experiments. 
Intracellular cytokine staining (see Figure 7.7A) revealed significantly more TNF-positive 
CD4+ cells in MIP-2 treated mice compared to controls (Figure 7.11) when restimulated with 
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BCG, and a similar trend for anti-CD3 restimulation (with BCG stimulation, MIP-2 median 
(IQR) 0.85% (0.67% – 0.91%), control median (IQR) 0.49% (0.31% - 0.57%), p = 0.003). 
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Figure 7.11. results of intracellular cytokine analysis on BCG-restimulated splenocytes from MIP-2-treated 
and control mice. Presented is the percentage of CD4+ lymphocytes staining for TNF in spleens from MIP2-
treated or control mice after restimulation with BCG or anti-CD3 antibody (αCD3). Data from two independent 
experiments, n = at least 5 per group per experiment. Column heights represent medians, error bars represent 
inter-quartlie range. p-values derived from Mann-Whitney tests. 
 
7.10   MIP-2 treatment increases IFN-γ release upon splenocyte restimulation 
3 weeks after vaccination 
IFN-γ ELISA was performed on supernatants aspirated 72 hours after splenocyte 
restimulation, as in depletion experiments. Results (Figure 7.12) demonstrate that MIP-2 
treated mice released significantly more IFN-γ: 54.01 +/- 34.02 ng/ml in  MIP-2 treated mice 
vs 26.28 +/- 18.59 ng/ml in controls, p = 0.006). Responses to anti-CD3 showed a similar 
pattern (175.5 +/- 68.87 ng/ml in MIP-2 treated mice vs 116.1 +/- 41.95 ng/ml in controls, p 
= 0.026), but as with depletion experiments many results were at the maximum limit for the 
197 
 
ELISA or extrapolated and this result is thus less accurate. Unstimulated control samples did 
not release detectable amounts of IFN-γ. 
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Figure 7.12. Results of IFN-γ ELISA on supernatants of BCG-restimulated splenocytes from MIP-2-treated and 
control mice. Splenocytes (5 x 10
5
 / well) harvested 3 weeks after BCG vaccination from MIP-2 treated or 
control mice were restimulated with 20,000 CFU BCG-lux for 72 hours. IFN-γ was measured in supernatants by 
ELISA. Data from three independent experiments, n = at least 5 per group per experiment. Column heights 
represent means, error bars represent standard deviation; p-value derived from unpaired t-test. 
 
7.11   Discussion 
The most striking finding in this chapter was the marked increase in restimulated mouse 
splenocyte cytokine responses in those animals which received BCG vaccination after MIP-2 
(CXCL2)-mediated recruitment of granulocytes. The mean IFN-γ release with antigen-specific 
restimulation was double that of controls, and this result was consistent across three 
experiments. Although MIP-2, a structurally-related functional homolog of IL-8, may 
potentially recruit cells other than neutrophils [246], data from the vaccination site revealed 
that the impact of chemokine treatment was to increase the proportion of organisms 
associating with strongly Gr-1 positive cells. Furthermore, depletion of neutrophils with the 
specific anti-Ly6G antibody 1A8 reduced the IFN-γ response from restimulated splenocytes 
two-fold, suggesting that the mechanism is indeed neutrophil-dependent. These latter 
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results occurred despite incomplete neutrophil depletion – a well-known issue with the 1A8 
antibody, despite its excellent specificity [247]. 
Although the same trends were broadly maintained, results from intracellular TNF staining 
were less satisfactory overall than for IFN-γ ELISA. Numbers of positive events were low and 
there was considerable variation in populations. Nevertheless, this analysis confirmed that 
the boosting of Th1 response seen when BCG vaccination is delivered after MIP-2 treatment 
appears consistent across methodologies and cytokines. 
Administration of MIP-2 reduced the proportion of organisms associating with MHC-II 
expressing cells at the vaccination site, while 1A8 treatment increased this proportion 
(Figures 7.5 and 7.11). Intuitively, increased delivery of BCG directly to antigen-presenting 
cells might be expected to improve vaccine responses. However, interaction with 
neutrophils [147] or acquisition of mycobacterial antigen via an apoptotic neutrophil [151] 
actually appears to improve the functional capacity of antigen-presenting cells to elicit T-cell 
responses. As mentioned in the introduction to this Chapter as well as in Chapter 1, the 
majority of existing evidence points towards a stimulatory effect of neutrophils on BCG 
vaccine responses, and my results would also support this. Indeed, the only research I am 
aware of which contradicts this position was performed in B-cell deficient mice [153] whose 
immune responses may be functionally very different from wild-type animals.   
Interestingly, recombinant BCG expressing inflammatory cytokines have been shown to 
elicit improved Th1 responses [248, 249], and although the mechanism may be multi-
faceted, it is noteworthy that many of these cytokines (eg GM-CSF or IL-15) will drive early 
recruitment of neutrophils. Neutrophils have also been shown to have a positive influence 
on the development of protective immune responses to other antigens and organisms, 
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including Candida [250] and the modified Vaccinia virus MVA85A used for vaccine delivery 
[251]. 
The exact mechanism by which neutrophils influenced the adaptive immune response in 
these experiments remains undefined. Manipulation of neutrophil numbers at the time of 
vaccination did not appear to affect immediately recoverable organism load at the 
vaccination site. However, sampling was only performed 2 hours post-vaccination and it is 
possible that there was an influence on the subsequent local bacillary load. Indeed, results 
in Chapters 3 and 6 suggest that excess neutrophils in ex vivo co-culture with BCG may 
increase the relative number of recoverable bacilli by 24 hours.  
There was also no difference in spleen cellularity between conditions and very little 
difference in cell proportions. However, administration of BCG at vaccination doses was 
unlikely to elicit gross changes in the spleen even if vaccine efficacy was enhanced. There 
was an apparently paradoxical increase in the proportions of neutrophils and eosinophils in 
1A8-treated mice compared to controls, but these results reached only marginal significance 
(p = 0.038 and p = 0.039 respectively) and should be interpreted cautiously in the context of 
multiple cell-type comparisons. Similarly, although the proportion of MHC-II+ cells among 
CD11b+ leukocytes was lower in 1A8-treated versus control mice, the reverse pattern of 
greater antigen-presenting cell capacity was not seen consistently in MIP-2 treated mice (in 
one experiment there was a significantly higher proportion of dendritic cells in the MIP-2 
treated mice, and in another experiment there was a significantly higher proportion of 
CD11b+/MHC-II+ cells in the MIP-2 treated mice versus controls, but neither comparison 
was significant for the entire dataset). I demonstrated in the previous chapter that excess 
neutrophils in human whole blood associate with decreased IFN-γ production, and it 
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remains possible that, under in vitro restimulation conditions outside the structure of a 
lymphoid organ, neutrophils acted to decrease elicited Th1 responses via either ‘antigen 
competition’ with professional antigen presenting cells or anti-inflammatory apoptotic cell 
death. However, the data pointing towards this as an explanation for my results is weak 
overall. 
My results are more likely to be due to factors beyond simply the numbers of phagocytes or 
lymphocytes in the spleen. As suggested by others [147, 151], they may relate to efficacy of 
antigen presentation and the generation of antigen-specific T-cells during the three weeks 
between vaccination and sampling. This mechanism needs further work to elucidate.  
To what extent the current results can be extrapolated to humans is unclear. Although the 
mouse has proven a useful model for studying host-mycobacteria interactions, there are 
clearly major inter-species differences in immunological function. In relation to neutrophils, 
key dissimilarities include the lack of α-defensins in mouse neutrophils [252], the fact that 
neutrophils constitute a smaller percentage of circulating cells in the mouse than the human 
[253], and that it remains unclear whether human neutrophils produce many of the 
cytokines that murine neutrophils convincingly do – including IL-4, IL-6, IL-10, IL17 and IFN-γ 
[148]. Nevertheless, the outcome in these experiments was clear and consistent, and 
manipulation of neutrophil response would be relatively easy to transfer to human BCG 
vaccination. 
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8. Neutrophilia in active tuberculosis 
 
8.1   Introduction 
Data presented in Chapters 3 and 6 show that, while neutrophils control mycobacterial 
growth in some conditions, high ratios of neutrophils to bacilli might lead to paradoxically 
greater ex vivo growth of organisms. I have hypothesised that this may relate to death of 
the neutrophils, since augmentation of blood with necrotic neutrophils also enhances 
bacillary growth and regulates the immune response by decreasing Th1 cytokines while 
increasing immunosuppressive IL-10 (Chapter 6). Large numbers of neutrophils at sites of 
pathological inflammation, where they might undergo rapid cell death, could therefore 
represent a negative influence on host response. 
Correspondingly, previously published data suggest that neutrophilia in human blood might 
associate with poor prognosis in tuberculosis patients. One study has indicated that high 
neutrophil percentage at diagnosis predicts a composite outcome of death or respiratory 
failure [175]. Higher neutrophil counts at diagnosis have also been shown to predict slower 
sputum conversion to negative during anti-tuberculosis therapy [178, 179]. However, these 
studies have not been powered to detect independent relationships between neutrophilia 
and mortality, and have included pulmonary tuberculosis patients only.  
Data on the prevalence and determinants of neutrophilia in tuberculosis are also scarce. 
Existing studies which have reported neutrophil counts in tuberculosis patients have been 
relatively small, usually restricted to a single disease site, with a limited range of ages and a 
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single or unreported ethnicity of patients (Table 1.5, Chapter 1). I thus investigated the 
phenomenon of neutrophilia in human tuberculosis in a dataset of tuberculosis patients 
powered to detect the potential influence of neutrophilia on risk of mortality. 
I aimed to include a variety of presentations of tuberculosis within a broad age range and 
ethnic mix of patients and a significant HIV-infected population. Demographic and 
laboratory data were used first to determine predictors of neutrophilia and subsequently to 
determine predictors of mortality. I then used these results to construct a preliminary 
model which can identify patients at low or high risk of death from tuberculosis.  
Patient identification from databases and recruitment of tuberculosis contacts is described 
in Section 2.1, and methodology in Sections 2.21 and 2.22. 
 
8.2   Patient characteristics 
1236 tuberculosis patients were initially identified from review of databases, of whom 855 
had available neutrophil counts and results for all demographic variables except HIV status 
and co-morbidity  (assigned an additional group of ‘unknown’ as per Section 2.21). There 
was no difference in age (p = 0.29), sex distribution (p = 0.80), ethnicity (p = 0.07) or 
neutrophil count (p = 0.55) between the included patients and excluded patients for whom 
this information was available (n = 379 for age, n = 352 for sex, n = 312 for ethnicity, n = 176 
for neutrophil count). 49 patients were transferred or lost to follow-up and a further 88 
patients lacked data for one or more laboratory parameters resulting in a total of 718 
patients entering case fatality analysis. 
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Table 8.1 details the characteristics of the 855 patients included in baseline analyses. 
Median age was 33.0 years (range 0 – 93 years) and 57.3% of patients were male. Black 
African was the most common ethnic group (49.0%), and HIV infection was known to be 
present in 13.5% of patients overall. Pulmonary tuberculosis was the most common disease 
site (49.4%).  
Table 8.1. Characteristics of tuberculosis patients entering baseline analyses (n = 855). 
Age (years) Median 
Range 
33.0 
0 – 93  
 
Ethnicity White    
Indian / Sri Lankan    
Pakistani    
Bangladeshi    
Black Caribbean    
Black African    
Black Other    
Chinese    
Other    
99 (11.6%) 
102 (11.9%) 
40 (4.7%) 
23 (2.7%) 
73 (8.5%) 
419 (49.0%) 
19 (2.2%) 
12 (1.4%) 
68 (8.0%) 
 
Sex Male    
Female    
490 (57.3%) 
365 (42.7%) 
 
Site of disease Pulmonary    
Peripheral LN only    
Central Nervous System    
Miliary    
Other extra-pulmonary *     
422 (49.4%) 
99 (11.6%) 
39 (4.6%) 
23 (2.7%) 
272 (31.8%) 
 
Co-morbidity † Absent    
Present   
Unknown    
564 (66.0%) 
53 (6.2%) 
238 (27.8%) 
 
Taking 
immunosuppressive 
medication ‡ 
No    
Yes    
804 (94.0%) 
51 (6.0%) 
 
 
HIV status Negative    
Positive    
Unknown    
280 (32.7%) 
115 (13.5%) 
460 (53.8%) 
* Includes pleural, mediastinal lymph node, spine, other bone / joint, gastro-intestinal, genito-urinary, blood 
culture only, ‘cryptic’  
† Identified co-morbidities: renal failure, hepatic failure, previous ischaemic cardiovascular events, diabetes 
mellitus, hypertension, sickle cell disease, respiratory failure, arthritis (unspecified), inflammatory bowel 
disease, celiac disease, ankylosing spondylitis. 
‡ Corticosteroids, azathioprine or cyclosporin. 
 
LN = lymph node; HIV = human immunodeficiency virus. 
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214 contacts were also analysed. Cases and contacts did not differ according to sex 
distribution (57.3% vs. 50.5% male respectively, p=0.07) but did differ in age (median age, 
33.0 vs. 30.0 years respectively, p=0.002) and ethnic distribution (11.6% vs. 16.4% 
respectively were white, 19.3% vs. 33.6% respectively were South Asian, 59.8% vs. 40.7% 
respectively were black and 9.4% vs. 9.3% were of other ethnic origin; p <0.001).  
 
8.3   Neutrophilia is common in patients with tuberculosis and is not 
associated with non-mycobacterial bacteremia 
Neutrophilia (peripheral blood neutrophil count ≥7.5 x109/L) was more common in patients 
with active tuberculosis disease than in healthy contacts of tuberculosis cases (158/855 
(18.5%) vs. 8/214 (3.7%)). The adjusted Odds Ratio [aOR] for neutrophilia among cases vs. 
contacts, after controlling for age and ethnicity, was 6.13 (95% Confidence Interval [CI] 
2.94–12.82), p<0.001). Median neutrophil count was also higher in cases than contacts (4.65 
(Interquartile range [IQR] 3.17–6.75) vs. 3.66 (IQR 2.78–4.78) x 109/L, p <0.0001; Figure 8.1).  
To assess whether neutrophilia in tuberculosis patients was explained by non-mycobacterial 
bacteraemia, we extracted details on all blood cultures performed on these patients. Out of 
297 cultures only three were positive for pathogenic bacteria other than M.tuberculosis 
(one methicillin-resistant Staphylococcus aureus, one Proteus vulgaris and one other 
coliform, not fully identified). Only the patient with Proteus vulgaris had concomitant 
neutrophilia, thus only 1 out of 158 recordings of high neutrophil count was associated with 
a pathogenic non-mycobacterial species grown from blood culture. 
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Figure 8.1. Comparison of neutrophils counts between contacts and cases. Peripheral blood neutrophil 
counts in contacts of tuberculosis (Contacts, n = 214) and patients with active tuberculosis (Cases, n = 855) are 
represented. Bars represent medians and p-value is derived from Mann-Whitney test.  
 
8.4   Determinants of neutrophilia 
I next sought to establish whether any risk factors could be identified for the development of 
neutrophilia during tuberculosis disease. Results from logistic regression are summarised in 
Table 8.2. In multivariate analysis, white ethnicity increased odds of neutrophilia when 
compared to black ethnicity (aOR 1.75, 95% CI 1.03–3.03, p = 0.036). Pulmonary disease was 
associated with increased risk of neutrophilia compared to tuberculosis confined to a 
peripheral lymph node (aOR 2.56, 95% CI 1.25–5.26, p = 0.011). HIV infection reduced risk of 
neutrophilia compared to HIV-uninfected (aOR 0.50, 95% CI 0.26–0.97, p = 0.039); however, 
this result is confounded by individuals with pathological neutropenia (5 of 13 patients 
(38.5%) with neutrophil count <1 x109/L were HIV-infected, and after removing all 
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pathologically neutropenic patients the association with HIV status was no longer 
significant). Neutrophil counts according to ethnicity and site of disease are presented in 
Figure 8.2. 
Table 8.2. Predictors of neutrophilia in patients with tuberculosis (n = 855). 
  Univariate analysis Multivariate analysis  
  Number (%) with 
neutrophilia 
OR 95% CI p-value OR 95% CI p-value 
 
Sex 
 
Male (n = 490) 
 
99 (20.2%) 
 
1 
     
 Female (n = 365) 59 (16.2%) 0.76 0.53 – 1.09 0.133    
         
Age (years) < 20 (n = 102) 16 (15.7%) 0.95 0.53 – 1.71 0.869 0.98 0.53 – 1.80 0.951 
 20 - 39 (n = 471) 77 (16.3%) 1   1   
 40 - 59 (n = 196) 40 (20.4%) 1.31 0.86 – 2.01 0.210 1.28 0.83 – 1.97 0.274 
  60 (n = 86) 25 (29.1%) 2.10 1.24 – 3.55 0.006 1.75 0.99 – 3.10 0.055 
         
Ethnicity White (n = 99) 30 (30.3%) 1   1   
 South Asian* (n = 165) 33 (20.0%) 0.58 0.32 – 1.02 0.059 0.71 0.39 – 1.30 0.272 
 Black† (n = 511) 81 (15.9%) 0.43 0.27 – 0.71 0.001 0.57 0.33 – 0.97 0.036 
 Other (n = 80) 14 (17.5%) 0.49 0.24 – 1.00 0.050 0.59 0.28 – 1.23 0.157 
         
Site of disease Pulmonary (n = 422) 92 (21.8%) 1   1   
 Peripheral LN only (n = 99) 9 (9.1%) 0.36 0.17 – 0.74 0.005 0.39 0.19 – 0.80 0.011 
 Central Nervous System  
(n = 39) 
8 (20.5%) 0.93 0.41 – 2.08 0.852 0.86 0.38 – 1.98 0.863 
 Miliary (n = 23) 5 (21.7%) 1.00 0.36 – 2.76 0.994 1.04 0.36 – 2.96 0.948 
 Other extra-pulmonary  
(n = 272) 
44 (16.2%) 0.69 0.47 – 1.03 0.069 0.69 0.46 – 1.03 0.071 
         
Immuno-
suppressives ‡ 
No (n = 804) 148 (18.4%) 1      
 Yes (n = 51) 10 (19.6%) 1.08 0.53 – 2.21 0.831    
         
Co-morbidity § No (n = 564) 103 (18.3%) 1      
 Yes (n = 53) 11 (20.8%) 1.17 0.58 – 2.35 0.655    
 Unknown (n = 238) 44 (18.5%) 1.02 0.69 – 1.50 0.940    
         
HIV status Uninfected (n = 280) 58 (20.7%) 1   1   
 Infected (n = 115) 13 (11.3%) 0.49 0.26 – 0.93 0.029 0.50 0.26 – 0.97 0.039 
 Unknown (n = 460) 87 (18.9%) 0.89 0.62 – 1.29 0.549 0.76 0.50 – 1.14 0.178 
* Includes Indian, Sri Lankan, Pakistani and Bangladeshi.  
† Includes Black African, Black Caribbean and Black Other. 
‡ Corticosteroids, azathioprine or cyclosporin. 
§ Identified co-morbidities: renal failure, hepatic failure, previous ischaemic cardiovascular events, diabetes 
mellitus, hypertension, sickle cell disease, respiratory failure, arthritis (unspecified), inflammatory bowel 
disease, celiac disease, ankylosing spondylitis. 
OR = Odds ratio; CI = confidence interval; LN = lymph node; HIV = human immunodeficiency virus. 
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Figure 8.2. Effect of site of disease and ethnicity on neutrophil count in active tuberculosis. Neutrophil counts 
are shown for 855 tuberculosis patients according to site of disease (A) and ethnicity (B). Bars represent 
medians and p-values are derived from Kruskal-Wallis test with Dunn’s correction for multiple comparisons. 
LN, lymph node 
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8.5   Neutrophilia independently predicts mortality 
Table 8.3 summarises results from logistic regression analysis on predictors of all-cause 
mortality in patients with available outcome data and all laboratory parameters (n=718). 
Neutrophilia was an independent risk for case fatality in multivariate analysis (aOR 2.93, 
95% CI 1.17–7.34, p = 0.022). Bootstrapping analysis (1000 samples) confirmed the result’s 
robustness (aOR 2.93, 95% CI 1.16–12.03, p = 0.018). Further laboratory parameters 
predicting fatality were hypernatraemia (serum sodium >140 mmol/L; aOR 4.59, 95% CI 
1.18–17.86, p = 0.028), hypoalbuminaemia (albumin <30g/L; aOR 4.43, 95% CI 1.79–11.00, p 
= 0.001), thrombocytopenia (platelet count <150 x109/L; aOR 3.75, 95% CI 1.25–11.22, p = 
0.018) and lymphopenia (lymphocyte count <1 x109/L; aOR 3.24, 95% CI 1.24–8.44, p = 
0.016). Increased age was also associated with increased mortality risk in multivariate 
analysis when compared to the 20–39 years group (for age range 40–59 years aOR 8.73 
(95% CI 2.88–26.84), p <0.001; for age ≥60 years aOR 8.68 (95% CI 2.30–32.71), p = 0.001). 
Strikingly, there were no deaths in patients aged under 20 years. The presence of co-
morbidity other than HIV was associated with increased risk of death (aOR 5.94 (95% CI 
1.65–21.37), p = 0.006) but receiving immunosuppressive medication was not. Figure 8.3 
presents case fatality rates according to age, blood platelet count, blood neutrophil count, 
and serum albumin concentration. 
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Table 8.3. Predictors of all-cause mortality in patients with tuberculosis (n = 718). 
 
  Univariate analysis Multivariate analysis 
  Number (%) 
Dead 
OR 95% CI p-value OR 95% CI p-value 
 
Sex 
 
Male (n = 408) 
 
29 (7.1%) 
 
1 
     
 Female (n = 310) 13 (4.2%) 0.57 0.29 - 1.12 0.103    
         
Age (years) < 20 (n = 82) 0 (0%) N/A   N/A   
 20 - 39 (n = 390) 6 (1.5%) 1   1   
 40 - 59 (n = 165) 26 (12.7%) 9.33 3.69 – 23.59 < 0.001 8.73 2.88 – 26.44 < 0.001 
  60 (n = 81) 15 (18.5%) 14.55 5.45 – 38.84 < 0.001 8.68 2.30 – 32.71 0.001 
         
Ethnicity White (n = 88) 13 (14.8%) 1   1   
 South Asian* (n = 120) 6 (5.0%) 0.30 0.11 – 0.83 0.021 0.57 0.16 – 2.05 0.385 
 Black† (n = 439) 20 (4.6%) 0.28 0.13 – 0.58 0.001 0.52 0.18 – 1.52 0.233 
 Other (n = 71) 3 (4.2%) 0.26 0.07 – 0.93 0.039 0.45 0.09 – 2.34 0.344 
         
Site of disease Pulmonary (n = 362) 27 (7.5%) 1      
 Peripheral LN only (n = 84) 2 (2.4%) 0.30 0.07 – 1.30 0.108    
 Central Nervous System  
(n = 31) 
2 (6.5%) 0.86 0.19 – 3.78 0.837    
 Miliary (n = 18) 1 (5.6%) 0.73 0.09 – 5.70 0.764    
 Other extra-pulmonary  
(n = 223) 
10 (4.5%) 0.58 0.28 – 1.23 0.155    
         
Immuno-
suppressives ‡ 
No (n = 679) 41 (6.0%) 1      
 Yes (n = 39) 1 (2.6%) 0.41 0.06 – 3.06 0.384    
         
Co-morbidity § No (n = 468) 20 (4.3%) 1   1   
 Yes (n = 42) 7 (16.7%) 4.48 1.77 – 11.32 0.002 5.94 1.65 – 21.37 0.006 
 Unknown (n = 208) 15 (7.2%) 1.74 0.87 – 3.47 0.116 1.18 0.45 – 3.10 0.732 
         
HIV status Uninfected (n = 243) 9 (3.7%) 1   1   
 Infected (n = 105) 11 (10.5%) 3.04 1.22 – 7.58 0.017 1.46 0.39 – 5.42 0.575 
 Unknown (n = 370) 22 (5.9%) 1.64 0.74 – 3.63 0.219 1.17 0.37 – 3.76 0.788 
         
Serum sodium < 130 mmol/L (n = 60) 10 (16.7%) 4.94 2.23 – 10.96 < 0.001 1.01 0.37 – 2.74 0.982 
 130 - 140 mmol/L (n = 591) 23 (3.9%) 1   1   
 > 140 mmol/L (n = 67) 9 (13.4%) 3.83 1.69 – 8.67 0.001 4.59 1.18 – 17.86 0.028 
         
Serum bilirubin  17 mol/L (n = 614) 29 (4.7%) 1   1   
 > 17 mmol/L (n = 104) 13 (12.5%) 2.88 1.45 – 5.75 0.003 1.52 0.57 – 4.05 0.398 
         
Serum albumin  30 g/L (n = 584) 14 (2.4%) 1   1   
 < 30 g/L (n = 134) 28 (20.9%) 10.76 5.48 – 21.11 < 0.001 4.43 1.79 – 11.00 0.001 
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Table 8.3 continued 
 
  Univariate analysis Multivariate analysis 
  Number (%) 
Dead 
 
OR 95% CI p-value OR 95% CI p-value 
Peripheral blood 
haemoglobin 
 11.5 g/dL (n = 346) 9 (2.6%) 1      
 < 11.5 g/dL (n = 372) 33 (8.9%) 3.65 1.72 – 7.73 0.001 2.34 0.81 – 6.76 0.116 
         
Peripheral blood 
platelet count 
< 150 x 109/L (n = 52) 16 (30.8%) 10.43 4.94 – 22.01 < 0.001 3.75 1.25 – 11.22 0.018 
 150 - 400 x 109/L (n = 465) 19 (4.1%) 1   1   
  400 x 109/L (n = 201) 7 (3.5%) 0.85 0.35 – 2.05 0.712 0.47 0.15 – 1.47 0.192 
         
Peripheral blood 
neutrophil count 
< 1 x 109/L (n = 13) 3 (23.1%) 7.11 1.82 – 27.78 0.005 0.73 0.05 – 9.80 0.813 
 1 - 1.99 x 109 / L (n = 50) 2 (4.0%) 0.99 0.23 – 4.34 0.987 0.54 0.08 – 3.71 0.528 
 2 - 7.49 x 109/L (n = 519) 21 (4.0%) 1   1   
  7.50 x 109 / L (n = 136) 16 (11.8%) 3.16 1.60 – 6.24 0.001 2.93 1.17 – 7.34 0.022 
         
Peripheral blood 
lymphocyte count 
< 1 x 109 / L (n = 252) 33 (13.1%) 7.35 3.46 – 15.63 < 0.001 3.24 1.24 – 8.44 0.016 
 1 - 4 x 109 / L (n = 448) 9 (2.0%) 1   1   
 > 4 x 109 / L (n = 18) 0 (0%) N/A   N/A   
         
Peripheral blood 
monocyte count 
< 0.2 x 109 / L (n = 38) 11 (28.9%) 7.91 3.51 – 17.82 < 0.001 1.51 0.43 – 5.35 0.524 
 0.2 - 0.8 x 109 / L (n = 490) 24 (4.9%) 1   1   
 > 0.8 x 109 / L (n = 190) 7 (3.7%) 0.74 0.32 – 1.75 0.497 0.92 0.31 – 2.69 0.876 
* Includes Indian, Sri Lankan, Pakistani and Bangladeshi.  
† Includes Black African, Black Caribbean and Black Other. 
‡ Corticosteroids, azathioprine or cyclosporin. 
§ Identified co-morbidities: renal failure, hepatic failure, previous ischaemic cardiovascular events, diabetes 
mellitus, hypertension, sickle cell disease, respiratory failure, arthritis (unspecified), inflammatory bowel 
disease, celiac disease, ankylosing spondylitis. 
 
OR = Odds ratio; CI = confidence interval; LN = lymph node; HIV = human immunodeficiency virus; mmol = 
millimoles; μmol = micromoles; L = litre; g = grammes; dL = decilitres; N/A = Not applicable. 
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Figure 8.3. Tuberculosis case fatality rates according to predictor variables. Case fatality is presented 
according to (A) Patient age, (B) Blood platelet count, (C) Blood neutrophil count, (D) Serum albumin 
concentration. Error bars represent 95% confidence intervals calculated by adjusted Wald method. P-values 
are derived from multivariate analysis (see Table 8.3)  
 
 
8.6   Predictive model for survival from tuberculosis 
Receiver Operating Curve analysis of the multivariate model revealed a high area under the 
curve (0.934; 95% CI 0.900–0.967), suggesting that the identified independent correlates of 
all-cause mortality might be used to predict prognosis. I therefore tested candidate variables 
identified by multivariate analysis for their positive and negative predictive value for death, 
with inclusion and thresholds varied iteratively as described in Chapter 2. Preliminary 
analysis revealed that four parameters (age, serum albumin concentration, blood platelet 
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count and blood neutrophil count) demonstrated the highest common odds ratios for death 
and I therefore extended the dataset to include all patients with complete information on 
survival and these four predictors. The final training set of King’s College Hospital patients 
thus included 696 patients (654 survived, 42 died), and the test set included 218 Newham 
University Hospital Trust patients (199 survived, 19 died). The four parameters (any one or 
more of age >50 years, albumin <30g/L, platelet count <150 x 109/L and neutrophil count >8 
x 109/L) predicted all but one death: for the training set sensitivity was 97.6%, specificity was 
63.1%, positive predictive value was 14.5%, negative predictive value was 99.8% and overall 
odds ratio for death was 70.3 (95% CI 9.6–514.0); for the test set sensitivity was 100%, 
specificity was 64.3%, positive predictive value was 21.1%, negative predictive value was 
100% and overall odds ratio for death was 36.1 (95% CI 4.7–274.3): see Table 8.4.  
I proceeded to derive a cumulative score from the identified parameters, awarding one point 
for each abnormality present (Table 8.5). There was a progressive increase in case fatality 
with increasing score: for the training/test sets respectively, Score ‘0’=0.24%/0%, Score 
‘1’=7.18%/12.5%, Score ‘2’=22.89%/37.5%, Score ‘3’=43.75%/100%, Score ‘4’=100% (no 
patients in the test set had a score of 4). I would suggest that anyone with a score ≥2 has 
particularly severe disease and high mortality risk. 
 
8.7   Discussion 
In this chapter I have demonstrated that neutrophilia is common in patients with 
tuberculosis and that it independently predicts case fatality. Despite mounting recent 
experimental evidence, neutrophilia in human tuberculosis has received little attention from 
clinicians and epidemiologists: my results would suggest that the phenomenon is important. 
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Table 8.4. Predictive model for mortality in tuberculosis patients. 
 
 Predictor variables. Any one (or more) of: 
- Hypoalbuminaemia (albumin < 30 g/L) 
- Thrombocytopenia (platelets < 150 x 10
9 
/L) 
- Neutrophilia (neutrophils > 8 x 10
9 
/ L) 
- Age > 50 years 
 
 
TRAINING SET  
(KCH patients, n = 696) 
 
Sensitivity 97.6% 
Specificity 63.1% 
Positive Predictive Value 14.5% 
Negative Predictive Value 
 
TEST SET  
(NUHT patients, n = 218) 
Sensitivity 
Specificity 
Positive Predictive Value 
Negative Predictive Value 
 
99.8% 
 
 
 
100% 
64.3% 
21.1% 
100% 
 
KCH = King’s College Hospital; NUHT = Newham University Hospital Trust; g = grammes; L = litre. 
 
 
Table 8.5. Case fatality according to score from predictive model (1 point for each of albumin < 30 
g/L, platelets < 150 x 109 /L, neutrophils > 8 x 109 / L, age > 50 years) 
 
TRAINING SET  (KCH patients, n = 696) 
 
Score Total Died Case fatality % 
0 414 1 0.24 
1 181 13 7.18 
2 83 19 22.89 
3 16 7 43.75 
4 2 2 100 
     
TEST SET (NUHT patients, n = 218) 
 
Score Total Died Case fatality % 
0 128 0 0 
1 64 8 12.50 
2 16 6 37.50 
3 5 5 100 
4 0 0 N/A 
 
KCH = King’s College Hospital; NUHT = Newham University Hospital Trust; N/A = Not applicable.
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A modest neutrophilic response was common in tuberculosis: even survivors with active 
tuberculosis had higher median neutrophil counts than healthy contacts. Others have reported 
that higher blood neutrophil counts correlate with sputum M.tuberculosis Polymerase Chain 
Reaction positivity and, especially, smear positivity [254], while separate studies have discovered 
higher neutrophil counts in those with slower conversion of sputum culture to negative [178, 179]. 
Together with my finding of a higher prevalence of neutrophilia in patients who die, these results 
suggest that the neutrophil count in tuberculosis positively correlates with the bacillary load. This 
is consistent with animal models [28, 154] and complements other human experimental results: 
for example, it is reported that neutrophils drive the transcriptomic signature of active 
tuberculosis [187].  
It is therefore important to know which factors predict neutrophilia in human tuberculosis. 
Importantly, I found no convincing evidence that non-tuberculous bacteremia explained the raised 
neutrophil counts, with only one potential association between positive blood culture and 
neutrophilia in all patients studied. Lower risk of neutrophilia when disease is confined to a 
peripheral lymph node (Table 8.2 and Figure 8.2) probably reflects lower mycobacterial burden 
and less systemic inflammation. The finding that white ethnicity independently predicts 
neutrophilia may be biologically important in tuberculosis. Previous analysis of a large European 
demographic surveillance dataset identified European ethnic origin as a risk factor for death 
independently of age [255], as did an earlier study in the Netherlands [256]. However, neither 
study controlled for white blood cell or neutrophil count. Thus, although the phenomenon was 
tentatively attributed to a ‘healthy migrant’ effect [256], a protective impact of benign ethnic 
neutropenia and a lower propensity to develop neutrophilia with physiological stress in non-white 
individuals [257] could offer a pathophysiological explanation. It is interesting to note that the 
lowest case fatality in my study was seen with neutrophil counts in the range 1–1.99 x109/L, below 
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the reference range for most UK laboratories and likely to largely reflect benign ethnic 
neutropenia.  
The apparent effect of HIV in reducing risk of neutrophilia is largely explained by pathological 
neutropenia, as explained above. HIV infection is known to cause neutropenia in some cases [196], 
perhaps due to diminished G-CSF production [197] or an effect of viral ‘negative factor’ (Nef) on 
the bone marrow [198]. 
As I had anticipated, neutrophilia independently predicted death in this dataset. Further important 
findings were that older age and co-morbidity strongly predicted case fatality. This may be 
intuitive, but it also presents an important argument for treating latent tuberculosis infection, 
especially in areas of low endemicity where risk of re-infection is low: reactivation of disease with 
advancing age or concomitant illness carries particularly poor prognosis. A similar relationship with 
age [175, 255, 256] or both age and co-morbidity [258-260] has been found by others. Differing 
from previous literature [261], I did not find that HIV infection independently predicted mortality. 
This may reflect improved care and treatment for HIV-infected individuals in the more recent 
years of this study. 
Hypoalbuminemia independently predicted death, consistent with some previous reports [183, 
262, 263]. Hypernatremia also predicted case fatality, perhaps reflecting dehydration; I am not 
aware of any reports previously describing this association. Overall, metabolic disturbances were 
common, with 18.7%, 17.7% and 14.5% of patients having abnormal albumin, sodium and bilirubin 
results respectively. Platelet count outside the normal range was also common (35.2% of patients) 
and thrombocytopenia strongly predicted death, consistent with previous literature [176, 264, 
265]; lymphopenia was seen in 32.9% of tuberculosis patients and was also independently 
associated with case fatality, as described [175, 262, 264]. Taken together, these findings confirm 
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that tuberculosis – and especially severe tuberculosis – is associated with systemic derangements 
commonly seen in bacterial sepsis.  
Some of these parameters, likely to reflect both high bacterial burden and aberrant host response, 
can be used together with patient age to predict survival in tuberculosis. My model (Table 8.4), 
derived from patients at KCH, reached 100% positive predictive value for death when applied to 
patients from NUHT. With current financial and political pressure to reduce in-patient care, 
identifying useful prognostic parameters is desirable for conditions such as tuberculosis which 
often result in hospitalisation. Although patients lacking any of the predictive criteria (albumin <30 
g/L, platelets <150 x109/L, neutrophils >8 x109/L, age >50 years) may still need a period of 
intensive treatment, these parameters should help to inform safe early discharge decisions. 
Conversely, the cumulative score (Table 8.5) was able to identify patients at high risk of death: I 
would suggest that anyone with a score ≥ 2 should receive particularly close monitoring including 
hospital admission. 
It should be noted that profound neutropenia (<1 x109/L) was associated with higher case fatality 
as compared to normal range neutrophil count (Table 8.3 and Figure 8.3). This phenomenon has 
been previously described in tuberculosis, often associated with particularly severe and 
disseminated disease [266]. Pathological neutropenia is presumably secondary to severe sepsis 
[267], marrow infiltration by granulomata [268] or secondary hemophagocytosis [269] in addition 
to the association between HIV infection and profound neutropenia as described above. 
This study does have some limitations. Missing data may have reduced power to detect the 
predictive effects of some variables: 381 potentially eligible patients were excluded, but they did 
not appear to differ in terms of age, sex or ethnicity from the included patients and hence my 
cohort is likely to be representative. Co-morbidity and HIV status were particularly poorly 
documented necessitating a third coding category of ‘unknown’. I believe these variables were 
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more likely to be undocumented when negative, as the odds ratios in the ‘unknown’ category in all 
analyses were more similar to the negative than the positive category. Nevertheless, I felt it 
important to include these two important predictors in analysis, and excluding patients with 
unknown results would have substantially reduced the statistical power to detect relationships in 
all variables. Tuberculosis cases and contacts differed in terms of age and ethnic distribution. 
However, I adjusted for these factors when comparing prevalence of neutrophilia. In terms of 
median counts, the difference in ethnic distribution (relatively more white and South Asian and 
less black contacts as compared to cases) acted to increase the count among contacts, and thus to 
reduce the demonstrated difference between cases and contacts: median neutrophil count in 
white contacts 4.15 (IQR 3.36–5.80), in South Asian contacts 4.07 (IQR 3.23–5.00), in black 
contacts 3.05 (IQR 2.20–4.10). Finally, both hospital sites included were in developed world, urban 
centres: caution should be used in extrapolating results to other settings.  
In summary, I have demonstrated that neutrophilia is not uncommon in tuberculosis and 
independently associates with increased risk of mortality. It is interesting to note that abrogating 
the immunopathological neutrophil response in some animal models improves outcome in acute 
infection [28, 154]. Such strategies might therefore have therapeutic application in humans with 
severe tuberculosis. 
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9. Conclusions and Future Directions 
9.1   The roles of neutrophils in host response against tuberculosis 
This thesis has examined the potential roles of neutrophils in the host response against 
tuberculosis; a schema synthesising the data and ideas discussed herein is presented in Figure 9.1. 
First, neutrophils may significantly influence the acquired immune response to BCG vaccination 
(Chapter 7); my results in a mouse model suggest a positive impact on the capacity of acquired 
immune cells to release interferon-γ upon rechallenge with mycobacteria, with a doubling of 
response when extra neutrophils are recruited to the vaccination site. A recent trial evaluating the 
novel tuberculosis vaccine MVA85A as a booster to BCG yielded disappointing results [270], but 
this may partly have resulted from poor baseline responses to BCG: strategies to improve the 
priming efficacy of BCG could therefore be of great significance in efforts to improve the function 
of novel ‘boosters’.  
In later life, exposure to M.tuberculosis is likely to elicit an early neutrophilic host response (see 
Chapter 1). I have demonstrated that neutrophils can phagocytose and kill mycobacteria (Chapter 
3), and thus theoretically could assist resident macrophages in lung (or other site of inoculation) to 
rapidly eliminate the bacilli. Neutrophils may be even more important in controlling dissemination 
of infection, especially via the bloodstream. I have shown that either depletion (Chapters 4 and 5) 
or augmentation (Chapter 6) of neutrophils in blood has a profound effect on control of 
M.tuberculosis: indeed, my data would suggest that these cells are the dominant host mechanism 
for mycobacterial control in blood, and that this is via a direct mycobactericidal mechanism rather 
than cytokine-mediated one (Chapter 4).  
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However, failure to eliminate the bacilli may allow neutrophils in blood (or lymphatics) to fulfil a 
pathological, ‘Trojan horse’ role. It is interesting to note in previous literature that poorer 
neutrophil function has been described in those individuals with disseminated miliary tuberculosis 
[271], although it is of course difficult to dissect cause from effect in this scenario. Such a 
phenomenon may be of particular importance in HIV infection, where phagocytic capacity is 
maintained but restriction of M.tuberculosis is impaired (Chapter 4).  
The next important role for neutrophils is in directing the development of the acquired immune 
response. Although depletion of neutrophils had relatively little impact on cytokines and 
chemokines measurable in blood supernatants (Chapters 4 and 5), augmentation of neutrophils 
(Chapter 6) had a highly significant effect on the profile of soluble mediators. It should be recalled 
that neutrophils are able to influence the cytokine/chemokine-producing cells (in blood 
predominantly CD14+ cells, and to some extent CD4+ cells, as established in Chapters 4 and 5) by 
their pattern of cell death as well as via the release of their own cytokines and other messengers. 
Live neutrophils induced a broadly anti-inflammatory immunophenotype (albeit this may be 
secondary to effective early killing of mycobacteria), while necrotic neutrophils impaired 
mycobacterial killing, reduced Th1 responses, enhanced IL-10 responses and elicited growth 
factors and chemokines which would attract even more neutrophils to the site of disease (Chapter 
6). Again this has particular significance for those with HIV infection, since neutrophil necrosis 
appears markedly accelerated in this group (Chapter 4): indeed, depletion of neutrophils from the 
blood of ART-naïve HIV-infected people actually increases IL-1β release. Revisiting Figure 1.1, 
redrawn here as Figure 9.2, I thus hypothesise that in HIV infection the path indicated by red 
arrows may be followed in the initial interaction with mycobacteria, resulting in the worst 
potential outcome for the host. Paradoxically, a poorly inflammatory immune environment may 
also be accompanied by excess neutrophil recruitment. 
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Figure 9.1. The potential roles of neutrophils in mycobacterial infection. 
Green boxes = Neutrophil actions. Blue boxes = Clinical outcomes. 
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Figure 9.2. Neutrophil-Macrophage co-operation in the early stages of tuberculosis infection. . 
Red arrow shows the probable path in HIV infected individuals, as predicted by results in this thesis.  
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This situation may help to explain the association of neutrophilia with clinical severity and 
poor outcome in established tuberculosis disease (discussed in Chapter 1 and demonstrated 
in Chapter 8, where neutrophilia independently associated with case fatality and formed 
one part of a predictive score for tuberculosis severity). Broadly speaking, I hypothesise that 
an excessive neutrophil response to mycobacterial challenge results from one or more of 
the following mechanisms: 
i. Immunological ‘loss of control’ of inflammation allowing unchecked neutrophil 
influx. 
ii. Neutrophilic ‘compensation’ for an inadequate mononuclear phagocyte or acquired 
immune response. 
iii. Dysfunction at the level of the neutrophil itself with impaired killing resulting in non-
specific inflammatory responses or excessive necrosis, driving ongoing recruitment.  
Neutrophilia may thus either reflect underlying immunopathology or directly lead to poor 
prognosis, especially if necrotic neutrophils alter the cytokine profile as described above and 
in Chapter 6. It is interesting to note that all three of these criteria may be satisfied in the 
context of HIV-1 viremia. Correspondingly, lesions of active tuberculosis in patients with 
HIV-1 infection are characterised by pronounced neutrophil influx [92, 272, 273] while 
simultaneously their mononuclear cells mount poorer Th1 immune responses [222, 223]. 
Similarly, in my experiments (Chapter 4) baseline immune responses were generally 
diminished in the blood of HIV-infected participants, although unfortunately several 
‘classical’ Th1- and Th2-type cytokines were not measurable.  
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9.2   Potential therapeutic and clinical applications 
This work has also explored potential therapeutic avenues relating to the interaction 
between neutrophils and mycobacteria, especially in the context of HIV. In addition to the 
potential to manipulate neutrophil responses to BCG vaccination (discussed above and in 
Chapter 7), I have investigated antiretroviral therapy (ART) and micro-nutrients. ART 
demonstrated an excellent capacity to restore dysfunctional neutrophil responses to 
mycobacteria towards those seen in HIV-uninfected controls. This was especially seen in 
terms of mycobacterial restrictive capacity and accelerated necrotic death (Chapter 5). 
Results of micronutrient experiments were less encouraging, although there may be a role 
for zinc in mitigating against accelerated cell death in HIV-infected people (Chapter 6). Other 
potentially important interventions are summarised in Table 9.1. Single, significant clinical 
exposures to M.tuberculosis might be treated with G-CSF to boost neutrophil numbers and 
hence elimination of the bacillary challenge. Human neutrophil peptides have been 
artificially synthesised [66] and could hold potential as the basis for anti-tuberculous drugs. 
Antibodies and complement are likely to be important for mediating internalisation into 
neutrophils and should thus be studied in more detail in vaccine trials [274]. The prognostic 
score derived in Chapter 8 should be validated and may be useful for clinical decision-
making. Finally, strategies to counteract neutrophil influx or necrosis may ameliorate 
severity in tuberculosis disease. 
All of these areas require detailed further research and translation. However, interest in this 
field appears to be growing. I therefore hope that, with this work as a significant 
contribution, we may soon resolve the many and varied roles of the long-neglected 
neutrophil in tuberculosis.  
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Table 9.1 Potential therapeutic applications relating to neutrophils in tuberculosis, and 
further research required 
Neutrophil physiological function or 
pathological role 
Therapeutic application or 
intervention 
Further research required 
Influence on BCG vaccination response Modify BCG vaccination to 
harness neutrophil effect 
Investigate effect of enhanced 
neutrophil recruitment or 
inhibition of recruitment (eg 
evasins) to BCG vaccine site in 
humans 
 
Direct mycobactericidal function Administer G-CSF to contacts with 
single, significant exposure to 
tuberculosis (eg healthcare 
workers) 
 
Therapeutic trial 
Mycobactericidal effect of HNP Potential basis for new anti-
tuberculous drugs 
Achieve resistance to proteases 
allowing oral administration 
 
Therapeutic trial 
 
Impaired mycobactericidal activity and 
accelerated cell death in HIV 
Commence ART on basis of HIV 
viral load or identification of 
neutropenia 
 
Zinc supplementation to ART-
naïve HIV-infected people 
Therapeutic trial 
 
 
 
Confirm ex vivo effect in further 
experiments, then therapeutic 
trial 
 
Neutrophil phagocytosis of mycobacteria 
via Fcγ and complement receptors 
Vaccines may require effective 
antibody responses, or 
complement levels may affect 
vaccine efficacy 
Investigate role of antibodies and 
complement in mediating 
neutrophil phagocytosis 
 
Correlate relevant antibody 
responses and complement levels 
with protection in recent vaccine 
trials 
 
Association of neutrophilia with poor 
prognosis in tuberculosis disease 
Blocking neutrophil recruitment 
to disease site or blocking 
neutrophil necrosis may improve 
outcome 
 
In vitro and animal models of eg 
Annexin I, evasins, cyclin-
dependent kinase inhibitors 
Neutrophilia as part of prognostic score 
for tuberculosis 
Use score to direct treatment 
decisions, eg early discharge or 
intensive monitoring 
 
Prospective validation of score in 
further cohorts 
BCG = Mycobacterium bovis-BCG; HNP = Human Neutrophil Peptides; ART = Antiretroviral therapy. G-CSF = 
Granulocyte Colony Stimulating Factor; HIV = Human Immunodeficiency Virus 
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